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1. Introduction 
 
1.1. The HIV-1 pandemic 
The human immunodeficiency virus type 1 (HIV-1) was first described as the causative 
agent of acquired immunodeficiency syndrome, short AIDS, more than thirty years ago.
1,2
 
Today, we know that four independent cross-species transmissions between apes and 
humans, most likely caused by bushmeat hunting, have led to the emergence of HIV-1, 
which can be subdivided into groups M (major), O (outlier), N (non-M/ non-O) and P 
(pending). While group M and N have been traced back to chimpanzee origin in 
Cameroon, the origin of group O is unknown and group P most likely derives from 
gorillas. Phylogenetic and statistical analyses have dated the first zoonotic transmissions to 
humans to the beginning of the 20
th
 century. While the other groups have remained 
relatively small in comparison, HIV-1 group M since then has developed into a pandemic 
with millions of infections worldwide.
3
 It is further subdivided into 9 different 
phylogenetic subtypes, the clades A to D, F to H, J and K, with A, B and C globally being 
the most prevalent.
4
 While clade A viruses are predominant in eastern Europe and eastern 
Africa, clade B prevails in western and central Europe, America and Australia. Subtype C 
accounts for almost 50 % of HIV-1 infections worldwide and is the major clade in 
countries which harbor 80 % of all global infections, such as Africa and India. In addition, 
the number of circulating recombinant forms (CRFs), which today constitute an estimated 
20 % of infections, is continuously increasing.
5
 
According to the “Joint United Nations Program on HIV AIDS” (UNAIDS) and the WHO, 
about 35 million people have died of HIV since the beginning of the epidemic and 
approximately 37 million people are currently living with HIV. However, the worldwide 
distribution still varies considerably. Nearly 70 % of HIV infected individuals are living in 
Sub-Saharan Africa, accounting for an infection rate of approximately 1 in every 25 adults 
(Figure 1).
6,7
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Figure 1: Global prevalence and distribution of HIV. More than 70 million people have already been 
infected with HIV, causing about 35 million AIDS related deaths. Globally, approximately 37 million people 
were living with HIV at the end of 2015, meaning that an estimated 0.8 % of adults aged 15 – 49 years were 
infected. The burden of the epidemic still varies considerably between regions, with Sub-Saharan Africa 
accounting for nearly 70 % of infections worldwide. From 
6
. 
 
Although eradication of HIV-1 infection from patients to avoid the burden of lifelong 
therapy is the subject of extensive research (reviewed in 
8
), a cure has only been reported 
once, in an acute myeloid leukemia patient receiving stem cell transplantation from a donor 
with a homozygous deletion in the CCR5 chemokine coreceptor used by HIV.
9
 The 
difficulty for HIV-1 eradication in an individual is caused by the formation of HIV-1 
reservoirs, which can develop within days of acute infection.
10
 Although transcriptionally 
silent and therefore not visible for the immune system or anti-retroviral treatment, the virus 
remains replication-competent within these cells. Hence, if anti-retroviral treatment is 
interrupted, these reservoirs are able to reignite new rounds of infection.
8
 The main 
reservoirs for HIV-1 represent latently infected resting memory CD4
+
 T cells. However, 
other cell populations like latently infected naïve CD4
+
 T cells, CD4
+
 memory stem cells 
or macrophage and monocyte populations may contribute.
8
 The potential reactivation of 
the virus in these cells poses the greatest obstacle in HIV-1 eradication, as each latently 
infected cell would have to be cleared to achieve a cure from HIV-1 infection.
8
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However, anti-retroviral therapy for HIV infected individuals has made significant 
progress during the last years. This, for example, accounts for the reduction of mother to 
child transmissions by 58 % from 2000 to 2014
11
 and an almost normal life expectancy of 
infected individuals,
12
 making HIV-1 a chronic infection for individuals with constant 
access to modern treatment. This, however, requires a high level of compliance with daily 
doses of pharmaceuticals.
13
 More importantly, still only about 49 % of infected individuals 
have access to the treatment.
7
 Especially for low income countries, this highlights the need 
for an efficient HIV-1 prophylactic vaccine in order to be able to eradicate the HIV-1 
pandemic. 
 
 
 
1.2. The HI Virus: particle structure and replication cycle 
HIV-1 is a retrovirus of the Retroviridae family with a diameter of about 100 to 120 nm. 
Viruses are enclosed by a lipid bilayer derived from the human cytoplasmic membrane. 
The group specific antigen (gag) proteins constitute the structural proteins of the viral 
particles. Myristinylated matrix protein gag p17 forms a layer on the inner side of the 
membrane, while gag protein p24 is arranged into the conical capsid (core). The capsid 
contains the two 9.2 kb RNA (+) strands that make up the viral genome, which are 
complexed with nucleocapsid protein gag p7. In addition, the core contains the viral 
enzymes (pol proteins) reverse transcriptase, integrase and protease. HIV-1 virus particles 
only possess one virus derived surface protein, the Envelope or short Env protein (Figure 
2).
14
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Each viral particle contains about 14 to 20 envelope spikes consisting of three gp41 and 
three gp120 subunits. Env initiates host cell infection by binding to the CD4 receptor on 
the surface of CD4
+
 immune cells. This leads to a conformational change in Env which 
exposes its coreceptor binding site (Figure 3; step 1). Possible coreceptors for HIV-1 are 
the chemokine receptors CCR5 or CXCR4. Coreceptor binding initiates fusion of the viral 
and host membranes and ultimately delivers the viral capsid into the cytoplasm (Figure 3, 
step 2). After capsid uncoating (Figure 3; step 3), the reverse transcriptase transcribes the 
viral RNA genome to double-stranded DNA (dsDNA) (Figure 3; step 4). Subsequently, 
the pre-integration complex (PIC) consisting of dsDNA and associated proteins (Figure 3; 
step 5) is transported into the nucleus (Figure 3; step 6). Here, the viral integrase inserts 
the dsDNA into the euchromatin of the host genome (Figure 3; step 7) and thus triggers 
the transcription of viral genes by the cellular RNA polymerase II (Figure 3; step 8). 
During the early phase of transcription, multiply spliced mRNAs are generated, encoding 
the regulatory proteins Tat (trans-activator of transcription) and Rev (regulator of 
expression of virion proteins) (Figure 3; step 9). After re-entering the nucleus (Figure 3; 
step 10), Tat further activates viral transcription, while Rev participates in the export of 
singly spliced and unspliced transcripts to the cytoplasm (Figure 3; step 11). During the 
late phase of replication, these mRNAs produce the remaining viral proteins (Figure 3; 
step 12). While the glycoprotein Env is translated into the ER and accumulates in the 
plasma membrane via the Golgi export pathway, all other viral proteins are translated in 
the cytoplasm. Group specific antigens (gag) and viral enzymes (pol) are translated as gag 
and gag/pol precursor proteins. After myristinylation, those are transported to the plasma 
Figure 2: Schematic structure of a mature 
HIV-1 particle. HIV-1 is an enveloped virus 
with one viral surface protein, the envelope 
(Env), a trimer of three gp120 and three gp41 
subunits. Each viral particle contains about 14 
to 20 Env spikes. The inner layer of the host 
derived membrane is lined with a matrix of 
p17. The conical capsid of p24 protein contains 
the viral genome, consisting of two copies of 
(+) strand RNA complexed with nucleocapsid 
protein p7. HIV-1 particles also contain the 
viral enzymes reverse transcriptase, integrase 
and protease, as well as several other viral 
accessory proteins such as Vif, Vpr or Nef (not 
shown). Adapted from 
180
. 
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membrane, where the assembly of the virions takes place (Figure 3; step 13). Via a psi (Ψ) 
sequence that only non-spliced, full-length RNAs contain, the viral genome binds to the 
gag precursor proteins. After budding of immature virus particles (Figure 3; step 14), the 
slightly acidic pH inside the particles leads to the activation of the viral protease, which in 
turn initiates virus maturation by cleavage of the gag and gag/pol precursors into the single 
proteins (Figure 3; step 15).
14,15
 
 
 
 
 
Figure 3: Schematic representation of the HIV-1 replication cycle. Small arrowheads: viral entry to 
integration. Curved arrows: early replication. Double-headed arrows: late replication. Binding of viral 
particles to the main receptor CD4 and the coreceptor (CCR5 or CXCR4) (1) leads to the fusion of viral and 
host membranes (2). After uncoating of the viral capsid (3), the viral reverse transcriptase transcribes the 
RNA genome into dsDNA (4). The pre-integration complex (PIC) consisting of dsDNA and associated 
proteins (5) is then transported into the cell nucleus (6). After integration of the viral dsDNA into the host 
euchromatin (7), transcription of viral factors starts with the early multiply spliced mRNAs (8). Translation 
of early regulatory proteins Tat and Rev (9), which are subsequently transported back into the nucleus (10), 
leads to increased transcription of viral mRNAs (Tat) and the export of singly spliced and unspliced viral 
mRNAs (Rev) (11). This results in the translation of all other virus encoded determinants, e.g. viral structural 
proteins (12). The assembly of viral particles takes place at the host plasma membrane (13). After budding of 
immature particles (14), a slightly acidic pH inside the viruses leads to the activation of the viral protease and 
subsequent maturation of the particles (15). From 
15
. 
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1.3. The HIV-1 envelope protein 
 
1.3.1. Structure of HIV-1 envelope 
The HIV-1 surface protein envelope (Env) is the only virus-encoded determinant present 
on the viral surface and thus visible to antibodies.
16
 Each viral particle displays about 14 to 
20 envelopes, which are synthesized as a gp160 precursor protein.
14
 During its synthesis in 
the ER, gp160 is heavily glycosylated, with mainly high mannose and complex N-linked 
glycans finally accounting for about half of the molecular protein mass.
17
 Golgi-associated 
furin proteases cleave gp160 into the two subunits gp120 and gp41. The functionally active 
envelope spikes are trimers of gp120-gp41 heterodimers with the three gp41 subunits 
forming the transmembrane-spanning region and the three gp120 subunits non-covalently 
attached on top.
18
  
With an estimated 35 % sequence variation between the different subtypes, Env constitutes 
the most variable protein in the HIV-1 genome.
19
 The gp120 subunit has a highly variable 
surface including five variable loops (V1–V5) (Figure 4A to C and E).18 Structurally, 
gp120 can be separated into an inner and an outer domain, connected by the bridging sheet, 
a four-stranded β-sheet domain (Figure 4D). While the inner domain forms the non-
covalent connection to gp41, the outer domain contains the CD4 receptor binding site.
20
 
Compared to gp120, gp41 is more conserved and consists of the fusion peptide (FP) and 
fusion peptide proximal region (FPPR), two heptad repeats (HR1 and HR2), the 
immunodominant C-C loop containing a conserved disulfide bridge, the membrane-
proximal external region (MPER), the transmembrane domain (TM) as well as the 
cytoplasmic tail (CT) (Figure 4A to C).
18
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Figure 4: Structure of the HIV-1 envelope protein. Structures are based on BG505 SOSIP.664, PDB ID 
4ZMJ. A: Schematic representation of HIV-1 envelope. Env is synthesized as a gp160 precursor protein and 
proteolytically cleaved into gp120 and gp41 by the Golgi-associated furin protease. gp120 consists of five 
constant regions (C1-C5), interspersed with five variable loops (V1-V5). gp41 contains the fusion peptide 
and fusion peptide proximal region (FP and FPPR), two heptad repeats (HR1 and HR2), the C-C loop with a 
conserved disulfide bond, the membrane-proximal external region (MPER), the transmembrane domain (TM) 
and a cytoplasmic tail (CT). Glycans are represented by tree-like symbols. B: Structure of one gp140 
protomer. The gp41 heptad repeats 1 and 2 (HR1, HR2) are positioned at the base of the trimer. The fusion 
peptide proximal region (FPPR) and fusion peptide (FP) are located at the gp120 interface and the variable 
loops V1, V2 and V3 are positioned at the top of the protomer. C: Side view of the Env trimer. CD4BS: 
Location of the CD4 binding site on one protomer. Structures of the membrane-proximal external region 
(MPER), transmembrane domain (TM), and cytoplasmic tail (CT) are schematically included, as they are not 
solved in the crystal structure. D: Structure of a gp140 protomer subdivided into the outer and inner domain, 
which are connected by the four-stranded bridging sheet. E: Top view of the Env trimer. The variable loops 
(V1–V5) are located at the apex of the trimer and project outward. V2 and V4 are indicated with broken lines 
as they are disordered in the structure. Freely reproduced from 
18
. 
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1.3.2. Function of HIV-1 envelope 
HIV-1 Env is the mediator of host cell entry. The first essential step of virus-host 
interaction constitutes the binding of the CD4 binding site on gp120 to the primary 
receptor CD4, a member of the immunoglobulin superfamily assisting the T-cell receptor 
in communicating with an antigen presenting cell.
21,20
 This makes CD4
+
 T cells as well as 
monocyte/macrophage lineages the target cells for HIV-1. Binding of Env to CD4 leads to 
a conformational rearrangement of the pre-fusion closed envelope spike. This includes the 
separation of V1/V2 from V3, resulting in the orientation of V3 towards the target cell 
membrane, as well as a rearrangement of the bridging sheet.
22
 These conformational 
changes expose the coreceptor binding site on Env, which then interacts with one of two 
possible coreceptors, the chemokine receptors CCR5 or CXCR4. This interaction brings 
viral and host membranes into close proximity and induces exposure of the hydrophobic 
gp41 fusion peptide. Insertion of the fusion peptides of each subunit into the host 
membrane tethers virus and host. Subsequently, folding of the fusion peptides at a hinge 
region brings the amino-terminal helical region HR1 and the carboxy-terminal helical 
region HR2 together, resulting in the arrangement of a 6-helix bundle (6HB).
22
 The 6HB is 
the driving force that brings both membranes closely together, allowing the formation of 
the fusion pore (Figure 5). In summary, coreceptor binding unlocks the potential energy of 
the gp41 fusion complex, resulting in 6HB formation, opening and stabilization of the 
membrane fusion pore, and subsequent delivery of the viral contents into the host cell 
cytoplasm.
21
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Figure 5: Schematic representation of HIV-1 cell entry. A functional, trimeric envelope spike initiates 
host cell infection by binding to the CD4 receptor on CD4
+
 cells (1). CD4 binding results in a conformational 
rearrangement of Env, including the exposure of V3 and the coreceptor binding sites (2). Suitable coreceptors 
are the chemokine receptors CCR5 or CXCR4. Coreceptor binding (3) leads to the exposure of the fusion 
peptide (4), which is then inserted into the host cell membrane (5). The fusion peptide of each gp41 subunit 
then folds at a hinge region (6), bringing heptad repeats HR1 and HR2 together to form a 6-helix bundle 
(6HB) (7). As the HR1 domains are in close proximity to the host cell membrane, and the HR2 domains are 
in close proximity to the viral membrane, the 6HB is the driving force that brings the opposing membranes 
together, resulting in the formation of a fusion pore (8) and subsequent delivery of the viral contents into the 
host cell cytoplasm (9). Grey: gp41, blue: gp120, green: V3, yellow: fusion peptide (FP), deep red: heptad 
repeat 1 (HR1), brown: heptad repeat 2 (HR2). EC: extracellular space, IC: intracellular space, host PM: host 
plasma membrane. Freely reproduced from 
23
. 
 
 
 
1.3.3. Immune evasion mechanisms of HIV-1 envelope 
The envelope protein is the only virus encoded antigen on the surface of infectious HIV-1 
particles
14
 and is therefore exposed to strong selection pressure by the host immune 
system.
24,25
 As such, it has developed several sophisticated mechanisms to escape an 
efficient humoral immune response: 
(i) Env variability (Figure 6B). With about 35 % sequence variation between the different 
subtypes, Env constitutes the most variable protein in the HIV-1 genome.
19
 It has been 
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estimated that the total hemagglutinin (HA) sequence variability for one year of an 
influenza epidemic is equivalent to the degree of HIV-1 Env sequence variability in a 
single individual.
19
 The five variable loops of gp120 are able to tolerate high mutation rates 
without altering viral fitness and possess a high level of flexibility. Under immune 
pressure, they are able to change length, amino acid composition as well as the number of 
glycosylation sites to quickly escape neutralizing antibody responses.
18,26,27
  The length of 
V1/V2, for example, can range from 50 to 90 amino acids (aa), while loops V4 and V5 
differ from 19 to 44 aa and from 14 to 36 aa, respectively.
28,27
  
(ii) Glycan shield (Figure 6A). The highly glycosylated surface of gp120 also serves as a 
physical barrier to the immune system. Although many glycosylation sites are highly 
conserved, the exact number of glycans varies among the different isolates. In general, 
about 50 % of the Env molecular mass is made up of N-linked glycans, mostly of the high 
mannose and complex type. The resulting glycan shield covering the surface of Env limits 
the accessibility of conserved sites. In addition, the on-demand repositioning of glycans 
obstructs Env recognition by neutralizing antibodies.
29
  
 
 
 
 
(iii) Conformational masking. The variable loops lie predominantly on the surface of 
gp120 (Figure 4B, C and E).
18
 All conserved regions of gp120 are located underneath the 
V1/V2/V3 cap or near the interface of the subunits, as e.g. in the case of the CD4 binding 
site. This limits the accessibility for antibodies, allowing them to approach only at a 
defined angle. Glycans, e.g. the conserved glycan at N276, further restrict access to 
Figure 6: Glycan shield and 
sequence variability of 
HIV-1 envelope compared 
to Influenza hemagglutinin. 
A: N-linked glycosylation. 
Conservation: light green 
>90 %; dark green <90 %; 
yellow: conserved glycan at 
N241 not present in BG505. 
B: Sequence variability. 
Structures are based on 
BG505 SOSIP.664 (PDB 
4TPV) and Influenza hem-
agglutinin H3 (PDB 2YP7). 
With minor modifications 
from 
22
 with permission of 
the Nature Publishing Group.  
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conserved regions like the CD4 binding site.
18,30,31
 In addition, the required two-step 
binding process to CD4 and the coreceptor, which triggers the spike-opening process of 
Env, is proposed to be an evolutionary adapted mechanism to protect conserved regions 
like the coreceptor binding site or the fusion machinery, which are prone to be targeted by 
neutralizing antibodies.
32
 This way, they only become accessible when the virus is already 
in close proximity to the target cell and the fusion process is already under way.  
(iv) Conformational flexibility. Env`s flexibility necessary for the profound 
conformational changes during host cell entry also contributes to immune evasion due to 
the multitude of Env conformations presented to the immune system (Figure 7). This is 
enhanced by the structural instability of Env. The non-covalent linkage of the gp120 
subunits to the gp41 transmembrane stem can lead to shedding of gp120. Open Env trimers 
and shedded gp120 result in the exposure of immunodominant epitopes usually hidden in 
the inner part of the functional, closed trimer spike, which leads to the induction of various 
non-neutralizing antibodies that further hinder an efficient humoral immune response.
22
 
 
 
 
 
Taken together, these escape mechanisms account for the lack of an efficient humoral 
immune response against HIV-1. Although most infected individuals develop neutralizing 
antibodies during the first year of infection, those are mostly strain-specific and can 
Figure 7: Conformational flexibility of HIV-1 
Env. The inherent flexibility of HIV-1 Env 
necessary for the profound conformational changes 
during host cell infection as well as gp120 shedding 
present the immune system with a multitude of 
different Env conformations. Immunodominant 
epitopes usually hidden in the inner part of the 
functional, closed Env trimer are exposed, leading 
to the induction of various non-neutralizing 
antibodies. Yellow: CD4 binding site, middle panel: 
light gray: gp120, dark gray: gp41, blue-gray: 
membrane. Upper and lower panel: light blue: 
closed state; gray: partially open state; green: open 
state; red: V1/V2; dark blue: V3. middle panel: with 
permission from 
110
, upper and lower panel: from 
181
. 
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quickly be circumvented by escape mutations or other quasi-species present in an infected 
individual.
33
 However, some infected individuals develop so called broadly neutralizing 
antibodies capable of neutralizing a broad panel of different isolates.
33
 The different types 
of antibody responses during HIV-1 infection are described in more detail in the following 
section.  
 
 
 
1.4. Antibody responses against HIV-1 
 
1.4.1. Timelines and stages of the antibody response against HIV-1 
The antibody response against HIV-1 can be divided into three major groups as reviewed 
in 
34
: Env-binding but non-neutralizing antibodies can be detected as early as one week 
after infection. Generally, antibodies against gp41 arise first, followed by antibodies 
targeting variable regions on gp120, e.g. V3. However, these antibodies do not seem to put 
selection pressure on the virus, nor affect plasma viral load
35,33
 and hence might mostly 
target dissociated gp120 and gp41 proteins or aberrantly folded trimers.
36
 Although non-
neutralizing, it is likely that some of these antibodies can convey Fc-mediated effector 
activities like ADCC (antibody-dependent cellular cytotoxicity) or ADCP (antibody-
dependent cellular phagocytosis) and thus they are also of functional interest.
34
 
Several weeks or months after HIV-1 infection, autologous neutralizing antibodies (nAbs) 
can be detected. The reason for their slow development is still unclear, but might be 
associated with impaired CD4
+
 T cell support in antibody maturation due to the HIV-1 
infection or the various immune escape mechanisms of HIV-1 Env (see 1.3.3). The very 
narrow neutralization profile, which is mostly limited to the autologous virus, only leads to 
the selection of other quasi-species not targeted by those nAbs or the insertion of escape 
mutations to avoid the neutralizing antibody response.
34
 
However, an ongoing co-evolution of escaping viruses and the humoral immune system 
adapting to these escape variants ultimately leads to increased neutralization breadth, 
resulting in broadly neutralizing antibodies (bnAbs) in about 10 - 50 % of infected 
individuals after several years of infection.
37,38
 The most potent bnAbs known today can 
neutralize more than 90 % of the different isolates tested.
39
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1.4.2. Broadly neutralizing antibodies 
Broadly neutralizing antibodies can neutralize a variety of different HIV-1 isolates, with 
the best among them being able to neutralize more than 90 % of the tested isolates
39
. In 
comparison to other antibodies, bnAbs share several unique features (reviewed in 
39,38
): 
(i) High amount of somatic hypermutation: Due to their long evolution time of several 
years, a commonly shared feature of HIV-1 bnAbs is their high level of somatic 
hypermutation (SHM). While most affinity-mutated VH domains carry between 15 and 20 
mutations at nucleotide level, HIV-1 bnAbs can exhibit 40 to 100 VH gene mutations.
32
  
(ii) Long CDR H3 loops: Several bnAbs also display long variable heavy-chain third 
complementary-determining regions (CDR H3). While the median length of CDR H3 lies 
at 13.5 amino acids, many HIV-1 bnAb CDR H3 loops reach up to 20 to 34 residues,
40
 
often enabling these antibodies to penetrate the glycan shield of Env.
32
 It is suggested that 
the development of such antibodies requires the engagement of rare germline B cells.
38
  
(iii) Poly- and autoreactivity: Third, bnAbs often display a certain level of poly- and/or 
autoreactivity.  
Taken together, these unusual features may pose some of the reasons why bnAbs only 
occur in approximately 10 to 50 % of infected individuals,
37,38
 as exceptionally high levels 
of SHM, long CDR H3 loops, as well as poly- and autoreactivity are associated with 
negative B cell selection, limiting the pool of B cells able to develop bnAbs (reviewed in 
32,40,41
). 
Before 2009, only a handful of bnAbs were known, all targeting three major antigenic 
sites: (1) the CD4 binding site (e.g. VRC01
42
, PGV04
43
 or HJ16
44
), (2) a glycan epitope in 
the outer domain of Env (2G12
45
), and (3) the membrane-proximal external region 
(MPER) in gp41 (e.g. 2F5, 4E10
46,47
 or 10E8
48,
). In recent years, however, the number of 
known bnAbs has increased drastically for several reasons. Due to the complex nature of 
HIV-1 Env (see 1.3), only core gp120 Env variants missing the variable loops were 
available for the analysis of sera for a long time. Today, new immunogens without any 
deletions and depicting native-like conformations are available.
49,50
 In addition, high-
throughput screening methods were developed to select broadly neutralizing B cells from 
the B cell repertoire of infected patients, e.g. using the newly available immunogens as 
baits in antigen-specific B-cell sortings
51,52,53
 or via high-throughput neutralization assays 
of immortalized B cell repertoires.
54,55
 This led to the discovery of a variety of new bnAbs 
with target sites distributed over the whole Env surface (Figure 8). One of the newly 
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identified antigenic sites includes a quaternary structure-dependent epitope spanning 
V1/V2 and specific N-linked glycans, which is e.g. targeted by bnAbs PG9, PG16 or 
PGT145.
56,57,58
 Other new target sites include V3 with (PGT121-134)
55
 or without 
(HGN194)
44
 recognition of the conserved glycan at position 332 and glycan-dependent 
epitopes on the gp41-gp120 interface targeted by PGT151
59
 or 35O22
60
. 
 
 
 
 
 
Figure 8: bnAb epitopes on HIV-1 Env. bnAb epitopes are distributed over the whole surface of Env and 
include the CD4 binding site, the trimer apex (V1/V2, including a conserved glycan at position N160), a 
N332 glycan-dependent V3 epitope, the gp120-gp41 interface, as well as the membrane-proximal external 
region of gp41 (MPER). From 
61
. 
 
 
Remarkably, after passive immunization of macaques, these broadly neutralizing 
antibodies were shown to provide protection against chimeric simian/human 
immunodeficiency virus (SHIV) infection.
62,63
 This led to the hypothesis that a preventive 
vaccine able to induce bnAbs would also result in protection against HIV-1 infection. 
However, none of the immunogens available to date were able to induce broadly 
neutralizing antibody responses in vivo. Hence, the currently most in-depth researched 
aspect of HIV-1 vaccine design is the development of HIV-1 immunogens and 
immunization strategies able to overcome this obstacle.  
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1.5. HIV-1 envelope as an immunogen 
 
1.5.1. HIV-1 envelope laboratory adaptations 
For analyses of HIV-1 Env, several truncated laboratory adaptations of the naturally 
occurring gp160 protein have been used over the years: for membrane-bound gp145, the 
cytoplasmic tail was removed to achieve enhanced expression and membrane 
incorporation.
64,65
 To obtain soluble protein, either gp120 was employed
20,42
 or Env was 
truncated N-terminally of the transmembrane domain to obtain soluble trimeric gp140 
variants
66,49
 (Figure 9). To avoid gp120-gp41 dissociation, the REKR furin cleavage site 
between gp120 and gp41 was often mutated to REKS or SEKS to obtain cleavage-
incompetent envelope proteins.
67,68,69
 
 
 
 
 
 
 
 
 
 
Figure 9: Laboratory 
adaptations of HIV-1 
envelope. Truncation of the 
cytoplasmic tail (CT), 
resulting in membrane-
bound gp145, led to 
increased Env expression 
and surface presentation. 
To obtain soluble Env 
gp140 trimers, the protein 
can be truncated N-
terminally of the trans-
membrane domain (TM). 
In addition, termination at 
the furin cleavage site 
(REKR) results in soluble 
gp120. (See Figure 4 for all 
other abbreviations in this 
schematic). 
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1.5.2. Clinical efficacy trials conducted until today 
So far, six clinical efficacy studies have been completed (reviewed in 
70
 and 
71
). The first 
efficacy studies for HIV-1 immunogens were started in the late 1990s with recombinant 
gp120 vaccines of bivalent subtype B/B for the North American trial (VAX 004) and 
bivalent subtype B/E for Thailand (VAX 003). The final results of these two trials 
indicated no protection against HIV infection.
72
  
This outcome of the VaxGen trials was an incentive for intensified research on the cell 
mediated immune response, especially as cytotoxic T-lymphocyte (CTL) responses play an 
important role in controlling replication in infected people and hence early viral control. 
This was mostly pursued by developing DNA and viral vector immunizations. Efficacy 
trials were carried out using replication defective recombinant Adenovirus 5 (Ad5) vector 
vaccines with HIV-1 clade B gag/pol/nef inserts in the Step trial starting in 2004 and the 
Phambili trial starting in 2007. Although the vaccine used for the Step trial was found to 
produce reasonable CD8
+
 T-cell responses, those were mainly directed against variable 
regions of the virus. In 2007, futility was acknowledged for the efficacy objective of both 
trials.  
The Step trial showed that pre-existing immunity to Ad5 increased risk of HIV-1 
acquisition. Therefore, the clinical trial HVTN505 evaluated the efficacy of a DNA prime - 
Ad5 vector boost vaccine in Ad5 seronegative individuals. Here, a plasmid mixture for 
clade B gag, pol and nef, as well as env from clades A, B and C was used, followed by an 
Ad5 vector boost to overcome the antibody and T-cell breadth problems demonstrated by 
the previous studies. However, this also did not result in efficacy against HIV infection or 
a reduction in viral load set point.  
The negative results from those trials brought on a rethinking in the field to search for 
more strategic and systematic HIV-1 vaccine approaches. The RV144 or Thai trial, which 
was conducted from 2004 to 2009, produced the first positive, albeit modest, result for an 
HIV vaccine efficacy trial. RV144 tested a prime-boost combination of two vaccines: 
ALVAC, a canary pox vector from Sanofi Pasteur expressing clade E gp120 and clade B 
Gag and Pro, followed by an AIDSVAX B/E gp120 boost, which was already tested in the 
VaxGen trials without showing efficacy. In 2009, the trial demonstrated an efficacy of 
about 31 % in preventing infection after 3.5 years. The immune correlates analysis 
published in 2012 suggests that non-neutralizing antibodies directed against V1/V2 may 
contribute to protection by eliciting effector responses like ADCC (antibody-dependent 
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cellular cytotoxicity).
73,74
 After these promising results, a pox-protein regimen adapted for 
Sub-Saharan Africa containing an ALVAC vector with clade C Env insert and a bivalent 
clade C recombinant gp120 will be tested in the HVTN702 trial starting in late 2016.
70
 
 
 
 
1.5.3. Immunogen efforts for the induction of cross-neutralizing 
antibody responses 
In order to develop a prophylactic vaccine based on the induction of broadly neutralizing 
antibodies, several strategies have been pursued and tested in animal models. They aim at 
overcoming the obstacles of an efficient neutralizing antibody response created by the 
various immune escape mechanisms of Env (see 1.3.3) and the resulting complex co-
evolution necessary for the emergence of bnAbs in vivo (see 1.4).  
Env variability and the resulting problem of antibody strain-specificity was e.g. addressed 
by a directed evolution approach screening a clade B chimeric gp120 Env library for 
improved binding to neutralizing monoclonal antibodies. Eventually, one of these variants, 
ST-008, was able to elicit improved neutralizing antibody responses in rabbits
75
. Other 
approaches used heterologous substitution or deletion of the V1 loop,
76
 or 
hyperglycosylation of variable loops
77
 to focus antibody responses to more conserved 
epitopes in soluble gp140 trimers. Although those approaches shifted immunogenicity in 
rabbits from the variable regions of Env to other epitopes like the CD4 binding site, the 
breadth of those antibody responses was limited, indicating the need for further modified 
Env variants. 
To address the problem of Env`s structural flexibility, which results in the presentation of 
non-neutralizing epitopes usually hidden in the inner part of the trimer, gp140 trimers were 
chemically cross-linked.
78,79
 Cross-linking largely conserved binding of bnAbs to their 
different epitopes, but reduced binding of several non- or weakly neutralizing antibodies 
and soluble CD4 (sCD4).
78
 Also, cross-linking significantly improved Env thermostability 
and trimer integrity with or without adjuvant
50
 and immunization studies in rabbits 
revealed significantly increased neutralization titers.
78,50
 
The so-called SOSIP and NFL approaches for soluble trimers also address the problem of 
structural heterogeneity caused by Env flexibility. Previously used gp140 variants usually 
had a mutated furin cleavage site to prevent gp120 – gp41 dissociation.80 Today, it is 
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known that this prohibits correct Env folding and leads to aberrantly folded Env trimers.
81
 
To overcome this problem, the cleavage-independent native flexibly linked (NFL) Env 
trimers were developed. With a glycine-serine (G4S) flexible peptide linker replacing the 
REKR furin cleavage site, the two subunits are able to fold homogeneously to form 
cleavage-independent, well-folded Env trimers. This is further supported by a trimer 
stabilizing proline mutation in gp41 (Figure 10). This strategy was successfully applied to 
several different HIV-1 subtypes.
82
 
Similarly, the soluble recombinant clade A Env trimer BG505 SOSIP.664 was designed to 
form well-folded trimers. The SOSIP strategy implements an improved 6xR furin cleavage 
site instead of REKR, resulting in fully cleaved gp140 trimers. gp120 shedding is 
prevented by a novel disulfide-bridge between gp120 and gp41 (SOS) and trimerization is 
enhanced by a trimer stabilizing isoleucine to proline mutation in gp41 (IP) (Figure 10). 
Termination of gp140 SOSIP variants at amino acid 664 diminishes protein aggregation.
49
  
 
 
Figure 10: Design of NFL (native flexibly linked) and SOSIP Env variants. Mutation of the REKR 
cleavage site to prevent furin cleavage between gp120 and gp41 and hence subunit dissociation resulted in 
aberrantly folded Env trimers. Two different strategies were developed to solve this problem: In native 
flexibly linked (NFL) trimers, the REKR cleavage site is replaced by a glycine-serine (G4S) linker. Together 
with a trimer stabilizing isoleucine to proline mutation in gp41, this allows proper folding of the two subunits 
and results in cleavage-independent, homogeneously folded trimers. In the SOSIP approach, furin cleavage is 
even improved by replacing REKR with 6xR. This leads to complete cleavage between gp120 and gp41. 
Dissociation is prevented by a newly introduced disulfide-bridge between the two subunits (SOS) and 
trimerization is supported by a trimer stabilizing isoleucine to proline mutation in gp41 (IP). In isolates which 
do not naturally bear the N-linked glycan at position 332 necessary for V3/Glycan-dependent bnAbs, this 
glycosylation site was artificially included (T332N). 
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Whereas all other Env immunogens tested before were only able to induce neutralizing 
antibody responses against easy to neutralize tier 1 virus strains, BG505 SOSIP.664 was 
able to induce neutralizing antibodies against the more neutralization-resistant, sequence-
matched tier 2 virus in mice, rabbits and macaques.
83,84
 Hence, SOSIP variants currently 
represent the most promising approach on the way to bnAb induction and are further 
pursued in different ways: To broaden the neutralizing antibody response induced by one 
SOSIP variant, SOSIPs for several different clades have already been developed.
85,86
 
However, in comparison to the original BG505 SOSIP, which forms over 90 % well-folded 
trimers, SOSIP variants of other subtypes fold less well, requiring antibody-based positive 
or negative selection of well-folded trimers.
87
 Hence, further efforts are made to identify 
additional stabilizing mutations. Insertion of an intra-protomer disulfide bridge that locks 
gp120 in the closed state as well as eight trimer-derived (TD) stabilizing mutations resulted 
in variants forming homogeneous and highly stable trimers no longer requiring positive or 
negative selection.
87
 Simultaneous or sequential delivery of different clade A, B and C 
SOSIPs resulted in autologous tier 2 neutralization for each of the immunogens. However, 
heterologous tier 2 neutralization was only observed sporadically and with limited 
breadth.
88
 Whether autologous nAbs can be the precursors of bnAb lineages is unclear, but 
insights into the natural progress of HIV-1 infection suggest that autologous nAbs may 
pressure the virus to expose immunotypes that trigger bnAb induction.
38,89
 Hence, 
autologous tier 2 neutralizing titers may be a step towards a cross-neutralizing antibody 
response. 
To mimic the complex co-evolution between Env and the immune system in vivo, 
sequential immunization with different Env immunogens was applied. These approaches 
intend to initially prime the germline receptor on B cells, and subsequently induce the 
mature bnAb over several intermediate stages.
90
 A recent study reported a sequential 
immunization strategy aiming at VRC01-class CD4 binding site bnAbs. The engineered 
envelope variant eOD-GT8
91,92
, which binds VRC01 germline antibodies due to eight 
germline-targeting mutations (GT8), was used as a priming immunogen in a transgenic 
mouse model expressing VRC01 germline-reverted heavy chain. Sequential immunization 
with a BG505 GT3 intermediate and a final boost with BG505 SOSIP N276D drove the 
maturation of primed B cells toward highly mutated VRC01-class nAbs.
93
 Similarly, 
sequential immunization experiments for the glycan-V3-targeting PGT121 bnAb were 
reported. Immunization with a germline-targeting prime, followed by several boosting 
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immunogens with gradual changes in Env structure induced high levels of somatic 
hypermutation, which was directly related to the acquisition of neutralizing activity.
84
 
Almost all of those strategies have one thing in common: the need for Env immunogens 
with high affinities towards the respective germline, intermediate or mature antibodies, 
representing the starting point of this thesis.  
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2. Objective 
The lack of HIV-1 envelope immunogens able to induce broadly neutralizing antibody 
(bnAb) responses in vivo is still the major obstacle of HIV-1 vaccine development. Recent 
studies suggest that trimeric envelope proteins with improved stability and antigenicity (i.e. 
preserved or improved binding to broadly neutralizing antibodies and reduced binding to 
non-neutralizing antibodies) are able to induce enhanced neutralizing antibody 
responses.
83,93,50,78,69
 However, regarding neutralization-resistant tier 2 viruses, which 
dominate human transmissions,
83
 neutralization breadth is still mostly limited to the 
autologous virus strain.
83,88
  
This thesis focused both on the development of a novel high-throughput screening 
approach for the identification of antigenicity-improved envelope vaccine candidates as 
well as on the rational design of next generation envelope immunogens. The first objective 
was to provide a proof of concept study to illustrate the capability of a mammalian cell 
display and cell sorting-based library panning approach to isolate trimeric envelope 
antigens according to their antibody binding properties. To this end, a model library of five 
chimeric Env variants was implemented. The second objective was to develop antigenicity 
and stability improved envelope immunogens. To this end, an Env alanine scanning 
approach in combination with mammalian cell display was to be applied to characterize 
Env – antibody interactions and identify mutations which improve bnAb recognition, while 
reducing binding of non-neutralizing antibodies. Subsequently, I aimed to further support 
antigenicity and stability of the resulting next generation envelope variants by chemical 
cross-linking and analyze the impact of these modifications on immunogenicity in a 
preclinical animal model. 
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3. Materials and Methods 
 
3.1. Human codon optimization 
All HIV-1 envelope variants in this thesis were optimized for human codon usage with the 
online tool “Geneart Geneoptimizer” (Thermo Fisher Scientific). 
 
 
 
3.2. Molecular Biology 
 
3.2.1. General Molecular Biology 
Unless specified otherwise, cloning of all DNA constructs was performed using common 
molecular biology protocols.
94
 For restriction digestion of vectors and inserts, 
endonucleases from New England Biolabs (NEB) or Fermentas (Thermo Fisher Scientific) 
were used according to manufacturer`s instructions.  
Inserts were either generated by direct restriction digestion from the appropriate plasmid or 
a preparative PCR using Phusion High Fidelity Polymerase (NEB, # M0530). For the 
latter, the use of appropriate oligonucleotides (Appendix Table 1) ensured attachment of 
the respective endonuclease restriction sites needed for cloning and, where necessary, the 
integration of mutations via fusion PCR.  
Amplified or restriction digested DNA was purified by 1 – 3 % agarose gel electrophoresis 
(depending on the size of the DNA fragments) and subsequent purification of the 
respective bands using Qiaquick gel extraction kit (Qiagen, # 28706). For the ligation of 
restriction digested vectors and inserts, T4 ligase (NEB, # M0202) was used with a three-
fold molar excess of insert in relation to the vector. For transformation, chemically 
competent or electro-competent Escherichia coli (E. coli) DH10B or DH5α were used. For 
vectors still containing a CcdB cassette
40
, the CcdB resistant strain DB3.1 was applied. 
Analytical PCR to identify insert-containing colonies was carried out using GoTaq Green 
MasterMix (Promega, # M712).  
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The cloning into QuickLigation (QL) vectors containing a CcdB killer gene cassette was 
performed using golden gate cloning as described previously using a combined restriction 
and ligation process.
96
 Shortly, a restriction mixture containing the QL plasmid, the 
respective DNA insert and the type 2S endonuclease Esp3I (Thermo Fisher Scientific, # 
ER0452) was incubated in a PCR cycler for 45 min at 37 °C. Subsequently, the ligation 
mixture was added and the reaction was further incubated at 25 °C, 37 °C and 25 °C for 45 
min each. 
Plasmids were isolated from LB cultures using GeneJET Plasmid Miniprep Kit (Thermo 
Fisher Scientific, # K0503) for Sanger sequencing purposes or Qiagen plasmid kits for 
higher DNA yield. For transfection of FreeStyle 293-F cells, DNA was purified using 
Qiagen Maxi or Mega Kits (# 12165 and 12183). DNA for transfection of HEK293T cells 
and subsequent FACS analysis was purified from 35 ml TB cultures using Qiagen Plasmid 
Plus Midi Kit (# 12945, high yield protocol). The purity and concentration of DNA was 
measured using a NanoDrop 1000 instrument (Thermo Scientific) and sequence 
correctness of all constructs was verified by Sanger sequencing (GATC, Konstanz, 
Germany; GeneArt, Regensburg, Germany or Seqlab, Göttingen, Germany). A detailed 
catalogue of all oligonucleotides used in this thesis is listed in Appendix Table 1, while 
vectors are shown in Appendix Table 2. 
 
E. coli DH5α supE44 ΔlacU169 (φ80 lacZ ΔM15) hsdR17 recA1 endA1 gyrA96 
thi-1 relA1  
E. coli DH10B F– mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 ΔlacX74 
recA1 endA1 araD139 Δ(ara leu) 7697 galU galK rpsL nupG λ–  
E. coli DB3.1 F- gyrA462 endA1 glnV44 Δ(sr1-recA) mcrB mrr hsdS20(rB
-
, 
mB
-
) ara14 galK2 lacY1 proA2 rpsL20(Sm
r
) xyl5 Δleu mtl1 
LB (lysogeny broth) medium 1% NaCl; 1% tryptone; 0.5% yeast extract; pH 7.5 
TB (terrific broth) medium 1.2% tryptone, 0.5% glycerol, 2.4% yeast extract, 0.17 M 
KH2PO4 and 0.72 M K2HPO4 
 
 
 
3.2.2. Permutation of selected 96ZM651 positions  
Sequential permutation of 96ZM651 Env gp145 at selected positions was performed by 
GeneArt, Regensburg, Germany. Variants were provided as pool of one position glycerol 
stocks. To separate the individual mutants, small amounts of the glycerol stocks were 
plated on LBAmp agar (100 µg/ml ampicillin) to obtain single clones. 96 single clones per 
permutated position were inoculated in 96-well LBAmp agar plates provided by GATC 
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Biotech, Konstanz, Germany and sent to GATC Biotech for 96-well Sanger sequencing 
(SupremeRun 96). After sequences and purified DNA were obtained back from GATC, 
one of each correct identified mutant was transformed back into E.coli DH10B and 
purified from 35 ml TB cultures using Qiagen Plasmid Plus Midi kit (# 12945, high yield 
protocol). Amino acid variants which could not be identified by this procedure were 
generated by overlap extension PCR using the reagents listed in 3.2.1 and appropriate 
oligonucleotides to insert the respective mutations (Appendix Table 1).    
 
 
 
3.3. Cell biology 
 
3.3.1. Cultivation of human cells 
The adherent eukaryotic cell lines HEK293T (ATCC, # CRL-11268), Flp-In™ T-REx™ 
293 (Thermo Fisher Scientific, # R78007) or stable cell lines generated from Flp-In™ T-
REx™ 293 cells were cultivated in Dulbecco’s modified Eagle medium (DMEM, 
Gibco/Thermo Fisher Scientific, # 11995-065) at 37 °C and 5 % CO2 according to 
common protocols with the respective supplements indicated in the table below. Cells were 
cultivated up to 80 % confluency and split at a ratio of 1:10 every two to three days by 
washing with phosphate buffered saline (PBS), detaching with Trypsin/EDTA solution 
(PAN-Biotech, # P10-023500) and resuspension in the respective culture medium. 
FreeStyle™ 293-F suspension cells (Thermo Fisher Scientific, # R79007) were cultivated 
at 37 °C, 8 % CO2 and 90 rpm in a culture volume of 300 ml using unbaffled 1 l flasks 
(Corning, # CORN431147), at cell concentrations from 0.1 to 1.6 Mio/ml in the medium 
indicated below. For sub-culturing, the respective amount of cells was centrifuged at 100 g 
for 5 min at RT, before pellets were resuspended. 
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PBS 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.47 mM 
KH2PO4, pH 7.4 
FCS for HEK293T cell cultivation GIBCO, # 10270-106 
Tetracycline free FCS for Flp-In™ T-REx™ 
293 cell cultivation (FCSΔtet) 
Biochrom, # S0115 
Penicillin/Streptomycin (Pen/Strep) 10000 U/ml penicillin, 10 mg/ml streptomycin, 
PAN Biotech, # P06-07100 
Culture Medium for HEK293T cells DMEM + 10 % FCS + 1% Pen/Strep 
Culture Medium for untransfected Flp-In™ 
T-REx™ 293 cell 
DMEM + 5 % FCSΔtet + 1 % Pen/Strep + 100µg/ml 
zeocin + 15 µg/ml blasticidin 
Culture Medium for stable cell lines 
generated from  Flp-In™ T-REx™ 293 cells 
DMEM + 5 % FCSΔtet + 1% Pen/Strep + 100µg/ml 
hygromycine + 15 µg/ml blasticidin 
Culture medium for FreeStyle™ 293-F Cells FreeStyle™ 293 Expression Medium 
(Thermo Fisher Scientific, # 12338018) + 0.5 % Pen/Strep 
 
 
 
 
3.3.2. Transient transfection of adherent human cells 
HEK293T cells were transiently transfected using polyethylenimine (PEI).
97
 For 96-well 
transfection, 3 – 4 x105 cells were seeded into a 96-well flat bottom plate the day before 
transfection to reach ca. 80 % confluency on the day of transfection. Directly before 
transfection, the medium was exchanged to 30 µl DMEM without supplements. After 10 
min of incubation at RT, the transfection mix containing 200 ng DNA, 0.8 µl PEI 
(Polyethylenimine, linear, Polysciences, # 23966-2, 1 mg/ml) and 30 µl DMEM without 
supplements was added to the cells. Five to six hours post transfection, the medium was 
changed back to HEK293T culture medium. For 6-well transfection, 5x10
5
 cells were 
seeded into each well the day before transfection. Directly before transfection, the medium 
was replaced with 1 ml DMEM without supplements. A transfection mixture containing 
100 µl DMEM without supplements, 2 µg DNA and 10 µl PEI (Polyethylenimine, linear, 
Polysciences, # 23966-2, 1 mg/ml) was incubated for 10 min at RT and then added to the 
cells. Five to six hours post transfection, the medium was replaced with HEK293T culture 
medium. In the case of SOSIP gp145 variants, the applied DNA for transfection consisted 
of the respective Env-containing plasmid and pcDNA3.1-furin at a ratio of 3:1 (150 ng:50 
ng for 96-well transfection and 1.5 µg:0.5 µg for 6-well transfection). 
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3.3.3. Flow cytometry analysis of transiently transfected cells 
48 h after transient transfection, cells were washed with PBS and detached with FACS 
buffer (PBS + 1 % heat inactivated FCS + 2 mM EDTA). Cells were transferred to a 96-
well round bottom plate and centrifuged at 500 g and 4 °C for 5 min. After removal of the 
supernatant, cells were stained for 1 h at 4 °C with the respective screening antibody (PG9-
Alexa647: 5 µg/ml, all other Alexa647-labeled antibodies: 4 µg/ml) and reference antibody 
5F3-PE (2.5 µg/ml) (antibodies and labeling kits listed in 3.4.6) in 30 µl FACS buffer. 
Subsequently, three washing cycles with 200 µl FACS buffer each followed 
(centrifugation at 500 g, 4 °C, 5 min). Soluble CD4 (sCD4) staining was carried out at a 
concentration of 1 µg/ml, followed by staining with 5F3-PE and the secondary antibody 
anti-human-CD4-APC (OKT4, eBiosciences, # 17-0048-42, 1:100 in FACS buffer), which 
has been shown to not interfere with the binding of sCD4 to gp120.
98
 After the washing 
procedure, cells were analyzed using a FACS-Canto II (BD), Attune or Attune NxT device 
(Thermo Fisher Scientific). Untransfected cells were used as a negative control (n=1), 
while 96ZM651 wildtype transfected cells served as a reference (n=3) on each 96-well 
plate. Cells were gated for living, single cells displaying envelope expression, as indicated 
by 5F3 binding above envelope negative cells. The mean fluorescence intensity (MFI) ratio 
between the screening compound and the reference antibody 5F3 was calculated and set 
into relation to wildtype binding (WT = 100 %). 5 to 6 independent measurements were 
carried out per analysis.  
 
 
 
3.3.4. 96ZM651 alanine scan 
Prior to this thesis, the alanine mutagenesis library was obtained from GeneArt/Thermo 
Fisher Scientific, Regensburg, Germany using 96ZM651 gp145 (GenBank No: AF286224) 
as a template. The sequence was adapted to human codon usage, the cytoplasmic tail was 
truncated (aa 718-868) and a C-terminal HA-Tag (YPYDVPDYA) was added. In addition, 
the cleavage site was mutated from REKR to REKS. The template sequence (96ZM651 
wildtype) was cloned into pWPXLd (Addgene plasmid # 12258) and alanine mutations 
were generated from amino acids 31 to 688 by fusion PCR, leaving cysteine residues 
unchanged. All mutants were verified by Sanger sequencing and plasmids were prepared 
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from 35 ml TB cultures using the high yield protocol of Qiagen Plasmid Plus Midi kit 
(#12945) according to manufacturer`s instructions. Concentrations of the alanine library 
were adjusted to 100 ng/µl in 96-well PCR plates. Transient transfection and FACS 
analysis of HEK293T cells was performed as described above (3.3.2 and 3.3.3) using a 
FACS-Canto II (BD). For statistical data analysis, R was used to apply a two-sided one 
sample t-test to the calculated percentage ratios against 1 for wildtype Env, while 
controlling the false discovery rate (FDR) to be smaller than 5 %, to adjust for the number 
of performed t-tests. Using PyMol (http://pymol.org/, download of educational version 
Sept. 14th 2010), significant gain or loss of binding mutations were plotted on the crystal 
structure of BG505 SOSIP.664 (PDB ID: 4ZMJ).  
 
 
 
3.3.5. TZM-bl neutralization assay 
Neutralization assays were carried out at the Duke Central Reference Laboratory, Durham, 
USA according to protocols for standardized assessments of neutralizing antibodies for 
HIV/AIDS vaccine development.
99
 Serial dilutions of unlabeled and labeled bnAbs were 
tested in a TZM-bl assay against a selected panel of HIV-1 Env pseudoviruses.  
 
 
 
3.3.6. Generation of stable cell lines using Flp-InTM T-RExTM 293 
cells 
Flp-In
TM
 T-Rex
TM
 293 cells (Invitrogen/Thermo Fisher Scientific, # K6500-01) were used 
to generate stable cell lines with inducible envelope expression regulated under the Tet 
operator/repressor system. Cells were cultivated in DMEM supplemented with 10 % FCS 
(tetracycline free, Biochrom, # S0115), 1 % Pen/Strep (Pan Biotech, # P06-07100), 100 
µg/ml zeocin and 15 µg/ml blasticidin. The day before transfection, 5x10
5
 cells were 
seeded into 6-well plates to reach 80 % confluency on the day of transfection. Directly 
before transfection, the medium was replaced with 1 ml DMEM without supplements. 2 µg 
of a plasmid mixture containing the respective pQL13-Env/V3 variant or the pQL13-
Env/V3 library and the helper plasmid pOG44 carrying the integrase (1.6 µg pQL13-
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Env/V3 variant or library + 0.4 µg pOG44) were mixed with 8 µl PEI (Polyethylenimine, 
linear, Polysciences, # 23966-2, 1 mg/ml) and 100 µl DMEM
 
without supplements. The 
mixture was incubated for 10 min at RT and then given onto the cells. After 6 h of 
incubation, medium was changed to 2 ml DMEM supplemented with 5 % tetracycline free 
FCS and 1 % Pen/Strep. After 48 h, cells were harvested and seeded into a T75 flask. After 
additional 5 h, the medium was replaced by 10 ml DMEM supplemented with 10 % 
tetracycline free FCS, 1 % Pen/Strep, 100 µg/ml hygromycin and 15 µg/ml blasticidin to 
select cells with stable integration events. Selection was carried out for the following 25 
days, with the medium being replaced every 72 h. Both stable cell lines from an equimolar 
plasmid mixture of all five variants as well as for each variant individually were generated. 
 
 
 
3.3.7. TaqMan copy number assay  
This assay was performed by Dr. Tim-Henrik Bruun and results are shown for better 
illustration of the panning procedure. Genomic DNA (gDNA) was prepared from all 
established cell lines (Qiagen, QIAamp DNA Blood Mini Kit, # 51104, blood and body 
fluids protocol) and samples were processed with TaqMan® Universal PCR Master Mix 
(Life Technologies/Thermo Fisher Scientific, # 4304437). The TaqMan® Copy Number 
Assay for Markers & Reporters (Life Technologies/Thermo Fisher Scientific, # 4400291) 
was used to determine the copy number of integrated pQL13 plasmids in all established 
stable cell lines. The TaqMan® Copy Number Reference Assay, TERT (telomerase reverse 
transcriptase), Human (Life Technologies/Thermo Fisher Scientific, # 4403316) was 
included to compare the number of insertions per cell to a genomic reference. Samples 
were analyzed in a StepOne Plus cycler (Applied Biosystems/Thermo Fisher Scientific) 
according to manufacturer`s instructions.  
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3.3.8. FACS analysis of the individual stable Env/V3 cell lines  
Stable cell lines were induced to express GFP and Env by supplementing the medium with 
1 µg/ml doxycycline (Dox.). After 24 h, cells were detached with FACS buffer (PBS + 1 % 
heat inactivated FCS + 2 mM EDTA) and centrifuged at 250 g for 5 min at 4 °C. Then 
cells were incubated with serial dilutions of Alexa Fluor 647 labeled (Thermo Fisher 
Scientific, Alexa Fluor 647 protein labeling kit, # A20173) 447-52D (Polymun, # AB014) 
or HGN194 (kindly provided by Prof. Dr. Antonio Lanzaveccia and Dr. Davide Corti) 
diluted in FACS buffer for 20 min at 4 °C to reach equilibrium binding. Subsequently, 
cells were washed three times with 1 ml ice cold FACS buffer (centrifugation for 5 min at 
250 g and 4 °C), resuspended in 100 µl FACS buffer and subjected to cytometric analysis 
using a FACS Canto II (BD). As GFP and envelope expression were genetically coupled, 
the ratio of Env and GFP MFIs was calculated to normalize for varying Env expression 
levels (relative MFI). Negative controls (Env-negative cells titrated with the very same 
antibody concentrations) were substracted to set the starting point of the curves to 0, then 
the curves were fitted using non-linear least squares regression (hyperbolar one-site 
binding, GraphPad Prism 5.0). To analyze the ratio of Env and GFP expression in each 
stable cell line, cells were stained with Alexa Fluor 647 labeled mAb 5F3 (Polymun, # 
AB010, 5 µg/ml) as described above and MFI correlations of 5F3 to GPF were compared 
for each stable cell line.  
 
 
 
3.3.9. FACS-panning: affinity enrichment of Env/V3 variants 
30x10
6
 cells of the Env/V3 cell library generated with an equimolar mixture of all five 
Env/V3 plasmids were seeded into a 15 cm dish and induced with doxycyline (1 µg/ml) the 
day before the panning procedure. After 24 hours, cells were stained with 1 ml Alexa Fluor 
647 labeled 447-52D (2.7 nM) or HGN194 (6.7 nM) according to the protocol described in 
3.3.8. Finally, cells were resuspended in FACS buffer (PBS + 1 % heat inactivated FCS + 
2 mM EDTA) at a maximal concentration of 60x10
6
 cells/ml and filtered with a 30 µm 
pre-separation filter (Miltenyi Biotech, # 130-041-407). 50 µl of sample were put aside to 
serve as an input control. Cells were sorted using a FACS Aria IIu (BD), with the 
instrument set to “single cell mode” to discard two-target-events and obtain the most 
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accurate counts for the sorting procedure.
96
 Triangle shaped gates were applied to sort cells 
with the highest or lowest antibody affinity in relation to their GFP signal. At least 20,000 
cells were collected per gate. The genomic DNA of both the sorted cells and the input 
control were prepared using QIAamp DNA Blood Mini Kit (Qiagen, # 51104, blood and 
body fluids protocol) according to manufacturer’s instructions, but without addition of 
carrier DNA and elution in only 20 µl 10 mM Tris/HCl pH 8.0. The genomic DNA was 
then used as a template for nested-PCR (primers see Appendix Table 1) to amplify the 
integrated Env genes isolated in the sorting procedure for re-cloning into pQL13 and 
subsequent analysis by qPCR, capillary sequencing of single clones or next generation 
sequencing (NGS). In addition, the genomic DNA was also directly subjected to NGS. 
 
 
 
3.3.10. Enrichment analysis using realtime PCR (qPCR)  
To determine the distribution of Env variants in the re-cloned pQL13 plasmids after FACS 
sorting, a qPCR assay was used as described previously.
96
 Shortly, the reverse-primers 
were designed to specifically bind one variant of the Env/V3 model library, whereas the 
probe and forward-primer were designed to bind every variant alike. Furthermore, an 
additional reverse-primer binding every variant alike was used as a reference primer, 
determining the total amount of applied Env genes. The reactions were performed 
according to manufacturer`s instructions (Thermo Fisher Scientific, DyNAmo Flash Probe 
qPCR Kit, # F-455). Primer sequences are listed in Appendix Table 1. 
 
 
 
3.3.11. Enrichment analysis using next generation sequencing 
NGS was performed on input and first round samples of the panning procedure using the 
Illumina MiSeq platform on both the envelope genes amplified from the gDNA and cloned 
back into pQL13, as well as directly on the genomic DNA of the selected cells and the 
input control. In both cases, Env/V3 loops were amplified in a two step PCR reaction to 
first add short universal adapter sequences on the 5´and 3´ends, and then add barcoded 
adaptor sequences according to TruSeq® Small RNA Sample Prep Kits (Illumina, Primer 
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sequences listed in Appendix Table 1). PCR products were purified using Agencourt 
AMPure XP magnetic beads (Beckman Coulter, # A63881) after each PCR reaction with a 
beads to sample ratio of 1 to 1.8. Sample preparation was performed in DNA LoBind tubes 
(Eppendorf, # 0030108051). AMPure beads were mixed with the DNA samples by 
pipetting thoroughly. After 5 min incubation at RT, samples were pulse-spinned and placed 
into a magnetic rack. After 3 min, supernatants were carefully removed and pellets were 
washed with 500 µl of freshly prepared 70 % ethanol. To this end, the tubes were turned 
around twice within one minute to move the beads around. After the suspensions cleared, 
supernatants were discarded. The washing procedure was repeated, then tubes were shortly 
centrifuged, placed back onto the magnetic rack and the remaining supernatant was 
carefully removed using a 20 µl pipette. The pellets were air-dried on the magnetic rack for 
3 min. Subsequently, 20 µl of 10 mM Tris/HCl pH 8.0 were added and the pellets were 
dispersed by pipetting and vigorous mixing. Subsequently, tubes were pulse-spinned and 
placed back into the magnetic rack. After 3 min, the supernatants were transferred to new 
1.5 ml LoBind tubes without disturbing the pellets. Quality control and quantification of 
PCR products was performed with a Bioanalyzer 2100 (Agilent) and High Sensitivity 
DNA Chips (Agilent, # 5067-4626). After quantification, samples were pooled and 
analyzed on a 300 cycles MiSeq V2 chip (Illumina, # MS-102-2002). To set up the sample 
sheet, the FastQ only, sample prep kit: true seq small RNA presetting was chosen. In the 
sample sheet, cycles were manually adjusted for 2x 151 reads to achieve sequencing from 
both the 5´ and the 3´ end. Sequence analysis was performed with CLC Main Workbench 
7. After import into CLC, the files containing the associated forward and reverse reads 
were paired, then overlapping pairs were merged into one file without altering the 
predefined settings of the program. After export as FastQ files, distribution of the five 
Env/V3 chimeras within each sample was investigated with the V3 analyzer tool 
programmed by Dr. Benedikt Asbach. 
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3.4. Protein biochemistry 
 
3.4.1. Construction of gp140 variants 
gp140 constructs were obtained by amplification from the respective gp160 or gp145 
containing plasmids. The transmembrane domain was omitted using suitable primers and, 
where necessary, the REKR cleavage site was mutated to REKS via overlap extension 
PCR (primers see Appendix Table 1). gp140 constructs were cloned into pQL13 or 
pcDNA3.1QL (Appendix Table 2) using golden gate cloning as described previously
96
 
and verified by Sanger sequencing (GeneArt, Regensburg, Germany or Seqlab, Göttingen, 
Germany). 
 
 
 
3.4.2. Purification of soluble gp140 Env variants 
Soluble gp140 proteins with or without His6-tag were purified from FreeStyle™ 293-F 
cells (Thermo Fisher Scientific, # R79007). Cells were cultivated according to 
manufacturer`s instructions in FreeStyle™ 293 expression medium (Thermo Fisher 
Scientific, # 12338018) supplemented with 0.5 % Pen/Strep (PAN Biotech, # P06-07100). 
For purification of soluble gp140 variants, 300 ml of HEK293-F suspension cells were 
grown to a cell concentration of 1 Mio/ml on the day of transfection. Before transfection, 
the 3x10
8
 cells were harvested at 100 g, 5 min and 4 °C and resuspended in 300 ml 
FreeStyle™ expression medium without supplements. 300 µg of Env gp140 containing 
plasmid DNA were mixed with 6.5 ml DMEM (Gibco/Thermo Fisher Scientific, # 11995-
065) without supplements. For expression of SOSIP gp140 variants, 225 µg of Env SOSIP 
gp140 plasmid DNA and 75 µg of pcDNA3.1-furin were mixed. Simultaneously, 1.5 ml 
PEI (Polyethylenimine, linear, Polysciences, # 23966-2, 1 mg/ml) were diluted with 6.5 ml 
DMEM without supplements. Both mixtures were incubated separately for 5 min at RT 
and then mixed to be incubated for further 20 min at RT before the transfection mixture 
was added to the cells. After 6 h of incubation, the medium was changed to 300 ml of 
FreeStyle™ 293 expression medium supplemented with 0.5 % Pen/Strep. For higher 
protein yield, this procedure was scaled up using 3x 300 ml 293-F suspension cells. On day 
5 after transfection, cells were harvested at 1000 g for 5 min at 4 °C and secreted gp140 
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variants were purified from the supernatant. To this end, the supernatant was filtered with a 
0.22 µm filter (Sarstedt, Filtropur L 0.2 LS, # 83.1827.001) and loaded onto a 5 ml lectin 
affinity chromatography column (Galanthus nivalis (Snowdrop) lectin, Agarose bound, 
Biozol, # VEC-AL 1243-5) at 4 °C overnight with a maximal flow rate of 1 ml/min. 
Unbound protein was washed out with 3 column volumes (CV) PBS/ 2 mM EDTA/ 2 mM 
EGTA. Then, the envelope protein was eluted with PBS/ 2 mM EDTA/ 2 mM EGTA/ 1 M 
α-D-mannopyranoside (Merck Millipore, # 462711-100GM). Protein containing fractions 
were pooled, concentrated to a volume of 0.8 to 1 ml (Merck Millipore, Amicon Ultra 15 
ml, 100K, # UFC910096) and Env was purified to trimer size homogeneity using a HiPrep 
16/60 Sephacryl S-300 HR size exclusion chromatography (SEC) column (GE Healthcare, 
# GE17-1167-01) in PBS. Trimer containing fractions were pooled and concentrated 
(Merck Millipore, Amicon Ultra 4 ml, 30K, # UFC803024). Purity of Env trimers was 
analyzed by Blue Native PAGE (Serva, # 43204.01) and subsequent Coomassie staining. 
Protein aliquots were frozen in liquid nitrogen and stored at -80 °C.  
 
Coomassie Brilliant Blue R-250 AppliChem (# A1092) 
Coomassie staining solution 1.25 % (w/v) Coomassie Brilliant Blue R-250, 
50 % (v/v) ethanol, 7 % (v/v) acetic acid 
 
 
 
3.4.3. Chemical cross-linking of gp140 trimers 
Cross-linking procedures used in this thesis were guided by published protocols.
78,79,50
 For 
glutaraldehyde cross-linking (GLA, Sigma Aldrich, glutaraldehyde solution, 25 % in H2O, 
# G5882), GLA and envelope trimers were  diluted in PBS, mixed at ratios of 100, 1000, 
2000, 3000, 4000, 5000 or 6000 mol GLA per mol envelope and incubated for 5 min at 
RT. To stop the reaction, 1 M Tris/HCl pH 7.4 was added to a final concentration of 75 
mM, followed by 5 min incubation at RT. For EDC/NHS cross-linking ([(1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride/N-hydroxysuccinimide]), Sigma 
Aldrich, # 03449-5G and Thermo Fisher Scientific, # 24500), EDC and NHS were mixed 
at a molar ratio of 100 to 1 in MES (2-(N-morpholino)ethanesulfonic acid) buffered saline, 
pH 6.0. Subsequently, EDC/NHS and envelope were mixed at ratios of 35 000, 100 000, 
160 000, 400 000 or 800 000 mol EDC per mol Env. Notably, the EDC/NHS mixture and 
envelope diluted in PBS were mixed using equal volumes. After incubation for 30 min at 
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RT, the reaction was stopped by adding a volume of 1 M glycine pH 7.4 equal to the 
volume of the total cross-linking reaction for 10 min at RT. Control gp140 envelopes for 
both cross-linking reactions received the same treatment without addition of cross-linking 
reagents. Success of cross-linking reactions was determined with reducing SDS-PAGE 
(5% separation gel, 5% stacking gel) as well as direct and capture ELISA immediately 
after cross-linking. If cross-linked envelopes were not instantly analyzed, buffer exchange 
to PBS was performed using Amicon Ultra 0.5 columns (Sigma Aldrich, # Z740174-
96EA). To this end, the cross-linking reaction was diluted with approximately 450 µl PBS 
and centrifuged at 4000 g and 4 °C until the initial sample volume was reached. This 
procedure was conducted three times. 
 
EDC stock solution 4 M N-(3-Dimethylaminopropyl-)-N’-ethylcarbodiimide hydrochloride  
(Sigma Aldrich, # 03449-5G) in MES buffered saline 
NHS stock solution 5 M N-Hydroxysuccinimide 
(ThermoFisher Scientific, # 24500) in MES buffered saline  
 MES buffered saline 50 mM MES monohydrate, 150 mM NaCl), pH 6.0 
 
 
 
3.4.4. SDS-PAGE and silver staining after cross-linking 
Cross-linked envelope trimers were analyzed via SDS-PAGE with a 5 % stacking gel and  
5 % separation gel. To this end, the protein samples were mixed with 5x Laemmli buffer, 
incubated for 5 min at 95 °C and shortly centrifuged (1 min, 5000 g). Electrophoresis was 
performed at 70 V for 20 min, followed by 90 V until the tracking dye reached the bottom 
of the gel. 
Gels were subsequently silver-stained. Each step of this procedure was carried out using 25 
ml of the respective solution at RT on an orbital shaker. First, fixing solution was applied 
for at least one hour (or overnight), followed by one wash step each with 50 % ethanol and 
30 % ethanol for 10 min. Subsequently, the gel was incubated in sodium-thiosulfate (0.2 
g/l) for 1 minute, followed by three wash steps for 20 seconds in H2O. To stain the 
proteins, staining solution was added for 20 min, followed by two wash steps with H2O for 
20 sec. Next, the gel was incubated with developing solution until the protein bands were 
well visible or to a maximum of 10 min. Then, stop solution was added for 5 min. Until 
documentation, developed gels were stored in H2O. 
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5x Laemmli buffer 312.5 mM Tris, 5 % SDS (20 %), 25 % β-
mercaptoethanol, 25 % glycerol (87%), 2.5 mM 
EDTA (0.5 M, pH 8.0), pH 6.8 (HCl) 
PageRuler
TM
 Plus Prestained Protein Ladder Thermo Fisher Scientific (# 26620) 
Fixing Solution 50 % (v/v) methanol, 12 % (v/v) acetic acid, 50 µl 
pro 100 ml formaldehyde 
Staining solution (100 ml) 0.1 % (w/w) AgNO3, 75 µl 37 % formaldehyde 
Developing solution (100 ml) 6 % (w/w) Na2CO3, 50 µl 37 % formaldehyde, 200 
µl 0.2 g/l sodium thiosulfate 
Stop solution  5 % (v/v) acetic acid 
 
 
 
3.4.5. ELISA 
ELISA plates (Nunc Maxisorp, # 442404) were coated with 200 µl of 1 µg/ml Galanthus 
nivalis lectin (Sigma, # L8275-5MG) in PBS overnight at 4 °C. All wash cycles were 
conducted with PBS/ 0.05 % Tween20 using a Tecan HydroFlex (HydroControl-Software 
Version 1.0.1.0). After coating, plates were washed three times and blocked for 2 h at RT 
with 200 µl 5 % (w/v) skimmed milk powder/ 5 % (v/v) heat inactivated FCS (Gibco)/ 0.1 
% Tween20. After three further wash cycles, 50 µl of gp140 Env variants at a 
concentration of 1 µg/ml in PBS were added for 1 h at RT, followed by six wash cycles. 
Subsequently, 50 µl of single concentrations or a dilution series of human monoclonal 
envelope antibodies in PBS/ 1 % BSA (w/v) were added for 1 h at RT to reach equilibrium 
binding. 5F3, which recognizes a linear epitope in gp41
46
 and should therefore recognize 
all variants alike, was used to monitor equal Env amounts for each variant on each plate. 
Unbound antibody was washed away with 10 wash cycles and bound antibody was labeled 
with 50 µl of horseradish peroxidase-coupled rabbit anti-human IgG (Agilent, Dako # 
P021402-2, 1:5000 in PBS/ 1 % BSA) for 30 min at RT, followed by 10 wash cycles and 
incubation with TMB substrate (TMB A: TMB B 20:1, composition see table below). The 
reaction was stopped with 25 µl 1 M H2SO4 and optical density at 450 nm (OD450) was 
analyzed in triplicates on a microplate reader.  
As sCD4 caused unspecific signals with lectin coated plates, 70 µl of gp140 envelope at a 
concentration of 3 µg/ml in PBS were directly immobilized on the Maxisorp plates at 4 °C 
overnight for all sCD4 ELISAs. After three wash cycles, plates were blocked for 2 h at RT 
as described above. After three additional wash cycles, 50 µl of sCD4 (Progenics, 
Tarrytown; NY, USA, 1 µg/ml) in PBS + 1 % BSA were added and incubated for 1 h at 
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RT, followed by six wash cycles. Next, 50 µl of a 1:2500 dilution of α-human CD4 
antibody (Biolegend, OKT4, # 317402) in PBS + 1 % BSA were added for 1 h at RT, 
followed by six wash cycles and subsequent incubation with 50 µl of rabbit α-mouse IgG-
HRP (Dako, # P016102-2 , 1:1000 in PBS + 1 % BSA) for 30 min at RT. After six wash 
steps, incubation with TMB substrate and all following steps were conducted as described 
above. Capture ELISAs for analysis of cross-linking reactions were conducted as described 
for the lectin capture ELISA above, but with 2 µg/ml envelope instead of 1 µg/ml. For 
direct ELISAs after cross-linking, 2 µg/ml envelope dilution in PBS were directly coated 
onto the Maxisorp plates overnight at 4 °C or at least 2 h at RT. After three wash cycles, 
blocking and all subsequent steps were conducted as described above.  
All curves were corrected by subtracting both the negative control signals obtained without 
envelope gp140 addition and without primary antibody and fitted using non-linear least 
squares regression (hyperbolar one site binding), GraphPad Prism 5.0 or 6.0). Area under 
the curve (AUC) values were also calculated in GraphPad Prism 6.0. 
 
Wash program Extraction of fluids 
Dispension of wash buffer (PBS/ 0.05 % Tween20, 300 µl/s) 
Wash cycles: 400 µl/s 
3 wash cycles: 1 ml wash buffer 
6 wash cycles: 2 ml wash buffer 
10 wash cycles: 3 ml wash buffer 
Extraction of fluids 
TMB A 30 mM potassium citrate, pH 4.2  
TMB B 10 mM tetramethylbenzidine (Roth 6350.2), 10 % (v/v) acetone, 90 % (v/v) 
ethanol, 80 mM H2O2 
 
 
 
3.4.6. Antibodies 
Human monoclonal antibodies HGN194 and HJ16 were kindly provided by Prof. Dr. 
Antonio Lanzavecchia and Dr. Davide Corti, Institute for Research in Biomedicine, 
Bellinzona, Switzerland. Antibodies PG9, 2G12, 4E10, 5F3 and 447-52D were purchased 
from Polymun Scientific, Klosterneuburg, Austria. VRC01, F105, PGT145, PGT151 and 
10E8 were purified in house. To this end, 300 ml FreeStyle
TM
 293-F cells (Thermo Fisher 
Scientific, # R79007) were cultivated to a concentration of 1 Mio/ml. Directly before 
transfection, cells were centrifuged at 100 g for 5 min and resuspended in FreeStyle 
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expression medium (Thermo Fisher Scientific, # 12338018) without supplements. 6.5 ml 
DMEM medium without supplements were mixed with 300 µg plasmid DNA (150 µg light 
chain containing plasmid + 150 µg heavy chain containing plasmid). Additionally, another 
6.5 ml DMEM without supplements were mixed with 1.5 ml PEI (Polyethylenimine, 
linear, Polysciences, # 23966-2, 1 mg/ml). After 5 min at RT, the two mixtures were 
combined and further incubated for 20 min at RT. Subsequently, the transfection mixture 
was given onto the cells. The cells were incubated at 37 °C, 8 % CO2 and 90 rpm for six 
hours. Then, the medium was replaced with FreeStyle medium supplemented with 0.5 % 
Pen/Strep. 5 days post transfection, cells were harvested at 1000 g and 4 °C for 10 min. 
The supernatant was loaded onto a Protein A column (0.3 g Protein A sepharose (Sigma 
Aldrich, # P3391-1.5G) quelled with 5 ml buffer A (0.02 M NaH2PO4, 0.15 M NaCl, pH 
8.0) for 30 min. Three column volumes of buffer A were used to wash out unbound 
protein, then the elution of IgG was carried out with 4 ml 100 mM glycine, pH 2.5. Eluted 
antibody was neutralized with stepwise addition of 1 M Tris/HCl, pH 8.0 until a pH of 6 to 
8 was reached. For antibodies with pI values near 7, e.g. PGT145, neutralization was 
stopped at pH 6.0 to avoid antibody aggregation. Subsequently, antibodies were dialyzed 
against PBS (Thermo Fisher Scientific, Slide-A Lyzer dialysis cassettes 3.5K MWCO, # 
66330). In the case of PGT145, the pH of PBS was adjusted from 7.4 to 6.0 to avoid 
antibody aggregation. Antibody concentration was determined using a NanoDrop 1000 
(Thermo Scientific) and, if necessary, IgGs were concentrated using Amicon Ultra 
concentrators (Merck Millipore, 30 kD MWCO, # UFC903024). Antibody purity was 
analyzed by SDS-PAGE. All other antibodies were provided by the NIH Aids Reagents 
Program or IAVI (International AIDS Vaccine Initiative). sCD4 was provided by 
Progenics (Tarrytown, NY, USA) as indicated by the NIH AIDS reagents program.
100
  
For FACS analysis, screening antibodies were labeled with Alexa Fluor 647 dye (Thermo 
Fisher Scientific, Protein labeling kits, # A-20173), while reference antibody 5F3 was 
labeled with R-Phycoerythrin (R-PE, Innova Biosciences, Lightning-Link® R-
Phycoerythrin Conjugation Kit, # 703-0015). Soluble CD4 (Progenics, Tarrytown, NY, 
USA) was detected using a secondary APC-labeled anti-human CD4 antibody (anti-human 
CD4 APC, OKT4, eBiosciences, # 17-0048-42, 1:100).  
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3.4.7. Differential scanning calorimetry (DSC) of soluble Env 
trimers 
Env trimers were dialyzed three trimes against PBS at 4 °C. Subsequently, dialyzed trimers 
as well as the final dialysis buffer were vented. Carefully avoiding the insertion of air into 
the sample, Env sample volumes were adjusted to 1 ml and a final concentration of 0.75 to 
1.5 µM using degassed dialysis buffer. The protein sample was then applied to the cell of a 
Microcal VP Differential Scanning Calorimeter, while the vented dialysis buffer was 
applied to the reference cell. Thermal denaturation was performed at 1 °C/min from 20 to 
95 °C and melting temperatures were calculated after normalization and baseline 
correction of the acquired data. 
 
 
 
3.4.8. Nano differential scanning fluorimetry (nanoDSF) of soluble 
Env trimers 
NanoDSF measurements were performed in cooperation with 2bind, Regensburg, 
Germany using a Prometheus NT.48 (NanoTemper). Briefly, 10 µl of gp140 trimers 
diluted to a concentration of 0.05 mg/ml in PBS were applied to Prometheus NT.48 series 
nanoDSF grade standard capillaries (NanoTemper) and measured with a temperature 
ingredient of 1 °C/min between 21 °C and 95 °C. A PBS negative control was used to 
exclude fluorescent signals caused by buffer components. 
 
 
 
3.4.9. Surface plasmon resonance (SPR) of soluble Env trimers 
SPR analysis for the comparison of labeled and unlabeled VRC01 and PG9 was carried out 
by the CAVD Central Service Facility at Duke University, Durham, USA. Briefly, the 
binding of 96ZM651 gp140 to Alexa Fluor 647-conjugated or unconjugated antibody of 
interest was measured on a Biacore 3000 (BIAcore/GE Healthcare). 96ZM651 gp140 was 
immobilized on a CM5 chip using standard amine coupling chemistry and serial dilutions 
of antibodies were injected. Alternatively, antibodies were captured with anti-human IgG 
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Fc antibody on a CM5 chip and a dilution series of 96ZM651 gp140 was used as soluble 
analyte. After each binding cycle, surfaces were regenerated with a 12 sec injection of 10 
mM phosphoric acid (H3PO4). All measurements were carried out in triplicates. Data 
analyses were performed with BIAevaluation 4.1 software (BIAcore/GE Healthcare) and 
non-specific binding of antibodies to a negative control IgG surface was subtracted from 
each curve.  
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4. Results 
 
4.1. Analysis of a mammalian cell display-based panning 
system for the high-throughput discovery of new 
AIDS vaccine candidates 
Protection against SHIV infection after passive immunization of macaques with 
bnAbs
101,63,62
 offered an important starting point for the development of an efficient HIV 
vaccine. Recent years have brought significant progress in envelope immunogen design 
(see 1.5.3). However, Env`s high variability,
18,26,27
 extensive glycosylation,
29,102
 
conformational masking of target sites
30,31
 and conformational instability
18,22
 all represent 
effective immune escape strategies which hinder an efficient humoral immune response 
(see 1.3.3). Thus, the elicitation of broadly neutralizing antibodies by active immunization 
is still a major obstacle in HIV vaccine design. This emphasizes the need for innovative 
screening systems able to identify new Env vaccine candidates according to their antigenic 
profiles. Prior to this thesis, a mammalian cell display and flow cytometry-based panning 
procedure was developed by Dr. Tim-Henrik Bruun (Bruun and Grassmann et al., in 
revision), which enables the selection of Env variants with modulated antibody affinity. 
Here, this system was further characterized using an already established five-member 
chimeric Env model library
96
 and human monoclonal antibodies (mAbs) HGN194
44
 and 
447-52D
103
. Analysis of enrichment rates was extended from qPCR and capillary 
sequencing of single clones to also include next generation sequencing (NGS) for the 
screening of larger envelope libraries. 
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4.1.1. Overview of the mammalian cell display-based panning 
system 
The mammalian cell display and panning procedure comprises six different steps. It starts 
with the generation of stable cell lines with single integrations of one given Env variant per 
cell at a defined locus (linked cellular Env library, Figure 11). To this end, FlpIn
TM
 T-
REx
TM
 293 cells are transfected with an Env library cloned into the plasmid vector pQL13 
(Appendix Table 2 and Figure 13A), which supports the integration of a single copy Env 
gene into the predefined Flp Recombination Target (FRT) site of a FlpIn cell (Figure 11, 
step 1). Stable integration of pQL13 into the FRT site results in the acquisition of a 
hygromycin resistance (Figure 13A). Hence, after about 25 days of antibiotic selection, 
each of the resulting cells represents one Env variant, leading to the genotype-phenotype 
linked cellular Env library (Figure 11, step 2). Notably, Env expression is under regulation 
of the Tat operator/repressor system and thus inducible. After induction with doxycycline, 
Env expressing cells are stained with an antibody of interest (screening antibody, Figure 
11, step 3) and variants can be selected by flow cytometry-based cell sorting according to 
their antibody binding profile (e.g. high affinity to a bnAb or low affinity to a non-
neutralizing antibody) (Figure 11, step 4). To determine the genotypes of the selected Env 
variants, the genomic DNA of sorted cells and input controls is isolated and the contained 
Env genes are amplified by nested-PCR (Figure 11, step 5). After cloning into pQL13 and 
further propagation in E. coli (Figure 11, step 6), plasmid DNA of both the input controls 
and the output samples can be used to monitor the enrichment status of the different Env 
variants via qPCR, capillary sequencing of single clones or, in the case of larger libraries, 
next generation sequencing. Alternatively, genomic DNA of cells isolated prior to and after 
FACS-sorting can also be directly subjected to NGS, facilitating analyses of larger 
libraries. If necessary, selected cells can also be re-expanded for another round of panning 
to increase enrichment rates with each cycle (not shown in Figure 11). The different steps 
of this procedure are described in more detail in the following sections. 
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Figure 11: Schematic overview of the FACS panning procedure. Stable cell lines are generated by a 
targeted transfection of FlpIn
TM
 T-REx
TM
 293 cells with pQL13 based Env constructs and the helper plasmid 
pOG44 carrying the integrase (1). Since FlpIn
TM
 T-REx
TM
 293 cells possess precisely one FRT site, a linkage 
between geno- and phenotype is achieved. Successful integration into the FRT site leads to the acquisition of 
a hygromycin resistance, allowing antibiotic selection of the stable cell lines (2). After induction of Env 
expression, the cellular library is stained with the screening antibody (3) and subsequently, envelopes with 
the desired phenotype regarding antibody binding are selected via flow cytometry-based cell sorting (4). The 
genomic DNA of selected cells and input controls is then recovered and Env genes contained within are 
amplified by nested-PCR (5). Amplified envelope genes are cloned back into pQL13 and analyzed by qPCR, 
Sanger sequencing of single clones or next generation sequencing (6). Alternatively, gDNA recovered from 
the input sample and the sorted cells can directly be subjected to NGS to facilitate enrichment rate analysis 
for larger libraries. To enhance enrichment rates, a portion of the sorted cells can be re-expanded for another 
panning cycle (indicated by the broken line). 
 
 
 
4.1.2. Generation of single-integration stable cell lines using a 
pQL13 based chimeric Env/V3 model library 
The data referred to in paragraph 4.1.2 were generated by Dr. Tim-Henrik Bruun prior to 
this thesis, but are shown to better illustrate the panning procedure. Five chimeric gp145 
Env variants were constructed based on a clade C 96ZM651 gp145 backbone. The V3 loop 
of this scaffold was seamlessly substituted with V3 regions of isolates MN, RF, CDC42, 
HXB2 or SF33 (Figure 12), which were known to exhibit distinguishable affinities 
towards the V3-targeting mAb 447-52D.
96,103 
Using the "golden gate" cloning procedure,
96
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the model library was then cloned into pQL13. The toxic CcdB cassette in the MCS of the 
pQL13 target vector thereby allows for an efficient selection of envelope positive clones to 
facilitate the library assembly in E. coli. 
 
 
 
 
 
 
The pQL13-Env/V3 model library was used to generate stable cell lines by targeted 
transfection of FlpIn
TM
 T-REx
TM
 293 cells with the helper plasmid pOG44 carrying the 
integrase and (i) an equimolar mixture of all five Env/V3 chimeras (cell library) or (ii) 
each Env/V3 chimera individually. While the cell library was applied in all panning 
experiments, the individual cell lines were used to characterize the antigenic profile of each 
chimera. All stable cell lines displayed several unique features:  
(i) Single integration of one Env variant per cell. Integration of pQL13 into the 
predefined FRT site at a specific locus (Figure 13A) ensured the presence of only one Env 
variant per cell, efficiently linking genotype and phenotype within the library. The 
integration of a single pQL13 copy per cell for all scenarios tested was shown with a 
TaqMan
®
 copy number assay probing for eGFP in relation to the human telomerase 
reverse transcriptase (TERT) genes (Figure 13B).  
(ii) Antibiotic selection. Cells with a successful integration event could be selected via a 
hygromycin resistance, which is acquired and constitutively expressed only after 
recombination into the FRT site, when the hygromycin gene lacking an ATG comes into 
contact with a start codon (Figure 13A, ca. 25 days of selection necessary).  
(iii) Translational coupling of eGFP and Env expression. Translational coupling of 
eGFP and Env by a "self-cleaving" TaV 2A peptide
96,104
 (Figure 13A) enabled 
normalization for Env expression according to eGFP fluorescence (MFI). The insect virus-
derived (Thosea asigna virus) 2A peptide impairs peptide bond formation by a ribosomal 
Figure 12: Schematic representation of 
the chimeric Env/V3 model library 
used in the panning approach. V3 of 
the common clade C 96ZM651 gp145 
scaffold was seamlessly substituted with 
the V3 regions of isolates MN, RF, 
CDC42, HXB2 or SF33, resulting in five 
chimeric variants. See Figure 4 for all 
other abbreviations in this schematic. 
 
Results 
44 
 
skip mechanism between the 2A glycine and the 2B proline of the consensus sequence 
2A,Asp-Val/Ile-Glu-X-Asn-Pro-Gly; 2B,Pro.
 
This should result in an equal expression 
level for eGFP and Env, while only one residue is N-terminally attached to the envelope 
protein. To investigate the correlated expression of eGFP and Env, doxycycline-induced 
cells were stained with mAb 5F3,
105
 which recognizes a linear epitope in the extracellular 
domain of gp41 present in all five Env/V3 variants. A correlation between eGFP and Env 
expression was observed for each chimera (Figure 13C), verifying eGFP as an indirect 
marker to normalize for Env expression. Notably, expression rates of the variants differed 
(with Env/V3-MN displaying the weakest signals), highlighting the importance of 
expression normalization. 
(iv) Inducible Env expression. Finally, the stable integration of the Tet repressor in the 
FlpIn
TM
 T-REx
TM
 cells in combination with the doxycycline-inducible CMV promotor of 
pQL13 results in the regulated expression (T-REx) of the integrated Env gene (Figure 
13A), allowing cultivation of the stable cell lines without negative effects potentially 
caused by Env cytotoxicity. Notably, the T-REx system only utilizes regulatory elements 
from the native Tet operon,
106
 avoiding the potentially toxic effects of viral transactivation 
domains utilized for other doxycycline-regulated systems.
107
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Figure 13: Characteristics of the 
pQL13-based stable cell lines. Stable 
cell lines were generated using separate 
transfection of each pQL13-Env/V3 
chimera or an equimolar mixture of all 
five Env/V3 variants (cell library). A: 
Schematic overview of the pQL13 vector 
system before and after stable integration 
into FlpIn
TM
 T-REx
TM
 293 cells. In 
pQL13, Env expression is genetically 
linked to eGFP expression by a TaV 2A 
peptide (TaVp2A). The eGFP/Env 
expression cassette is integrated into a 
distinct Flp Recombination Target (FRT) 
site in the FlpIn
TM
 T-REx
TM
 293 cells, 
bringing the hygromycin gene in contact 
with a start codon and hence resulting in 
the acquisition of a hygromycin (Hyg) 
resistance for selection of stable cell 
lines. Expression of eGFP and Env is 
under inducible regulation of the Tet 
operator/repressor (TO/TR, T-REx
TM
). 
Note that pQL13 is a circular plasmid 
which is here represented by its 
horizontal vector map and that the 
symbols for the FRT site (52 bp) and the 
TO  (9  bp)  are  not  in  scale.  B: Single 
integration  of  one  pQL13  per  genome could be verified using a TaqMan copy 
number assay on four individual samples of gDNA for each cell line and probing 
for eGFP in relation to the human telomerase reverse transcriptase (TERT) 
(differences between the six stable cell lines statistically n.s., p>0.05). C: 3x10
5
 
doxycycline-induced cells of each individual stable cell line were stained with 
mAb 5F3, which binds a constant region shared by all variants (n=2). 2.5x10
4
 
cells were recorded per sample and the correlation between APC and GFP signal 
intensities was analyzed for each stable cell line (3000 events shown). 
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4.1.3. The Env/V3 model library exhibits distinct binding profiles to 
the monoclonal antibodies 447-52D and HGN194 
Using the individual stable cell line of each Env/V3 chimera, the binding profiles of V3-
targeting mAbs 447-52D and HGN194 to each variant were determined by FACS 
equilibrium titration (Figure 14B and D). Env/V3-MN proofed to have the highest affinity 
towards 447-52D and HGN194, followed by chimeras –HXB2 and –CDC42. Whereas 
HGN194 did bind neither Env/V3-RF, nor -SF33, 447-52D could still bind Env/V3-RF to 
some extent. For these non- or only weakly binding variants, KD values could not be 
calculated. For all other variants, KD values are summarized in Table 2. Figure 14A and C 
show the distinct binding of 447-52D and HGN194 to the five chimeras at the respective 
antibody concentration used in the panning procedure.  In conclusion, the demonstrated 
distributions of affinities were considered feasible for the purpose of evaluating the stable 
cell line-based panning procedure. 
 
 
 
 
Figure 14: Affinity analysis of the individual Env/V3 gp145 chimeras to 447-52D and HGN194. Induced 
stable cell lines were equilibrium stained with mAbs 447-52D or HGN194 (n=3). Relative MFI values of 
antibody binding in relation to GFP were calculated to normalize for Env expression levels. A and C: Cells 
were stained with 2.7 nM 447-52D (A) or 6.7 nM HGN194 (C) as used in all FACS-sorting experiments. B 
and D: Serial dilutions of 447-52D (B) or HGN194 (D) were applied to obtain a concentration-dependent 
binding profile and calculate KD values (Table 2) (n=3). Chimera Env/V3-MN depicted the highest affinity to 
447-52D and HGN194, followed by -CDC42 and -HXB2. 447-52D still showed weak binding to chimera 
Env/V3-RF but did not recognize -SF33. HGN194 did bind neither -RF nor -SF33. 
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4.1.4. Single-round FACS panning of the Env/V3 cell library leads 
to selective isolation of high or low affinity variants  
The cell library generated with an equimolar mixture of all five Env/V3 chimeras was 
subjected to flow cytometry-based cell sorting using approximately 3x10
7
 cells per sort. 
Triangular gates were chosen to sort cells with the highest (P5) or lowest (P7) 447-52D or 
HGN194 signal in relation to GFP, thus selecting cells with the highest or lowest antibody 
affinity relative to Env expression (Figure 15).  
 
 
 
Figure 15: Gating strategy of the panning procedure. A typical sorting experiment is shown (50,000 
events recorded). Living, single cells were gated according to common hierarchical gating strategies (gates 
P1-4, not shown). Cells split up into uninduced cells (low GFP/ low APC) and induced cells with a higher 
GFP signal. The latter can be further divided into cells with high APC signals (high affinity antibody 
binding) and cells with low APC signals (low affinity antibody binding). Induced cells were gated for highest 
(P5) or lowest (P7) APC signals (447-52D or HGN194) in relation to GFP (expression control), resulting in 
triangular gates. P6 represents a gate for the sorting of medium affinity binders between P5 and P7 (not 
shown). P5 was set to contain 600 – 800 of the 50,000 recorded cells, while P7 was chosen to contain 
approximately half of the induced population with low APC signal intensity. 
 
 
 
The genomic DNA from an input sample and the sorted cells (~30,000 cells/sorting gate) 
was recovered and Env genes were amplified by nested-PCR and cloned back into pQL13. 
The distribution of Env/V3 variants in the input control and after one cycle of panning was 
monitored by qPCR, capillary sequencing of single clones and NGS using the pQL13 
plasmid DNA recovered from E. coli. In addition, NGS was performed directly on the 
gDNA to provide a facilitated analysis approach for larger libraries (Figure 16). 
In the case of 447-52D, a statistically significant enrichment of high affinity Env/V3 
variant -MN out of an equal distribution of all variants was demonstrated for each analysis 
Results 
48 
 
approach (Figure 16A). Thereby, enrichment rates of up to 56-fold could be achieved after 
only a single round of panning (calculation Table 1). Gate P7 selectively enriched low 
affinity variant Env/V3-SF33 (Figure 16A), with enrichment factors of up to 237-fold 
(Table 1). Hence, this panning technology can similarly be used to isolate Env variants 
with particularly low binding to unwanted antibodies, e.g. non-neutralizing mAbs targeting 
the CD4-induced Env conformation. In summary, the MFIs measured at a distinct 447-52D 
antibody concentration (Figure 14A) as well as binding affinities of the individual Env/V3 
chimeras (Figure 14B, Table 2) correlated with the copy number (qPCR) or number of 
sequences (Sanger sequencing, NGS) quantified after the single-round FACS panning 
process. These findings could also be confirmed with the independent HIV-1 Env V3-
specific monoclonal antibody HGN194 (Figure 16B). Here, high affinity variant -MN 
could be enriched up to 55-fold fold after one round of panning (Table 1). Similarly, as 
chimeras Env/V3-RF and -SF33 both did not show binding to HGN194 (Figure 14C and 
D, Table 2), low signal gate P7 selectively enriched those two variants with enrichment 
factors of up to 4-fold for chimera -RF and up to 5-fold for chimera -SF33 (Figure 16B, 
Table 1).  
Notably, results from the already established Sanger sequencing and qPCR analyses were 
conform with the newly established NGS approach using the Illumina Miseq platform on 
both the re-cloned plasmid DNA as well as directly on the genomic DNA. While NGS will 
enable the panning of very large libraries, the direct analysis of recovered gDNA will 
additionally avoid the difficulties originating from re-cloning a high number of different 
variants. Variations in enrichment factors between the different analyses (Table 1) may be 
caused by diverging inherent properties of the different methods and the sensitivity of the 
applied formula, which considers both the enriched chimeras as well as the depletion of all 
other variants. As NGS supplies a very high sequence coverage for the here applied five-
member model library, these findings might be the most accurate.  
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Figure 16: Single-round FACS panning using the Env/V3 cell library. 24h after doxycycline induction, the stable cell line containing the complete Env/V3 model library 
(cell library) was used in the FACS panning procedure with A: 2.7 nM 447-52D or B: 6.7 nM HGN194 (n=3). Envelope genes selected after one panning cycle as well as 
from the input control were amplified from the genomic DNA, cloned back into pQL13 and plasmid DNA recovered from E. coli was analyzed by qPCR, Sanger sequencing 
of single clones and next generation sequencing using the Illumina MiSeq platform. In addition, NGS was performed directly on the genomic DNA. Relative amounts per 
variant in the input mixture and after the 1
st 
round of panning are shown in %. Statistically significant enrichment of the high affinity variant Env/V3-MN was achieved for 
both 447-52D and HGN194 (P5). Similarly, gate P7 led to selective enrichment of the low affinity variants (Env/V3-SF33 for 447-52D and both Env/V3-RF and -SF33 for 
HGN194). Statistics were calculated using an unpaired t-test in GraphPad Prism 5. *=p<0.05, **=p<0.01 and *** p < 0.001.  
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Table 1: Enrichment rates of Env/V3 chimeras selected from the FACS-sorting procedure after one 
round of panning.  
  
Fold enrichment
a
 in 
high affinity gate P5 
Fold enrichment
a
 in low affinity gate P7 
  
MN RF SF33 
447-52D 
qPCR (pDNA) 56 No enrichment 237 
Sanger (pDNA) 43 No enrichment 68 
NGS (pDNA) 23 No enrichment 41 
NGS (gDNA) 11 No enrichment 10 
HGN194 
qPCR (pDNA) 55 4 5 
Sanger (pDNA) 14 2 4 
NGS (pDNA) 16 3 4 
NGS (gDNA) 9 3 4 
a)
 calculations were made according to the formula from 
108
 
( 
𝑀𝑁 #1
𝑀𝑁 #0
 / 
𝑁𝑜𝑛−𝑀 𝑁 #1
𝑁𝑜𝑛−𝑀𝑁 #0
 , 
𝑅𝐹 #1
𝑅𝐹 #0
 / 
𝑁𝑜𝑛−𝑅𝐹 #1
𝑁𝑜𝑛−𝑅𝐹 #0
  or  
𝑆𝐹33 #1
𝑆𝐹33 #0
 /  
𝑁𝑜𝑛−𝑆𝐹33 #1 
𝑁𝑜𝑛−𝑆𝐹33 #0
) 
 
 
 
 
4.1.5. Soluble gp140 Env/V3 chimeras display a similar binding 
pattern to 447-52D and HGN194 as membrane-bound 
variants. 
The five soluble Env/V3 gp140 chimeras were purified to trimer homogeneity and 
affinities towards 447-52D and HGN194 were analyzed by ELISA equilibrium titration 
(Figure 17). This resulted in very similar binding patterns compared to the gp145 Env-
displaying cell lines (Figure 14) and dissociation constants (KD) were found to be in the 
same order (Table 2), with Env/V3-MN displaying the highest affinity, followed by           
-CDC42 and -HXB2. Also in agreement with the membrane-bound variants, 447-52D still 
showed weak binding to Env/V3-RF, while HGN194 did neither bind Env/V3-RF nor        
-SF33. For those low affinity binders, KD values were not calculable. 
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Figure 17: ELISA titration of soluble gp140 Env/V3 chimeras. Trimeric gp140 envelopes were purified 
and equilibrium titrated with 447-52D or HGN194 via ELISA (n=3, one biological replicate exemplary 
shown). The soluble trimers depicted the same 447-52D and HGN194 binding patterns as membrane-bound 
gp145 variants (Figure 14). 
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Table 2: Dissociation constants (KD) of membrane-bound gp145 chimeras obtained by FACS equilibrium titration and soluble gp140 chimeras obtained by ELISA 
equilibrium titration. N=3. R
2
 values of the respective fits (hyperbolar one site binding, GraphPad Prism 5.0) are included in brackets. Due to low antibody binding, KD 
values of Env/V3-SF33 to both 447-52D and HGN194 and of Env/V3-RF to HGN194 were not calculable. KD values of V3 peptides to 447-52D, which served as a selection 
criteria for the different V3 loops, are taken from 
103
. Membrane-bound and soluble Env/V3 chimeras of the model library displayed the same affinity ranking. 
 447-52D HGN194 
Env/V3 
chimera 
KD [nM] of  
V3 peptides 
KD [nM] of membrane-
bound gp145 (flow 
cytometry titration, 
n=3) 
KD [nM] of soluble 
gp140 (ELISA titration, 
n=3) 
KD [nM] of membrane-
bound gp145 (flow 
cytometry titration, 
n=3) 
KD [nM] of soluble 
gp140 (ELISA titration, 
n=3) 
MN 0.6 0.9 ± 0.1 (R
2
=0.990) 0.4 ± 0.02 (R
2
=0.995) 0.6 ± 0.04 (R
2
=0.981) 0.2 ± 0.05 (R
2
=0.926) 
RF 0.9 7 ± 1 (R
2
=0.972) 74 ± 7 (R
2
=0.992) NA NA 
CDC42 5 3 ± 0.2 (R
2
=0.996) 1 ± 0.4 (R
2
=0.983) 1 ± 0.2 (R
2
=0.973) 0.6 ± 0.2 (R
2
=0.797) 
HXB2 24 2 ± 0.2 (R
2
=0.991) 0.5 ± 0.002 (R
2
=0.983) 2 ± 0.09 (R
2
=0.951) 7 ± 5 (R
2
=0.537) 
SF33 NA NA NA NA NA 
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4.1.6. Summary 
In sum, the FACS panning procedure was able to enrich high and low affinity binders from 
a cell surface-displayed envelope library, as expemplified with the five-member model 
library and mAbs 447-52D and HGN194. Analysis of the membrane-bound and soluble 
Env/V3 variants demonstrated a clear correlation between (i) the MFIs measured at a 
distinct 447-52D or HGN194 antibody concentration for the individual Env/V3 chimeras 
(Figure 14A and C), (ii) their binding affinities to 447-52D or HGN194 (Table 2), (iii)  
the copy number (qPCR) or number of sequences (capillary sequencing or NGS) of the 
respective Env/V3 chimeras after sorting (Figure 16) and (iv) binding affinities of 447-
52D or HGN194 to the soluble Env/V3 trimers (Figure 17, Table 2). Notably, the 
enrichment analysis of the sorting procedure could successfully be adapted to enable the 
efficient screening of large libraries. 
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4.2. Development of HIV-1 envelope immunogens with 
improved antigenicity and stability using a cell-based 
epitope mapping platform 
Understanding Env – bnAb interactions in detail is valuable for the rational design of next 
generation Env immunogens aiming at a more potent and cross-neutralizing antibody 
response in vivo. However, these reverse vaccinology approaches are highly dependent on 
structural and functional data regarding epitope characterization. The required information 
is often obtained from Env/antibody co-crystallization
109,110
, binding studies with envelope 
mutants
111,54,112
 or peptide scans
44,113
. Here, a cell surface antibody mapping (CSAM) 
platform was utilized to characterize envelope - bnAb interactions and identify mutations 
for the rational design of novel Env immunogens. To this end, an Env alanine library was 
applied in a mammalian cell display-based high-throughput flow cytometry assay, enabling 
native folding and mammalian glycosylation as well as display of trimeric Env in its 
natural membrane context. 
 
 
 
4.2.1. General setup of the epitope mapping procedure 
The envelope library as well as the general procedure of the CSAM platform was 
developed by Dr. Alexander Kliche prior to this thesis. An alanine mutagenesis library 
based on the C clade isolate 96ZM651 was generated to address the globally most 
prevalent subtype C. To ensure efficient Env expression and surface presentation, the 
sequence was adapted to human codon usage
114
 and the cytoplasmic tail was truncated
64,65
. 
Alanine mutants were generated from the signal sequence C-terminus to the N-terminus of 
the transmembrane domain (Figure 18, Library Design). Cysteine residues were excluded 
from mutagenesis to preserve Env structure, resulting in a total of 605 variants. In addition, 
the furin protease cleavage site was mutated from REKR to REKS to prevent processing of 
the precursor protein into the non-covalently linked gp120-gp41 complex prone to gp120 
shedding.
115,116
 
The gp120 mutants of this library were applied in high-throughput 96-well transfection of 
HEK293T cells (one variant per well) and Env expressing cells were analyzed by flow 
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cytometry to assess each amino acid mutation for its impact on antibody binding. To this 
end, the antibodies used in this procedure were covalently labeled with a fluorescent dye 
(Alexa Fluor 647 or R-Phycoerythrin (R-PE)), resulting in a direct correlation between 
antibody binding and the fluorescence signal intensity and allowing the simultaneous use 
of more than one mAb from the same species. 48 h after transfection, each well was 
simultaneously stained with the screening antibody and reference antibody 5F3. This 
antibody recognizes a linear epitope in the C-terminal heptad region of gp41
46
 and should 
therefore bind all gp120 alanine variants alike. Hence it was used to normalize for varying 
Env surface expression levels and transfection efficiencies (Figure 18, Separate 
Transfection and Antibody Staining). MFI ratios for the screening and the reference 
antibody were calculated and all gp120 mutants were analyzed for significantly altered 
binding levels in comparison to the WT reference (Figure 18, High-Throughput FACS 
Analysis).  
As a first proof of concept, Dr. Alexander Kliche analyzed the binding of HGN194, a 
neutralizing mAb with a linear epitope previously mapped to the crown of the V3 loop.
44
 A 
profound and statistically significant reduction of HGN194 binding was only observed for 
variants I307A, I309A, G310A and Q313A (data not shown, numbering according to 
HXB2). These alanine mutants only showed between 5 and 26 % binding capacity for 
HGN194 compared to the 96ZM651 wildtype and were previously published by Corti et 
al. to be critical for HGN194 binding in pep-scan analysis
44
. 
In the course of this thesis, the CD4 binding site-targeting bnAb VRC01 was screened, as 
well as quaternary structure-dependent, apex-targeting bnAb PG9. In addition, a soluble 
CD4 (sCD4) alanine scan previously performed by Dr. Alexander Kliche was newly 
analyzed and significant mutations were further utilized. 
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Figure 18: Schematic representation of the cell surface antibody mapping platform. A 96ZM651 gp145 
(clade C) alanine scanning library was generated. The gp120 alanine mutants were used for separate 96-well 
transfection of HEK293T cells (one variant per well). 48 h post transfection, Env expressing cells were 
stained with the screening antibody and a gp41 reference antibody (5F3), which recognizes a linear epitope 
present in all variants, allowing normalization for varying transfection efficiencies and Env surface 
expression levels. Stained cells were analyzed by flow cytometry and MFI ratios of the screening antibody 
and the reference antibody were analyzed for significantly altered antibody binding in comparison to the 
wildtype. SP: signal peptide, C1-C5: constant regions of gp120, V1-V5: variable loops of gp120, TM: 
transmembrane domain. 
 
 
 
4.2.2. Evaluation of the alanine scanning procedure for sCD4, 
VRC01 and PG9 
For all screening reagents of this thesis (i.e. sCD4, CD4 binding site-targeting bnAb 
VRC01 and apex-targeting bnAb PG9), the following parameters of the CSAM procedure 
were evaluated: (i) use of cleavage-incompetent gp145 REKS for library generation, (ii) 
direct labeling of the applied antibodies and (iii) simultaneous staining with the screening 
and reference antibody.  
(i) Validation of 96ZM651 cleavage-incompetent (REKS) gp145 for the mapping of 
sCD4, VRC01 and PG9. The binding of sCD4, VRC01 and PG9 to the 96ZM651 
cleavage-competent REKR wildtype as well as to the cleavage-defective REKS mutant 
used for library generation was compared in the flow cytometry-based assay format 
described above. The cleavage-defective 96ZM651 gp145 showed no difference in binding 
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to sCD4, VRC01 and PG9 compared to cleavage-competent Env, even when cleavage was 
supported by co-transfection of furin (Figure 19), validating the use of the cleavage-
incompetent REKS library for these reagents.  
 
 
Figure 19: Impact of cleavage site mutation on the binding of sCD4, VRC01 and PG9. HEK293T cells 
were transfected with (i) the cleavage-defective (REKS) gp145 which served as a basis for the alanine 
scanning library, (ii) 96ZM651 cleavage-competent (REKR) 96ZM651 gp145 and (iii) 96ZM651 cleavage-
competent (REKR) gp145 and furin to support cleavage. 48 h post transfection, Env expressing cells were 
stained with sCD4, VRC01 or PG9. To normalize for Env expression levels, 5F3 co-staining was applied. 
Neither sCD4, nor VRC01 and PG9 showed significantly altered binding to the cleavage-defective variant in 
comparison to 96ZM651 gp145 wildtype (REKR), even when cleavage was supported by co-transfection of 
furin. n=2. 
 
 
(ii) Direct labeling of antibodies for the CSAM procedure. While sCD4 could be 
detected by an anti-human sCD4 secondary antibody in this assay setup, the envelope 
antibodies of interest for epitope mapping as well as the reference antibody 5F3 are of 
human origin. This prevents the use of an anti-human IgG secondary antibody for 
detection. Hence, antibodies applied in the CSAM procedure were directly labeled with a 
fluorescent dye (Alexa Fluor 647 for screening antibodies or R-PE for reference antibody 
5F3). To analyze the effect of this untargeted labeling reaction on the binding capacity of 
VRC01 and PG9, the binding of unmodified vs. labeled antibodies to 96ZM651 gp140 WT 
was compared by surface plasmon resonance (SPR). In addition, antibody functionality 
was analyzed against a small number of different isolates. Labeling reduced VRC01 
binding capacity approximately 2.5 to 3-fold in two different SPR settings (Figure 20A 
and C). In accordance with these results, VRC01-Alexa647 also showed about threefold 
decreased activity in the TZM-bl neutralization assay (Table 3). PG9-Alexa647 also 
exhibited slightly reduced binding compared to the unmodified mAb (Figure 20B and D), 
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although in this case antibody functionality was not influenced (Table 3). The untargeted 
labeling reaction used in the CSAM procedure covalently attaches four to six dye 
molecules per antibody molecule based on a covalent linkage of the succinimidyl ester 
group of the fluorescent dye to the primary amines of the antibody. Amino groups in the 
antibody paratope reacting with the fluorescent dye may therefore lead to blockage of the 
paratope in a certain percentage of antibody molecules. In the case of VRC01, a lysine 
residue at position 52 in the heavy chain forms a hydrogen bond to Ala281 of gp120.
42
 For 
PG9, crystal structures with V1/V2 peptides indicate an interaction of different heavy and 
light chain lysines with Env.
117
 However, blockage of the antibody paratope would only 
lead to a diminished effective concentration of applied antibody, therefore Alexa647 
labeled mAbs were still deemed suitable for epitope mapping. 
 
 
 
Figure 20: Impact of direct fluorescent labeling on antibodies VRC01 and PG9. mAbs VRC01 and PG9 
were labeled with fluorescent dye Alexa Fluor 647 and binding of unmodified and labeled antibodies to 
96ZM651 gp140 was analyzed by SPR. A and B: Antibodies were captured on a CM5 chip using anti-human 
IgG Fc antibody and 96ZM651 gp140 was applied as soluble analyte. C and D: 96ZM651 gp140 was 
directly immobilized on a CM5 chip using amine coupling and mAbs VRC01 and PG9 were used as soluble 
analytes. RU: resonance units. Labeling reduced gp140 binding of both VRC01 and PG9. 
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Table 3: Impact of direct fluorescent labeling on VRC01 and PG9 functionality. VRC01-Alexa647 
showed weaker neutralization capacity than the unmodified mAb in a TZM-bl assay against a panel of 
different pseudoviruses, while PG9 functionality was not affected. 
 
 IC50 Titers in TZM-bl cells (µg/ml) 
Virus Clade VRC01 
VRC01-
Alexa647 
PG9 
PG9-
Alex647 
Q23.17 A 0.09 0.33 0.00 0.00 
Q842.d12 A 0.03 0.09 0.03 0.02 
REJO4541.67 B 0.09 0.30 0.01 0.01 
TRJO4551.58 B 0.08 0.31 0.61 0.40 
WITO4160.33 B 0.10 0.38 0.01 0.01 
SC422661.8 B 0.14 0.55 0.60 0.96 
AC10.0.20 B 1.49 4.67 0.11 0.12 
ZM249M.PL1 C 0.10 0.31 0.06 0.06 
ZM53M.PB12 C 0.62 3.42 0.06 0.05 
ZM197M.PB7 C 0.42 2.22 0.54 0.63 
Murine Leukemia 
Virus 
Neg. 
Control 
>50 >50 >50 >50 
 
 
 
(iii) Simultaneous staining of Env expressing cells with the screening reagent and 
reference antibody 5F3. MFI values of the screening compounds sCD4, VRC01 and PG9 
were comparable after single staining and simultaneous staining with 5F3 (Figure 21A), 
indicating that no sterical hindrances arise from the double staining procedure. 
Furthermore, a correlation between signal intensities of 5F3 and each screening compound 
was observed for gp145 wildtype transfected cells (Figure 21B, Table 4). Several 
statistical parameters were collected to evaluate assay quality for each screening reagent 
(Table 4). As standard deviations must always be understood in relation to the mean of the 
data and mean values varied considerably for the different compounds, the coefficient of 
variation, also known as relative standard deviation, was calculated as a standardized 
measure of data point dispersion. Coefficients of variation were found to be 26 % for 
reference antibody 5F3, while all other screening compounds reached values under 20 %. 
Confidence intervals (p = 0.05) were low, ranging from 2.9 % (VRC01) to 5.5 % (5F3). 
This indicates that e.g. for 5F3, 95 % of the measured values would not differ more than 
5.5 % from the mean. In addition, the Z´-value was calculated, which describes an 
excellent assay with 0.5< Z´<1, a doable assay with 0<Z´<0.5 and Z´=0 as a yes/no type of 
assay.
118,119,120
 While the Z´-value was not largely influenced by 5F3 normalization in the 
case of VRC01, Z´ could be improved from 0.35 to 0.57 for sCD4. The most profound 
effect of 5F3 normalization was observed for PG9, where an improvement from 0.27 to 
0.58 was reached. In comparison to the other screening compounds, PG9 depicts weak 
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affinity to 96ZM651 envelope and only showed a signal to background ratio of 3 (Table 
4). Hence, this alanine scan was more error-prone than the others and might therefore have 
benefitted the most from normalization. In summary, the setup of the screening procedure 
was deemed suitable for the mapping of sCD4, VRC01 and PG9 binding sites.  
 
 
 
Figure 21: 5F3 as a reference antibody to normalize for Env surface presentation. A: To analyze the 
influence of simultaneous staining with a screening compound and 5F3, 293T cells were transiently 
transfected (n=10) with 96ZM651 gp145 REKS. 48 h post transfection, cells were either stained with the 
indicated interaction partner alone (grey bars) or in combination with antibody 5F3 (white bars) and analyzed 
by flow cytometry. No sterical hindrances could be detected for the simultaneous staining approach. B: A 96-
well plate of 293T cells was transfected with 96ZM651 gp145 REKS and mean MFIs of each well were 
analyzed for correlation between the signals of reference antibody 5F3 and the respective screening 
compound (n=80). 
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Table 4: Statistical parameters of the FACS-based alanine scanning procedure. 293T cells were transfected with 96ZM651 gp145 REKS in a 96-well format (n=80, 
negative control: n=6) and simultaneously stained with one of the screening compounds (sCD4, VRC01 or PG9) and 5F3 to be analyzed by flow cytometry. Several statistical 
parameters were calculated to describe assay performance for each interaction partner. SD: standared deviation. Based on low confidence intervals, coefficients of variation 
and Z´-values > 0.5, the CSAM procedure was deemed suitable for the purpose of epitope mapping. 
 
Non-normalized values of the screening compounds Values normalized by reference antibody 5F3 
 
Mean 
MFI 
SD 
Confidence 
interval, p=0.05 
Signal to 
background 
ratio 
Coefficient 
of variation 
(SD/Mean) 
Z´ 
Mean 
MFI 
SD 
Confidence 
interval, p=0.05 
Coefficient 
of variation 
(SD/Mean) 
Z´ 
R
2
  
(screening 
AB / 5F3) 
sCD4 5168 925 
4977 – 5369 
or ± 3.7% 
40 18% 0.35 0.340 0.065 
0.327 – 0.354 or 
± 3.9% 
19% 0.57 0.381 
VRC01 2061 294 
2000 – 2121 
or ± 2.9% 
15 14% 0.61 0.196 0.043 
0.186 – 0.205 or 
± 2.0% 
22% 0.53 0.602 
PG9 2411 378 
2333 – 2489 
or ± 3.4% 
3 16% 0.27 0.193 0.020 
0.189  – 0.197 or 
± 4.0% 
10% 0.58 0.611 
5F3 12484 3305 
11802 – 13167 
or ± 5.5% 
29 26% 0.19 
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4.2.3. Analysis of envelope interactions with soluble CD4 
 
4.2.3.1. Alanine scan of soluble CD4 
Dr. Alexander Kliche analyzed the well-characterized interaction of Env and sCD4
20,111,121
 
to validate the CSAM method for complex discontinuous epitopes. All shown analyses of 
this screening were newly conducted by me. The sCD4 scan identified 159 alanine 
mutations which resulted in significantly reduced binding compared to the parental 
envelope. 48 out of those were located within the inner domain
20
 of gp120 and are thus 
buried in the native trimer, while 70 mutations were located in the outer domain
20
. Of the 
latter, 29 were in the variable loops V1/V2 and one in V3. In addition, six significant 
mutations were located in the bridging sheet (Figure 22).  
 
 
 
Figure 22: Alanine scan of 
soluble CD4.  5F3 normalized 
fold changes of sCD4 binding 
relative to 96ZM651 WT 
(WT≙1) are shown for every 
gp120 mutant of the alanine 
scanning library (n=6). The 
diagrams show A: all positions 
screened with the CSAM 
method (N=447), B: all 
positions which showed 
statistically significant fold 
changes (FDR<0.5, N=159) 
and C: all positions which 
reached significance and are 
located in the outer domain of 
Env and in the bridging sheet 
(N=76) and are thus accessible 
from the surface. Statistical 
significance was determined in 
R using a two-sided one 
sample t-test against 1, while 
controlling the false discovery 
rate (FDR) to be smaller than  
5 % to adjust for multiple 
testing. 
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All statistically significant mutations are illustrated on the crystal structure of BG505 
SOSIP.664 (PDB ID: 4ZMJ)
122
 and compared to the CD4 contact residues defined by 
Kwong et al. (Figure 23).
20,42
 In summary, Dr. Kliche could identify several CD4 contact 
residues by significantly reduced binding of sCD4 to the generated alanine mutants 
(Figure 23A). However, not every contact site mutation could decrease sCD4 recognition. 
Especially in β20/β21 of the bridging sheet, only mutation of N425 and the highly 
conserved W427 had a severe impact on CD4 binding (Figure 23A).
123
 Several reasons 
might account for this: In contrast to crystallography, which detects the whole interaction 
surface of two binding partners, this mapping technology only detects contacts that 
contribute to the interaction energy and are hence really necessary for binding.
124
 On the 
other hand, the alanine scan only removes side chain interactions between Env and the 
ligand. If an alanine exchange does not lead to a significant alteration of backbone 
architecture, main-chain-only contacts would not be detected.
125,111
 This, for example, 
could explain the negative influence of mutations N425A and W427A in the bridging 
sheet, where main chain and side chain contacts account for the interaction.
42
 In contrast, 
neighbouring residues like M426, Q428 and G431 were not influenced, as only main chain 
interactions play a role at these positions (Figure 23A).
42
 In summary, the general region 
of the epitope could be made apparent (Figure 23C).  
In addition to residues with direct contact to sCD4, significantly reduced sCD4 binding 
could also be observed for other alanine substitutions, for example within the α1 helix 
(Figure 23B, black arrow). The proper packing of the α1 helix of the inner domain with 
the outer domain and the β20/β21 strands is critical for the formation of the four-stranded 
bridging sheet.
126
 In addition, most of the additional residues which significantly 
influenced sCD4 binding, including those in α1, could also be observed for the structure-
dependent antibodies VRC01 and PG9 (Appendix Table 3). Notably, these residues are 
located in the constant regions of Env and are, with very few exceptions, highly conserved.  
Hence, it is likely that they are important for correct Env folding. 
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4.2.3.2. Further analysis of N425 and W427 mutants 
Binding of Env to its primary receptor CD4 initiates the profound conformational change 
necessary for host cell entry. Thereby, various epitopes for non-neutralizing antibodies 
usually hidden in the inner part of functional, closed trimers are revealed.
22
 Hence, Env 
immunogens that do not bind endogenous CD4 would likely be less prone to induce non-
neutralizing antibodies. Furthermore, decreased CD4 binding would improve 
bioavailability, as Env antigens could not be trapped on the surface of host CD4
+
 immune 
cells.
79
 To be included into next generation envelope immunogens, mutations which 
significantly decrease CD4 binding would additionally have to preserve bnAb recognition. 
Hence, after comparison with all available bnAb alanine scanning data in the group (data 
not shown), four of the significant sCD4 loss of binding (LOB) mutants were tested against 
Figure 23: Structural analysis of the 
FACS-based sCD4 alanine scan.    A: 
5F3 normalized alanine scan fold 
changes (FC) relative to 96ZM651 WT 
are indicated for the published contact 
residues of gp120 (HXB2 numbering) 
with sCD4. Statistically significant 
(FDR<0.05) results are asterisked. 
Contact residues are taken from 
42
 with 
open circles (○) denoting gp120 main-
chain-only contacts, open circles with 
rays (☼) denoting gp120 side-chain-
only contacts, and filled circles (●) 
denoting both main chain and side chain 
contacts. B: Ribbon diagram of BG505 
SOSIP.664 (PDB ID: 4ZMJ). Cyan: 
inner domain, blue: outer domain, 
green: bridging sheet, gray: gp41, black 
arrow: α1 helix. C: Surface 
representation of BG505 SOSIP.664 
(PDB ID: 4ZMJ). For B and C, 
statistically significant amino acids 
(FDR<0.05) from the alanine scan are 
shown in red, CD4 contact residues as 
determined by crystallography
20,42
 in 
yellow and the overlap between the two 
methods is depicted in orange.  
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a panel of bnAbs targeting different epitopes. Two of those, variants N425A and W427A, 
showed profoundly reduced binding of sCD4 in the flow cytometry-based assay, while 
bnAb binding was preserved (Table 5). Notably, both mutations also led to severely 
reduced binding of non-neutralizing antibody 17b, which targets the CD4-induced (CD4i) 
conformation of Env (also seen in the 17b alanine scan, Appendix Table 4). Therefore, 
N425A and W427A represent valuable candidates for the rational design of new Env 
immunogens. 
 
Table 5: Impact of N425A and W427A on different epitopes on 95ZM651 gp145. 5F3 normalized fold 
changes for the binding of 96ZM651 gp145 N425A and W427A to different mAbs and sCD4 as determined 
by flow cytometry are given (n=3, WT≙1). Both mutants showed profoundly reduced binding to sCD4 and 
17b, while bnAb binding to different epitopes was preserved. MPER: membrane-proximal external region. 
CD4BS: CD4 binding site, CD4i: CD4-induced envelope conformation. Data were generated during the 
master thesis of Matthias Glögl under my experimental supervision. 
 
 
In addition, the sCD4 loss of binding effects could be transferred to gp145 envelopes from 
clades A, B and C. In agreement with the data obtained for 96ZM651, W427A thereby 
showed the more profound fold change and was hence also introduced into two SOSIP 
constructs, which exhibited the same effect (Table 6). This highlights that results from the 
96ZM651 alanine scanning procedure can also be valuable for the rational design of Env 
immunogens from other clades or modern approaches like the SOSIP design. 
 
 
Table 6: Transfer of N425A and W427A to other isolates. 
gp145 mutants of clades A, B and C were analyzed by flow 
cytometry. Fold changes of 5F3 normalized sCD4 MFIs in 
relation to the respective WT are given (n=3). In agreement with 
the data obtained for 96ZM651, W427A reduced sCD4 binding 
more profoundly for all isolates tested and was therefore also 
introduced into BG505 SOSIP and 16055 SOSIP, yielding 
similar results. Data were generated during the master thesis of 
Christina Schmalzl under my experimental supervision. 
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4.2.4. Analysis of envelope interactions with CD4 binding site-
targeting bnAb VRC01 
 
4.2.4.1. Alanine scan of VRC01 
The screening of all gp120 alanine variants with bnAb VRC01 resulted in 81 statistically 
significant changes in binding capacity. 66 of those were located in the outer domain of 
Env, whereof two residues were located in V3. 14 positions were located in the inner 
domain (Figure 24).  
 
 
 
 
Figure 24: Alanine scan of 
VRC01.  5F3 normalized fold 
changes of VRC01 binding 
relative to 96ZM651 WT 
(WT≙1) are shown for every 
gp120 mutant of the alanine 
scanning library (n=6). The 
diagrams show A: all positions 
screened with the CSAM 
method (N=477), B: all 
positions which showed 
statistically significant fold 
changes (FDR<0.5, N=81) and 
C: all positions which reached 
significance and are located in 
the outer domain of Env and 
the bridging sheet (N=66) and 
are thus accessible from the 
surface. Statistical significance 
was determined in R using a 
two-sided one sample t-test 
against 1, while adjusting the 
false discovery rate (FDR) to 
be smaller than 5 % to correct 
for multiple testing. 
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Co-crystallization of VRC01 and Env reported 36 contact residues for this interaction.
42
 
The 96ZM651 alanine scan was able to identify 17 of those 36 contacts by a significant 
impact on VRC01 binding. Seven of the 19 amino acid positions that could not be 
confirmed are proposed to be main-chain-only contacts
42
 (Figure 25A) and would 
therefore not be expected to alter VRC01 binding in this assay, as the backbone structure 
of Env in the respective area would likely not be influenced.
111,125
 80 of the 81 significant 
alanine mutations led to a severe loss of VRC01 binding, while one position, mutant 
T278A (HXB2 numbering), resulted in a 1.8 fold increase in VRC01 recognition (Figures 
24 and 25A). This position is part of a crucial N-glycosylation site (N276 X277 T278) at 
the CD4 binding site that many VRC01-class bnAbs avoid by a CDR-L1 deletion. In 
addition, this glycan results in a steric clash for the germline version of VRC01 and has to 
be removed in order to allow germline binding.
91
 This suggests that removal of this glycan 
leads to better accessibility of the CD4 binding site, thus facilitating VRC01 recognition. 
However, also N276A would remove this glycan, but with a fold change of 0.87 (data not 
shown), the alanine scan could not detect a significant influence (p = 0.99) of this mutation 
on VRC01 signal intensities. The beneficial effect of glycan removal by N276A could 
supposedly be abolished by a negative structural effect of this mutation on the CD4 
binding site, as this mutant also showed significant reduction of sCD4 binding (fold 
change: 0.6, p = 0.03, Appendix Table 4), although N276 is not a contact residue for 
sCD4 (Figure 23A).
42
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Figure 25: Structural analysis of the FACS-based alanine scan of VRC01. A: Binding data of the 
96ZM651 alanine scan for the published contact residues of VRC01 with gp120. The numbering of amino 
acids is based on HXB2. 5F3 normalized fold changes (FC) of VRC01 signals compared to wildtype binding 
levels are given and statistically significant results (FDR<0.05) are asterisked. Contact residues are taken 
from 
42
 with open circles (○) denoting gp120 main-chain-only contacts, open circles with rays (☼) denoting 
gp120 side-chain-only contacts, and filled circles (●) denoting both main chain and side chain contacts. B: 
Ribbon diagram of BG505 SOSIP.664 (PDB ID: 4ZMJ). Cyan: inner domain, blue: outer domain, light 
green: bridging sheet. Statistically significant amino acids (FDR<0.05) showing a loss of VRC01 binding in 
the alanine scan are depicted in red, the statistically significant gain of binding mutation in dark green (black 
arrow), VRC01 contact residues as determined by crystallography
42
 in yellow and the overlap between 
crystal structure contact residues and the alanine scan is shown in orange. C and D: Surface representation of 
BG505 SOSIP.664 (PDB ID: 4ZMJ). The statistically significant gain of binding mutation is depicted in dark 
green. Statistically significant amino acids found to reduce VRC01 binding in the alanine scan are shown in 
red, VRC01 contact residues (C) or CD4 contact residues (D) identified by crystallography
42,20
 in yellow and 
the overlap of amino acids between the alanine scan and crystal structure data is shown in orange.  
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4.2.4.2. Further characterization of T278 mutants 
Position T278 was permutated to evaluate whether other amino acid substitutions at this 
site can lead to further improvement of VRC01 binding. Cysteine and proline likely 
disturbed Env structure and therefore resulted in reduced recognition of VRC01. In 
accordance with the hypothesis that glycan removal at N276 allows better access to the 
CD4 binding site,
91
 most other amino acid substitutions resulted in increased VRC01 
signals, with T278H depicting the most pronounced fold change (Figure 26A and C). This 
superior effect of the histidine mutant might be explained by the close proximity of 
position 278 to Y28 and Y91 of the VRC01 light chain, as a positive charge could 
strengthen the interaction with those VRC01 residues (Figure 26B). Also, as its 
conformational epitope renders VRC01 structure-dependent, the additional benefit of 
T278H compared to T278A might be caused by a positive influence of the histidine mutant 
on Env tertiary structure. KD values of VRC01 binding to membrane-bound 96ZM651 
could not be reliably determined, as binding curves did not reach saturation (Figure 26C).  
Notably, the effect of enhanced VRC01 binding for T278A and H in membrane-bound 
gp145 was also transferable to soluble 96ZM651 gp140. While 96ZM651 gp140 WT 
showed a KD value of 38.7 nM to VRC01 in ELISA measurements, T278A and T278H 
depicted KD values of 16.1 and 11.4 nM, respectively (Table 8). Interestingly, T278H not 
only positively influenced VRC01 binding, but also resulted in increased affinity of apex-
targeting bnAb PG9, accounting for approximately threefold increased PG9 signals for 
membrane-bound T278H compared to 96ZM651 WT and a KD improvement from 62.0 to 
30.3 nM for soluble gp140 (Tables 7 and 13).  As PG9 is a quaternary structure-preferring 
antibody
127
 and T278A did not affect PG9 affinity (Table 13), this further supports the 
hypothesis that T278H improves Env folding.  
Other bnAb epitopes on Env could be preserved for both membrane-bound and soluble 
96ZM651 variants (Table 7).  
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Table 7: Impact of T278A and T278H on different epitopes of 96ZM651 membrane-bound gp145 and 
soluble gp140. Fold changes are indicated for gp145 as determined by flow cytometry (5F3 normalized) and 
gp140 trimer fractions as determined by ELISA, with utilized antibody concentrations determined from 
Appendix Figure 3 (n=3, WT≙1). Both gp145 and gp140 T278H depicted improved signals for VRC01 and 
PG9, while other bnAb epitopes were preserved. MPER: membrane-proximal external region, CD4BS: CD4 
binding site, CD4i: CD4-induced conformation of Env. Data for T278A gp145 were generated during the 
master thesis of Matthias Glögl under my experimental supervision. 
 
 
Figure 26: Permutation of position T278. A: Position T278 
was permutated into every natural amino acid and mutants 
were analyzed by flow cytometry. 5F3 normalized fold changes 
(WT≙1) are shown (n=3). Most substitutions led to increased 
VRC01 signals, with T278H having the most pronounced 
effect. B: Environment of T278 in the co-crystal structure of 
VRC01 and ZM176.66 gp120 (PDB ID: 4LST). The positive 
charge of histidine at this position might result in beneficial 
interactions with the VRC01 light chain. Grey: ribbon diagram 
of VRC01 with Y28 and Y91 of the light chain shown as stick 
representations. Blue: ZM176.66 gp120 with Env T278 
illustrated as stick representation and coloured in green. C: 5F3 
normalized FACS titration of 96ZM651 gp145 WT, T278A 
and T278H with VRC01 (n=2). KD values could not reliably be 
determined, as saturation could not be reached. 
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To test whether the benefits observed for 96ZM651 are transferable to other isolates, 
T278A and H were introduced into BG505 (clade A), HXB2 (clade B), JRFL (clade B) and 
16055 (clade C), as well as into the trimer-stabilized constructs BG505 SOSIP and 16055 
SOSIP. Flow cytometry analysis of the respective gp145 variants confirmed that both 
mutations led to increased recognition of VRC01 for all tested isolates, with T278H 
tending to exhibit the superior effect (Table 8). Therefore, all histidine mutants were 
purified as soluble gp140 trimers and KD values to VRC01 were determined by ELISA 
titration, resulting in approximately two- to threefold higher affinity for all T278H variants 
compared to the respective WTs (Table 8). Notably, magnitudes of KD values thereby 
varied between the isolates, with 96ZM651 depicting the lowest and BG505 the highest 
inherent affinity to VRC01. 
 
Table 8: Binding of VRC01 to membrane-bound gp145 and soluble gp140 T278A and T278H mutants 
of different isolates. Env gp145 T278A and T278H mutants of isolates from clades A, B and C were 
analyzed for VRC01 binding by flow cytometry (n=3). 5F3 normalized fold changes (FC) are indicated for 
each variant relative to the respective WT. Both mutations led to increased VRC01 binding, with T278H 
having a slightly superior effect. Hence, T278H mutants were further analyzed as soluble gp140 trimers by 
ELISA (n=2), where KD values were found to be reduced about threefold for all variants compared to gp140 
WTs. Corresponding ELISA titration curves are shown in Appendix Figure 2. Data were generated during 
the master thesis of Christina Schmalzl under my experimental supervision. 
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4.2.5. Analysis of envelope interactions with quaternary structure-
dependent bnAb PG9 
 
4.2.5.1. Alanine scan of PG9 
PG9 is a quaternary structure-dependent antibody asymmetrically targeting V1/V2 of two 
of the three protomers at the apex of the envelope trimer.
58
 All 96ZM651 alanine mutants 
contained in gp120 were screened with the CSAM procedure. In total, 26 mutants showed 
significantly altered binding towards PG9 (Figure 27). 12 of those were located in the 
inner domain of Env and 14 in the outer domain, with seven significant mutations in 
V1/V2 and two in V3. 25 of the statistically significant mutations led to a profound loss of 
PG9 binding, while mutant L111A depicted increased PG9 signals (Figure 27). 
Comparing the alanine scanning data to previously published crystallization and 
neutralization data,
117
 most of the described contact residues between PG9 and Env could 
be identified by reduced PG9 binding with fold changes of 0.5 to 0.6 relative to 96ZM651 
WT (Figure 28A). As PG9 bound weakly to 96ZM651 gp145, with MFIs of only about 
two- to threefold above background (Table 4), these fold changes already represent a 
prominent loss of antibody binding, although the weak signal intensities meant that only 
six of the described contact residues reached statistical significance. Of the described core 
epitope (N156, N160, K168, K169, Q170, K171, where underlined positions are especially 
important),
58
 mutants N160A, K168A and K169A depicted a statistically significant 
decrease in PG9 binding with fold changes between 0.44 and 0.59, while K171A showed a 
slightly enhanced, though not significant, gain of PG9 signal intensity. Mutant N156A also 
exhibited a fold change of 0.59. Although not statistically significant, this also indicates the 
importance of this N-glycosylation site for PG9 binding. Q170A still depicted a fold 
change of 0.88, however, this position is only described as a contact residue in one of the 
two available co-crystallizations of PG9 with different V1/V2 peptides.
117
 In general, most 
of the positions with a prominent loss of PG9 binding in the CSAM method were located at 
the trimer apex (Figure 28B and C), validating the mapping procedure for trimer-
preferring
127
 mAb PG9. 
Most interestingly, L111A resulted in increased PG9 signal intensities, with a fold change 
of 2.2 compared to WT-like PG9 binding (Figure 27C and D). Position L111 is not 
located at the trimer apex and can therefore not be a direct interaction partner of PG9. 
Instead, the gp120 inner domain residue
128
 faces the interaction surface of the different 
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trimer protomers (Figure 28C). L111A was previously described to strongly decrease 
aberrant dimerization of YU2
128,129
 (clade B) and BG505
130
 (clade A) gp120, thus 
facilitating gp120 monomer production. Furthermore, gp120 L111A mutants showed 
decreased affinity to sCD4 and the non-neutralizing antibodies targeting the CD4-induced 
Env conformation. Notably, this could be verified in the alanine scans of sCD4 and 17b, 
where L111A resulted in statistically significant reduction of binding with fold changes of 
0.51 and 0.19, respectively (Appendix Table 4). 
 
 
Figure 27: A: Alanine scan of 
PG9. 5F3 normalized fold 
changes of PG9 binding 
relative to 96ZM651 WT 
(WT≙1) are shown for every 
gp120 mutant of the alanine 
scanning library (n=6). The 
diagrams show A: all positions 
screened with the CSAM 
method (N=477), B: all 
positions which showed 
statistically significant fold 
changes compared to the WT 
(FDR<0.5, N=26) and C: all 
positions which reached 
significance and are located in 
the outer domain of Env and 
the bridging sheet (N=14) and 
are thus accessible from the 
surface. Statistical significance 
was determined in R using a 
two-sided one sample t-test 
against 1, while controlling the 
false discovery rate (FDR) to 
be smaller than 5 % to adjust 
for multiple testing. D: FACS 
titration of 96ZM651 gp145 
WT and L111A with PG9. One 
of two biological replicates is 
shown, as varying MFI values 
did not allow pooling of the 
data. The second dataset, which 
depicted the same result, is 
shown in Appendix Figure 1. 
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Figure 28: Structural analysis of the FACS-based PG9 alanine scan. A: Binding data of the alanine scan 
for published contact residues of Env (HXB2 numbering) to PG9. The core epitope of PG9 as described in 
58
 
is underlined and amino acids of special importance within the core epitope are bolded. 5F3 normalized fold 
changes (FC) of PG9 binding relative to 96ZM651 WT are given and statistically significant results 
(FDR<0.05) are asterisked. Contact residues and structural effects of mutating the respective positions were 
determined by co-crystallization of PG9 with V1/V2 peptides of isolates Cap45 and ZM109, or in 
neutralization assays.
117
 B: Top view and C: Side view of the Env trimer (BG505 SOSIP.664, PDB ID: 
4ZMJ). Amino acid mutations resulting in a fold change <0.6 and those of statistical significance 
(FDR<0.05) in the alanine scan are shown in red, the statistically significant gain of binding mutation in dark 
green (C, middle view) and the core epitope of PG9
58
 in yellow. The overlap between the core epitope and 
the alanine scan is depicted in orange. The right side of B and all representations in C show one protomer of 
the gp140 trimer as a surface model, while the other protomers are illustrated as ribbon diagrams. 
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4.2.5.2. Permutation of significant positions from the PG9 alanine scan  
PG9 recognizes the envelope trimer asymmetrically by interacting with variable loops V1 
and V2 from two of the three trimer protomers.
127
 Hence, significant loss of PG9 binding 
mutations located in V1/V2 as well as the gain of signal mutation L111A were chosen for 
permutation. For the loss of binding positions, this generally led to severely impaired PG9 
recognition for almost all natural amino acids (Figure 29B-K). However, S158T resulted 
in a significant increase in PG9 signal intensity (Figure 29D). This serine to threonine 
mutation exchanges the wildtype sequence N-X-S to N-X-T. Both represent sequons for N-
linked glycosylation, but N-X-T motives are thought to be more frequently and more 
extensively used,
131
 supposedly because of their higher affinity to the 
oligosaccharyltransferase.
132
 As the glycan at N156 is part of the core epitope of PG9,
58
 
S158T might therefore increase PG9 binding by influencing N-linked glycosylation at this 
site. However, mutant S158T depicted severely reduced expression levels (data not shown) 
and was not transferable to other isolates (Appendix Table 5). Hence, this mutation was 
not further pursued. Permutation at position L111, where the alanine scan detected a 
positive influence of L111A on PG9 binding, did not result in additional PG9 gain of 
signal mutants (Figure 29A).  
To test whether these 11 alanine mutations have the same impact on other isolates, they 
were transferred to BG505 (clade A) and 16055 (clade C), which both served as a basis for 
SOSIP and NFL variants.
49,50,82
 Most loss of PG9 binding mutations identified in the 
96ZM651 alanine scan also severely impaired PG9 signals for both isolates. Only E164A, 
which depicted a fold change of 0.62 for 96ZM651, resulted approximately in wildtype-
like binding levels in both BG505 and 16055. Notably, mutant L111A also showed 
significantly increased signal intensities for BG505 and 16055, with fold changes of 1.64 
and 1.48, respectively (Figure 29L). 
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Figure 29: Permutation of significant positions from the PG9 alanine scan and transfer to other isolates. A to K: Position L111 (PG9 alanine scan gain of signal) as 
well as significant loss of signal mutations located in V1/V2 were permutated in 96ZM651 gp145 and mutants were analyzed for altered PG9 binding by flow cytometry 
(n=4-6). 5F3 normalized fold changes are indicated (WT≙1). Only S158T resulted in increased PG9 binding, while most other mutants also displayed a loss of PG9 signal. L: 
Transfer of significant loss of signal alanine mutations located in V1/V2 and the gain of signal mutation L111A to isolates 16055 (clade C) and BG505 (clade A). All 
mutations except E164A proofed to be transferable. Data were generated during the master thesis of Krystina Beer under my experimental supervision. Statistical significance 
was determined in R using a two-sided one sample t-test against 1, while adjusting the false discovery rate (FDR) to be smaller than 5 % to correct for multiple testing. 
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4.2.5.3. Further characterization of mutant L111A 
 
4.2.5.3.1. Impact of L111A on soluble gp140 trimer formation 
The increased PG9 signal intensity observed for mutant L111A via flow cytometry could 
be caused by a direct increase in bnAb affinity. As PG9 is a trimer-preferring, quaternary 
structure-dependent antibody,
127
 the increased signal may, however, also be the result of a 
higher trimer proportion on the cell surface. Although 5F3 normalizes for envelope surface 
presentation levels, it binds to a linear epitope
46
 and thus presumably recognizes Env 
monomers, dimers and trimers alike. A shift in this distribution towards a higher trimer 
ratio would therefore not be easily visible in this flow cytometry-based assay format. As 
L111A is located in the inner part of the trimer (Figure 28C) and thus not part of the PG9 
epitope, the gain of signal effect would be most likely caused by an influence of L111A on 
trimer structure. To further analyze this, soluble gp140 envelope trimers lacking the 
cytoplasmic tail as well as the transmembrane domain were expressed in HEK293-F 
suspension cells and purified from the supernatant using lectin affinity chromatography 
(Figure 30A) and subsequent size exclusion to reach trimer homogeneity (Figure 30B). 
Interestingly, insertion of L111A led to a profound reduction of monomeric gp140 (Figure 
30B and C), indicating facilitated trimer formation for this mutant. 
 
 
Figure 30: Exemplary elution profiles of 96ZM651 gp140 purifications. Soluble envelope gp140 trimers 
were purified from the supernatant of HEK293-F suspension cells by lectin affinity chromatography and 
subsequent size exclusion to selectively purify Env trimers. mAU: absorption units at 280 nm. A: elution 
profile of the Galanthus nivalis lectin chromatography. After washout of other proteins in the supernatant, 
Env was eluted with 1 M α-D-mannopyranoside, resuling in a single Env peak (highlighted in grey). B: Size 
exclusion chromatography elution profile of 96ZM651 gp140 WT. Env elutes as an aggregate shoulder, 
overlapping trimer (highlighted in gray) and dimer fractions and a monomer peak. C: Size exclusion 
chromatography elution profile of 96ZM651 gp140 L111A. The trimer fraction is highlighted in gray. 
Mutation L111A leads to a markedly reduced monomer peak. 
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4.2.5.3.2. Impact of L111A on Env thermostability 
96ZM651 gp140 trimer fractions of wildtype and mutant L111A were subjected to 
differential scanning calorimetry (DSC). Both soluble trimers exhibited melting 
temperatures of approximately 60 °C, however, melting curves markedly differed between 
WT and mutant. Although the wildtype trimer was administered at approximately twice the 
concentration compared to L111A, the mutant depicted a more precise melting curve with 
considerably higher signal intensities (Figure 31). This is supposedly caused by a more 
homogeneous folding of mutant L111A compared to WT gp140, resulting in a more 
synchronous unfolding process for the variant and hence a more homogeneous melting 
curve. Measurements repeated with independent protein purifications and equal trimer 
concentrations yielded similar curves, excluding any influence of the purification process 
on these results (Appendix Figure 4).  
 
 
Figure 31: DSC analysis of 96ZM651 gp140 wildtype and mutant L111A. Trimer fractions of Env gp140 
WT and L111A were purified by lectin affinity chromatography and subsequent size exclusion and analyzed 
by DSC. For 96ZM651 WT (A), a higher concentration (1.35 µM) was administered, but still only weak 
signal intensity and a very inhomogeneous peak was obtained. In the case of mutant L111A (B), a lower 
concentration (0.74 µM) already resulted in higher signal intensity and a more homogeneous melting curve, 
suggesting improved trimer folding. L111A did not alter Env thermostability (Tm: melting temperature). Red 
lines represent the fitted data used for Tm calculation. 
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4.2.5.3.3. Antigenicity of 96ZM651 L111A 
Mutation L111A increased PG9 affinity to soluble 96ZM651 from a KD value of 62.0 to 
39.0 nM (Tables 10 and 13), further indicating improved Env folding of this variant. 
Moreover, comparing 96ZM651 WT and L111A for both membrane-bound gp145 via flow 
cytometry as well as for soluble gp140 by ELISA, mutant L111A showed preserved 
binding to bnAbs targeting different epitopes (Table 9). In addition to the positive 
influence on PG9 binding, improved binding was also observed for VRC01 (CD4BS), 
which was, although not statistically significant, already visible in the VRC01 alanine scan 
(Appendix Table 3). In addition, L111A resulted in slightly increased signal intensities for 
bnAb 2G12, which binds to a conserved mannose-patch on gp120.
45
 Interestingly, in 
agreement with data for BG505 gp120,
129
 L111A also decreased sCD4 binding to gp145 
and severely impaired recognition of non-neutralizing mAb 17b for both membrane-bound 
and soluble envelope (Table 9). 
 
 
Table 9: Impact of L111A on different epitopes on membrane-bound and soluble 96ZM651 envelope. 
gp145 L111A was analyzed by flow cytometry (n=3), while gp140 trimer fractions were analyzed by ELISA 
(n=3), with utilized antibody concentrations determined from Appendix Figure 3. Fold changes are given 
relative to 96ZM651 WT (WT≙1). For gp145, values were normalized with 5F3. L111A increased signals of 
PG9, VRC01 and 2G12 while other bnAb epitopes were preserved. L111A also reduced sCD4 (gp145) and 
17b binding (gp145 and gp140). Data for gp145 were obtained during the master thesis of Matthias Glögl 
under my experimental supervision. 
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4.2.5.3.4. Transfer of L111A to other isolates 
To analyze its effect on other isolates, L111A was transferred to membrane-bound gp145 
and soluble gp140 of BG505 (clade A), HXB2 (clade B), JRFL (clade B) and 16055 (clade 
C), as well as BG505 SOSIP and 16055 SOSIP. Analysis of gp145 variants by flow 
cytometry resulted in increased PG9 signals for BG505 and 16055 SOSIP, although 
96ZM651 still displayed the highest fold change. BG505 SOSIP, HXB2 and 16055 showed 
approximately wildtype-like binding, while JRFL exhibited a slightly decreased fold 
change. Similarly, apart from 96ZM651, increased fold changes of VRC01 signal intensity 
were observed for BG505 and BG505 SOSIP, as well as 16055 SOSIP. JRFL showed 
unchanged VRC01 binding, while signals for HXB2 and 16055 were slightly reduced 
(Table 10, left side). In contrast, L111A in soluble gp140 resulted in heightened affinity to 
PG9 and VRC01 for most isolates, with fold changes of approximately two. Only 16055 
SOSIP gp140 L111A showed approximately WT-like affinity to both bnAbs, while HXB2 
exhibited decreased affinity to PG9 (Table 10, right side). In sum, the impact of L111A on 
antigenicity proved to be transferable to most isolates tested. However, PG9 fold changes 
for gp145 and gp140 variants were not always in agreement (e.g. for JRFL, which did not 
show increased signal intensities for gp145 in the flow cytometry assay but exhibited 
enhanced affinities to both PG9 and VRC01 in the case of soluble gp140). This supports 
the hypothesis that different effects like shifted monomer to trimer ratios on the cell 
surface and altered Env folding play a role for L111A mutants, impairing the correlation 
between PG9 MFIs and its affinity to the respective variant. Notably, in accordance with 
T278 mutants (Table 8), magnitudes of VRC01 and PG9 affinity varied between the 
different isolates, with 96ZM651 exhibiting particularly low affinity to both bnAbs. 
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Table 10: Transfer of L111A to other isolates. gp145 L111A variants were analyzed for altered PG9 and 
VRC01 binding by flow cytometry. 5F3 normalized fold changes (FC) are indicated relative to the respective 
WT (n=3). gp140 L111A trimers were analyzed via ELISA titration (Appendix Figure 2, n=2). L111A 
increased signal intensities (gp145) as well as affinity of PG9 and VRC01 (gp140) for most tested constructs. 
Data (except 96ZM651) were generated during the master thesis of Christina Schmalzl under my 
experimental supervision. 
 
 
 
Notably, L111A also resulted in altered SEC elution profiles for all soluble trimers. Similar 
to 96ZM651, the gp140 monomer peak was markedly reduced for HXB2, JRFL and 
16055, while trimer yield was distinctly increased for 16055 SOSIP. In the case of BG505, 
the monomer peak was shifted to a higher elution volume, indicating a tighter folding of 
the protein, while a newly arising shoulder for BG505 SOSIP suggests a better separation 
of trimer, dimer and monomer fractions. However, for BG505 SOSIP, L111A also 
negatively influenced Env expression (Figure 32). In accordance with results for 
96ZM651, L111A did not alter thermostability in any of the variants tested (Table 11). 
In conclusion, L111A resulted in facilitated gp140 trimer formation as well as increased 
PG9 and VRC01 affinity for most of the different isolates and SOSIP constructs tested. 
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Clade Isolate TM WT TM L111A 
A BG505 59.6 ± 7.1 56.9 ± 0.1 
A BG505 SOSIP 65.7 ± 0.8 66.8 ± 0.2 
B HXB2 58.8 ± 1.8 58.3 ± 0.2 
B JRFL 57.5 ± NA 56.6 ± NA 
C 16055 66.7 ± 15.7 68.2 ± 16.2 
C 16055 SOSIP NA NA 
C 96ZM651 58.4 ± 1.8 58.9 ± 0.7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32: Size exclusion 
elution profiles for gp140 
WT and L111A envelopes 
from different isolates. 
gp140 trimers were purified 
from the supernatant of 
HEK293-F suspension cells 
with lectin affinity 
chromatography and 
subsequent size exclusion 
(SEC). SEC elution profiles 
are shown with WT proteins 
in dark grey and L111A 
variants in light gray. Trimer 
fractions are marked by 
circles, monomer peaks with 
squares. L111A altered the 
elution profile of all tested 
constructs. Data for all 
isolates except 96ZM651 
were generated during the 
master thesis of Christina 
Schmalzl under my 
experimental supervision. 
 
Table 11 : NanoDSF analysis of gp140 WT 
and L111A trimers of different isolates. (n=2) 
Melting temperatures (TM) were not influenced 
by L111A. 
 
Results 
83 
 
4.2.6. Combination of significant mutations from the sCD4, VRC01 
and PG9 alanine scans 
In summary, the performed alanine scans and subsequent permutation identified several 
mutations which positively influenced Env antigenicity. W427A showed profoundly 
decreased binding of sCD4, which would supposedly prohibit the opening of trimeric Env 
immunogens in vivo and thus decrease non-neutralizing antibody titers.
79
 Notably, this is 
further supported by the markedly reduced binding of non-neutralizing CD4i mAb 17b 
(Table 5). In addition, mutants T278A and H increased affinity of CD4BS-targeting bnAb 
VRC01, with T278H being slightly superior for most isolates tested and supposedly having 
a positive influence on Env folding (Tables 8 and 13). Furthermore, L111A enhanced 
trimer formation and apparently improved Env folding (Figures 30 to 32). This resulted in 
increased affinities of both PG9 and VRC01 to most tested isolates (Table 10), while 
simultaneously reducing 17b binding (Table 9). Notably, none of these mutations 
significantly impaired other bnAb epitopes (Tables 5, 7 and 9). Hence, 96ZM651 gp145 
combination mutants of L111A, T278A or H and W427A were generated to combine these 
favorable phenotypes into a single Env immunogen (Table 12, upper panel). While other 
bnAb epitopes could be preserved, double mutants L111A/T278A and L111A/T278H both 
exhibited enhanced PG9 and VRC01 binding. In accordance with T278 single mutants, 
L111A/T278H thereby depicted the superior effect for both bnAbs. Notably, L111A 
strongly reduced 17b binding in both double mutants. However, L111A/T278H showed 
slightly increased sCD4 recognition. In agreement with previous results (Table 5), 
inclusion of W427A resulted in decreased sCD4 binding. While sCD4 recognition was 
almost completely abolished for L111A/T278A, the slight enhancement of sCD4 binding 
observed for T278H counteracted this effect, resulting in a fold change of 0.59 for 
L111A/T278H/W427A. However, in addition to impairing sCD4 recognition, W427A also 
slightly decreased the gain of binding effects for PG9 and VRC01 (Table 12). Therefore, 
as a potentially beneficial effect of loss of CD4 binding on immunogenicity would only be 
visible in a more complex, human CD4 transgenic or humanized animal model, only 
double mutants L111A/T278A and L111A/T278H and one selected triple mutant 
(L111A/T278A/W427A) were analyzed as soluble trimers. As already observed for gp140 
L111A, all purified double and triple mutants also showed improved trimer formation 
(Figure 30), rendering the monomer fractions even smaller than for the trimer-stabilized 
BG505 SOSIP (Figure 33). 
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Figure 33: Exemplary size exclusion elution profiles for 96ZM651 gp140 WT, L111A, and selected 
combination mutants. L111A reduced monomer peaks in all variants. 
 
 
Although fold changes for PG9 and VRC01 were not as enhanced as for gp145, 
antigenicity profiles of membrane-bound variants were well transferable to soluble 
96ZM651 gp140 double and triple mutants (Table 12, lower panel). Notably, the slightly 
enhanced sCD4 binding of mutant T278H as observed for gp145 was thereby not 
confirmed for soluble trimers. In agreement with membrane-bound gp145, 96ZM651 
L111A/T278H depicted the most pronounced gain of binding effects for both VRC01 and 
PG9. ELISA titration of 96ZM651 single, double and triple mutants with both bnAbs 
confirmed these results, with gp140 T278H and L111A/T278H depicting approximately 
threefold increased affinities to VRC01 (Table 13). Most interestingly, however, the 
supposed structural effects of L111A and T278H seemed to act additive regarding PG9 
affinity, resulting in a KD value of only 9.3 nM for L111A/T278H double mutant and 
hence an improvement of nearly sevenfold compared to 96ZM651 WT (Table 13). This 
could be independently confirmed during the master thesis of Helene Hierl (Table 15). 
Thermostability, which was shown to correlate with serum neutralization activity after 
vaccination,
50
 was preserved for all tested 96ZM651 gp140 trimers (Table 13).  
In conclusion, both membrane-bound and soluble envelope immunogens with increased 
affinity to bnAbs VRC01 and PG9 could be generated, while bnAb binding to other 
epitopes was preserved. Simultaneously, recognition of both sCD4 and non-neutralizing 
CD4i mAb 17b was reduced, further supporting a neutralizing antibody response in vivo. 
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In summary, double mutant L111A/T278H thereby exhibited the most promising 
antigenicity profile. 
 
 
Table 12: Influence of L111A, T278A/H and W427A combination on different epitopes on membrane-
bound and soluble 96ZM651 envelope. gp145 variants were analyzed by flow cytometry (n=3), while 
soluble gp140 trimers were analyzed by ELISA (n=2), with applied antibody concentrations determined from 
Appendix Figure 3. Fold changes are indicated relative to 96ZM651 gp145 or gp140 WT, respectively. In the 
case of gp145, fold changes were normalized with 5F3. Antigenicity effects of the single mutants were 
observed to be combinable in both membrane-bound and soluble 96ZM651 envelope. 
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Table 13: Thermostability of 96ZM651 single, double and triple mutants and their affinity to PG9 and 
VRC01. A summary of 5F3 normalized fold changes to VRC01 and PG9 as determined by flow cytometry 
for gp145 (n=3), KD values for gp140 trimers as determined by ELISA titration (Appendix Figure 2, n=2) 
and melting temperatures of soluble trimers (TM) as determined by nanoDSF (n=2) is given.  
 
 
 
Next, L111A/T278A, L111A/T278H, L111A/T278A/W427A and L111A/T278H/W427A 
were applied to the previously applied gp145 panel of different isolates and SOSIP 
variants. In agreement with data collected for the single mutants (Table 10), the beneficial 
impact of L111A on PG9 binding was not visible for all isolates, presumably due to an 
interplay of different effects (e.g. altered trimerization, Env folding and affinity). Also in 
accordance with the single mutants (Table 8), VRC01 signals were increased for all double 
variants tested, with 16055 SOSIP displaying the most pronounced fold change and 
L111A/T278H at a slight advantage in all tested isolates. Similar to 96ZM651 combination 
mutants (Table 12), addition of W427A markedly reduced sCD4 binding for almost all 
triple variants, but also diminished the enhancement of VRC01 and PG9 binding (Table 
14). 
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Table 14: Flow cytometry analysis of membrane-bound gp145 combination mutants from different 
isolates. 5F3 normalized fold changes relative to the respective wildtype are indicated for binding of PG9, 
VRC01 and sCD4 as determined by flow cytometry (n=3). While a PG9 gain of signal was not observed for 
most isolates, higher signal intensities were obtained for VRC01, with T278H-containing mutants at a slight 
advantage. Inclusion of W427A resulted in almost complete abolishment of sCD4 binding, but also decreased 
bnAb recognition.  
 
 
 
In summary, double mutant L111A/T278H showed the most promising binding to VRC01 
and PG9 for both membrane-bound and soluble 96ZM651 (Table 12) as well as for the 
membrane-bound variants of all other tested isolates and SOSIP constructs (Table 14). 
Hence, soluble L111A/T278H gp140 trimers were purified for BG505, BG505 SOSIP, 
16055 and 16055 SOSIP, which are currently prominent in the literature.
50,85,130
 In 
agreement with previously obtained data for L111A single mutants (Figure 32), the 
favorable effect of L111A on Env trimer formation was also visible for 16055 and 16055 
SOSIP, but not BG505 and BG505 SOSIP double mutants.  
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In accordance with 96ZM651 single mutants (Tables 8 and 10), L111A/T278H variants of 
all tested isolates showed decreased KD values for VRC01 and PG9 (Table 15). Notably, 
however, magnitudes of KD values again varied between the different isolates, with 
96ZM651 exhibiting markedly lower affinity to both bnAbs. 
 
 
 
Figure 34: Exemplary size 
exclusion elution profiles of WT 
and L111A/T278H gp140 
envelopes from different isolates. 
gp140 proteins of BG505 (clade A), 
16055 (clade C), 96ZM651 (clade 
C) as well as BG505 SOSIP and 
16055 SOSIP were purified from 
the supernatant of HEK293-F 
suspension cells with lectin affinity 
chromatography and subsequent 
size exclusion (SEC). SEC elution 
profiles of WT proteins are shown 
in black and of L111A/T278H 
variants in gray. All purifications 
were conducted from an equal 
volume of cell suspension, except 
for BG505 SOSIP, where the 
L111A/T278H mutant was purified 
from a threefold volume compared 
to BG505 WT. Trimer fractions are 
marked by circles, monomer peaks 
with squares. L111A improves 
trimer formation in the double 
mutants of 96ZM651, 16055 and 
16055 SOSIP. Data were generated 
during the master thesis of Helene 
Hierl under my experimental 
supervision. 
 
Table 15: Affinities of 
L111A/T278H gp140 trimers 
of different isolates to VRC01 
and PG9. BG505, BG505 
SOSIP, 16055, 16055 SOSIP 
and 96ZM651 trimers were 
titrated with PG9 and VRC01 
via ELISA (n=2-3). All 
mutants showed increased 
bnAb affinity. Data were 
generated by Helene Hierl 
under my experimental 
supervision. 
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4.2.7. Stabilization of L111A/T278H envelope trimers by 
chemical cross-linking 
 
Recently published findings suggest that cross-linking of envelope trimers supports well-
ordered trimer integrity, thus reducing the exposure of non-neutralizing epitopes located in 
the inner part of the trimer.
78,79
 In addition, increased thermostability of cross-linked 
envelope antigens correlates with the neutralization capacity of induced antibody 
responses.
50
 Hence, L111A/T278H gp140 trimers of 96ZM651, BG505, BG505 SOSIP, 
16055 and 16055 SOSIP were subjected to cross-linking by glutaraldehyde (GLA) and 
EDC/NHS (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride/N-
hydroxysuccinimide). The homo-bifunctional aldehyde GLA links amine groups, with 
lysine residues most commonly affected. Thereby, a five-residue carbon chain is inserted 
between the two cross-linked groups. In contrast, the hetero-bifunctional EDC reaction, 
which is catalyzed by NHS, cross-links an amino- to a carboxyl-group without inserting 
additional atoms.
79
 All experiments regarding cross-linking were performed by Helene 
Hierl under my experimental supervision.  
To determine optimal cross-linking rates for each isolate, all variants were treated with 
different molar ratios of Env to GLA or EDC/NHS. The success of the cross-linking 
reactions was visualized by SDS-PAGE and further analyzed by ELISA using (i) VRC01 
and PG9 to assess the maintenance of bnAb epitopes and L111A/T278H gain of binding 
effects and (ii) non-neutralizing CD4i antibody 17b to evaluate well-folded trimer 
integrity. In accordance with  literature data,
79,50
 two different ELISA formats were 
performed: a capture ELISA, in which Env trimers were captured by Galanthus nivalis 
lectin to preserve trimer structure, as well as a direct ELISA, in which gp140 trimers were 
directly coated onto the plate, resulting in hydrophobic interactions and hence mildly 
denaturating conditions. For both settings, area under the curve values (AUC)
78,79,92
 were 
determined as a means to compare antigenicity profiles of the differently cross-linked 
trimers. While we wanted to preserve at least 75 % of VRC01 and PG9 recognition, 17b 
binding should be reduced to less than 50 % compared to unmodified trimers.  
For GLA, all cross-linking concentrations which reduced 17b signals to fewer than 50 % 
also severely impaired PG9 recognition (Figure 35). In contrast, EDC/NHS cross-linking 
could preserve both VRC01 and PG9 binding while simultaneously reducing 17b 
recognition. While 160 000 mol EDC/NHS per mol envelope met the above defined 
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criteria for 16055, 16055 SOSIP, BG505 and BG505 SOSIP L111A/T278H variants,       
35 000x EDC/NHS to Env qualified for 96ZM651 (Figure 36). 
 
 
Figure 35: Antigenicity profiles of GLA cross-linked envelope trimers. GLA cross-linking was performed 
with 2000, 3000, 4000 and 5000 mol GLA per mol Env. Cross-linked trimers were analyzed by SDS-PAGE 
(right hand side; M: monomer, D: dimer, T: trimer, A: aggregate) and ELISA (left hand side) in a lectin 
capture format (preserves Env trimer structure) and direct coating format (mildly denaturating conditions 
promoting trimer opening and unfolding). Areas under the curve (AUC) were determined for VRC01 and 
PG9 binding to determine bnAb epitope integrity and maintenance of L111A/T278H gain of binding effects, 
as well as for CD4i antibody 17b, to analyze well-folded trimer integrity. AUCs were normalized to 
unmodified L111A/T278H variants (≙1). Although VRC01 signals could be maintained, PG9 binding was 
severely hindered at all concentrations where 17b recognition could be successfully diminished to ≤50 %. 
n=1. 
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Figure 36: Antigenicity profiles of EDC/NHS cross-linked envelope trimers. EDC/NHS cross-linking 
was performed with 35 000, 100 000, 160 000 and 400 000 mol EDC/NHS per mol Env. Cross-linked trimers 
were analyzed by SDS-PAGE (right hand side; M: monomer, D: dimer, T: trimer, A: aggregate) and ELISA 
(left hand side) in a lectin capture format (preserves Env trimer structure) and direct coating format (mildly 
denaturating conditions promoting trimer opening and unfolding). Areas under the curve (AUC) were 
determined for VRC01 and PG9 binding to determine bnAb epitope integrity and maintenance of 
L111A/T278H gain of binding effects, as well as for CD4i antibody 17b, to analyze well-folded trimer 
integrity. AUCs were normalized to unmodified L111A/T278H variants (≙1). Arrowheads indicate cross-
linker concentrations where PG9 and VRC01 signals could be preserved (≥75 %), while 17b binding was 
reduced (≤50 %). n=1. 
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To further ensure that bnAb affinities of other epitopes on Env were sustained, 
L111A/T278H variants cross-linked with the respective optimal EDC/NHS concentration 
were analyzed with a broader antibody panel. This included the non-neutralizing or weakly 
neutralizing mAbs 17b (recognizing the open CD4i conformation) and F105 (targeting the 
CD4BS of aberrantly folded trimers), as well as bnAbs HGN194 (V3), PGT121 (V3-
Glycan), HJ16 (CD4BS), VRC01 (CD4BS), PG9 (V1/V2), PGT145 (V1/V2) and PGT151 
(gp120/gp41 interface). Using unmodified wildtype and L111A/T278H gp140 trimers as 
controls, cross-linked double mutants were analyzed by lectin capture and direct ELISA.   
Consistent with previous experiments (Table 12, Figure 36), L111A/T278H double 
mutants already displayed weaker affinity to 17b, which could be further reduced by 
EDC/NHS cross-linking. In addition, cross-linking severely reduced F105 binding for most 
isolates in both ELISA settings, further supporting the notion of a favorable effect of cross-
linking on trimer integrity. As T278H removes the glycan at N276 necessary for HJ16 
recognition, L111A/T278H double mutants showed impeded HJ16 binding. This, however, 
was not further influenced by cross-linking (Figure 37A and Appendix Figure 6A). Also 
in agreement with previous data (Table 15), insertion of L111A and T278H resulted in 
increased binding of VRC01 for most variants, which was not significantly influenced by 
cross-linking. Similarly, PG9 binding was slightly enhanced or preserved in the untreated 
double mutants and after cross-linking (Figure 37B). In addition, affinities to all other 
bnAb epitopes tested, including the V3 loop, were neither influenced by the two mutations, 
nor by subsequent cross-linking. This is consistent with previous results for L111A/T278H 
variants (Table 12) as well as literature findings regarding EDC/NHS cross-linking.
79
  
PGT145, a highly quaternary structure-dependent, apex-targeting bnAb,
58
 and PGT151, 
which recognizes the gp120/gp41 interface and is therefore highly cleavage- and 
quaternary structure-dependent,
59
 only showed noteworthy binding to BG505 SOSIP and 
16055 SOSIP and not to the other cleavage-defective REKS mutants (Figure 37B and C). 
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Figure 37A: Antigenicity profile of 
EDC/NHS cross-linked soluble envelope 
trimers. Antibody binding to WT, 
L111A/T278H and EDC/NHS cross-linked 
L111A/T278H gp140 trimers was analyzed 
by lectin capture (preserves trimer integrity) 
and direct ELISA (mildly denaturating 
conditions supporting trimer opening/ 
unfolding). A panel of different antibodies 
was used, including the non- or weakly 
neutralizing mAbs 17b (CD4i) and F105 
(CD4BS), as well as bnAb HJ16 (CD4BS). 
Two biological replicates were carried out; 
however, the shown data represent one 
biological replicate as varying OD450 values 
did not allow pooling of the data. The second 
dataset, which depicted similar results, is 
shown in Appendix Figure 6A. 
L111A/T278H resulted in decreased 17b 
recognition, which could further be enhanced 
by EDC/NHS cross-linking. Also, cross-
linking diminished F105 binding. HJ16 
recognition was impeded due to T278H, but 
was not further influenced by cross-linking.  
 
Results 
94 
 
Figure 37B: Antigenicity profile of 
EDC/NHS cross-linked soluble 
envelope trimers. Antibody binding to 
WT, L111A/T278H and EDC/NHS cross-
linked L111A/T278H gp140 trimers was 
analyzed by lectin capture (preserves 
trimer integrity) and direct ELISA (mildly 
denaturating conditions supporting trimer 
opening/ unfolding). A panel of different 
antibodies was used containing bnAbs 
VRC01 (CD4BS), HGN194 (V3) and 
PGT121 (V3-Glycan). Two biological 
replicates were carried out; however, the 
shown data represent one biological 
replicate as varying OD450 values did not 
allow pooling of the data. The second 
dataset, which depicted similar results, is 
shown in Appendix Figure 6B. 
L111A/T278H resulted in increased 
VRC01 recognition, which was not 
severely influenced by cross-linking. The 
two mutations as well as cross-linking 
had no effect on V3 antibodies HGN194 
and PGT121.  
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Figure 37C: Antigenicity profile of 
EDC/NHS cross-linked soluble envelope 
trimers. Antibody binding to WT, 
L111A/T278H and EDC/NHS cross-linked 
L111A/T278H gp140 trimers was analyzed 
by lectin capture (preserves trimer integrity) 
and direct ELISA (mildly denaturating 
conditions supporting trimer opening/ 
unfolding). A panel of different antibodies 
was used containing quaternary structure 
dependent bnAbs PG9 (V1/V2), PGT145 
(V1/V2) and PGT151 (gp120/gp41 interface). 
Two biological replicates were carried out; 
however, the shown data represent one 
biological replicate as varying OD450 values 
did not allow pooling of the data. The second 
dataset, which depicted similar results, is 
shown in Appendix Figure 6C. 
L111A/T278H led to increased PG9 
recognition with varying magnitude, which 
was not influenced by cross-linking. PGT145 
and PGT151 recognition was not influenced 
by L111A/T278H or cross-linking, but these 
antibodies only showed noteworthy binding 
to the two SOSIP constructs.  
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Apart from the similarities of the different constructs regarding the effects of 
L111A/T278H and EDC/NHS cross-linking on antigenicity, all analyzed variants 
inherently depicted different affinity levels to the applied antibody panel (Figure 38 and 
Appendix Table 7). 96ZM651, for example, showed markedly higher binding levels to 
F105, which recognizes aberrantly folded trimer,
133
 although this was largely reduced by 
cross-linking. For BG505 and BG505 SOSIP, the unmutated wildtypes already exhibited a 
higher affinity to VRC01 than the other isolates, while 16055 and 16055 SOSIP showed 
higher recognition of PGT121 and marginally of PG9. PGT151 and PGT145, both highly 
dependent on proper trimer quaternary packing,
58,59
 only recognized the well-folded 
engineered constructs BG505 SOSIP and 16055 SOSIP with satisfying affinity. 
 
 
 
Figure 38: Antigenicity profiles of gp140 wildtypes, L111A/T278H mutants and EDC/NHS cross-linked 
L111A/T278H mutants of different isolates. KD values (see Appendix Table 7) were calculated from 
titration curves of Figure 37 and Appendix Figure 6 (n=2). C: lectin capture ELISA, D: direct ELISA, 
CD4BS: CD4 binding site, CD4i: CD4-induced Env conformation. High to low KD values are graded from 
red to green. White panels indicate non-calculable KD values due to insufficient signal intensities (no 
binding). 
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In agreement with previous nanoDSF analyses of L111A single mutants (Table 11) and 
96ZM651 combination mutants (Appendix Table 6), insertion of L111A/T278H did not 
significantly alter melting temperatures in any of the tested isolates. Cross-linking, 
however, increased thermostability for 16055 SOSIP and BG505 SOSIP, with cross-linked 
16055 SOSIP exhibiting a TM increase of approximately 6 °C (Table 16). Notably, melting 
curves of 96ZM651 allowed only inadequate analysis of melting temperatures due to low 
signal intensities, while 16055 could not be analyzed at all (Appendix Figure 5). This was 
most likely caused by inhomogeneous folding of the cleavage-incompetent REKS variants. 
 
Table 16: Thermostability of cross-linked gp140 trimers. Thermostability of EDC/NHS cross-linked 
L111A/T278H trimers was analyzed by nanoDSF in comparison to unmodified WTs and L111A/T278H 
mutants (n=2). While insertion of L111A/T278H did not affect thermostability, cross-linking led to increased 
melting temperatures (TM), most profoundly for 16055 SOSIP. Note that melting curves of 16055, BG505 
and 96ZM651 were only poorly analyzable due to low signal intensities (Appendix Figure 5).  
 TM in °C 
 WT L111A/T278H L111A/T278H x-link 
96ZM651 60.4 ± NA 61.1 ± 0.7 61.4 ± NA 
16055 NA NA NA 
16055 SOSIP 58.3 ± 0.3 59.6 ± 0.1 65.4 ± 0.1 
BG505 58.1 ± 1.1 57.0 ± 0.0 61.1 ± 0.9 
BG505 SOSIP 66.5 ± 0.1 67.0 ± 0.0 69.8 ± 0.2 
 
 
In conclusion, 16055 SOSIP showed one of the more promising antigenicity profiles. In 
contrast to the cleavage-incompetent REKS variants, this included higher affinity to the 
quaternary structure-dependent bnAbs PG9 and PGT145, which target the trimer apex, as 
well as gp120/gp41 interface-targeting PGT151. In addition, 16055 SOSIP benefitted most 
from cross-linking regarding thermostability, which correlates with serum neutralization 
activity after immunization.
50
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4.2.8. Summary 
In summary, application of the membrane-bound envelope alanine scanning library of 
clade C isolate 96ZM651 in a flow cytometry-based high-throughput assay enabled the 
identification of several mutations which improve the antigenicity profile of envelope 
immunogens. Thereby, W427A severely reduced CD4 recognition (Table 6), while 
mutants T278A/H and L111A exhibited increased signal intensities for bnAbs VRC01 and 
PG9, respectively (Table 13). Reduced CD4 binding would likely diminish the opening of 
the Env trimer, supporting a neutralizing antibody response in vivo. However, W427A also 
decreased the positive antigenicity effects of L111A and T278A/H (Tables 12 and 14), and 
was hence excluded from further analysis. Examination of the purified soluble 96ZM651 
trimers revealed improved affinity of mutant T278A to VRC01. Interestingly, T278H and 
L111A gp140 trimers exhibited increased affinities to both VRC01 and quaternary-
preferring PG9 (Table 13), hinting at potentially improved trimer folding for these 
variants. Additionally, L111A also enhanced envelope trimerization (Figure 30). Hence, 
T278H and L111A were analyzed in more detail in several membrane-bound and soluble 
variants of clades A, B and C, where both antigenicity and trimerization were also 
enhanced. Of note, this could also be demonstrated for isolates BG505 and 16055, as well 
as their trimer-stablilized SOSIP variants (Tables 8 and 10, Figure 32), which are 
currently extensively prevalent in the literature.
49,50,85,88
 
Ultimately, the combination of T278A/H and L111A resulted in Env immunogens of 
different clades which show reduced recognition of non-neutralizing antibodies (Table 12, 
Figure 37), improved trimerization (Figures 33 and 34) as well as increased PG9 and 
VRC01 affinity. Specifically, soluble 96ZM651 L111A/T278H trimers exhibited six- to 
sevenfold enhanced affinity to PG9 and 47-fold improved affinity to VRC01, while the 
L111A/T278H double mutants of the other clades exhibited approximately twofold 
improved KD values to PG9 and about fivefold enhanced affinities to VRC01 (Tables 13 
and 15). Chemical cross-linking was able to further reduce the recognition of non-
neutralizing antibodies (Figures 37 and 38) as well as increase envelope thermostability 
(Table 16).  
Notably, the analyzed isolates inherently displayed varying magnitudes of affinities 
towards the applied antibody panel. Thereby, 96ZM651 exhibited markedly higher KD 
values to both PG9 and VRC01 (Tables 8, 10 and 15), while also showing the weakest 
signals for quaternary-specific PGT145 and PGT151 (Figure 38). In contrast, 16055 and 
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16055 SOSIP L111A/T278H variants exhibited high affinities to the tested bnAb panel, 
including the quaternary-specific bnAbs (Figure 38). In addition, the 16055 SOSIP double 
mutant depicted the most profound improvement of trimerization (Figure 34) as well as 
the highest increase in thermostability after cross-linking (Table 16). Hence, 16055 
L111A/T278H and 16055 SOSIP L111A/T278H, both with and without chemical cross-
linking, will be further evaluated in a preclinical immunization study (Figure 39), to 
evaluate whether the herein demonstrated improved antigenicity and stability will 
ultimately translate into improved immunogenicity. 
The most relevant effects of the mutations identified in this thesis for all tested constructs 
are summarized in Table 17. 
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Table 17: Summary of the effects of mutations L111A, T278A/H and W427A as well as their combinations on different isolates of clades A, B and C. The varians which are currently 
evaluated in a preclinical animal study are highlighted in red. 
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SOSIP 
Yes 0 0 + +++ Yes --- * ++ + +++ ++ / +++ * Yes ↑ (~ 3 °C) 
B HXB2 No 0 - ++ ++ Yes --- ## -- 0 +++ NA NA Yes NA 
B JRFL No - 0 ++ ++ Yes --- ## +++ + ++ NA NA Yes NA 
C 16055 No 0 - + + Yes --- ## + ++ +++ 
+++ / 
++++ 
## Yes NM 
C 
16055 
SOSIP 
Yes + 0 + ++ Yes -- ### 0 0 ++ + / ++++ ### Yes ↑↑ ( ~ 6 °C)
 
C 96ZM651 No ++ + + +++ Yes --- ## + + +++ 
++++ / 
++++ 
## Yes NM 
 
Fold changes for gp145 and gp140 mutants compared to WT binding levels: 
++++: FC ≥ 5, +++: FC ≥ 2.5;  ++: 2 ≤ FC < 2.5;  +: 1.5 ≤ FC < 2;  0: 0.75 ≤ FC < 1.5;  - : 0.5 ≤ FC < 0.75;  -- : 0.1 ≤ FC < 0.5, --- : 0 ≤ FC <0.1 
 
a) FC: Fold Change, GoB: Gain of Binding, TM: Melting Temperature; NA: not available as measurements were not conducted; NM: not measurable due to too low signal intensity caused by 
aberrant trimer folding 
 
b) Alterations in SEC elution profiles: 
0: no effect; *: reduced expression yield;  #: improved peak separation in SEC elution profiles ;  ## : improved trimerization/ reduced monomer formation;  ### : improved trimerization and 
increased trimer yield 
 
L111A  
and 
T278H 
were 
further 
evaluated 
in soluble 
trimers 
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5. Discussion 
HIV`s vast diversity has impeded the success of common vaccine strategies like life 
attenuation or chemical inactivation.
16
 Currently, HIV vaccine development focuses on the 
induction of broadly neutralizing antibodies, which target several different sites on the 
trimeric envelope protein.
33
 However, Env`s immense diversity,
19,26
 extensive glycan 
shield,
29
 structural shielding of conserved sites
30,31
 and structural instability
22
 delay bnAb 
development up to several years during natural infection. Hence, induction of broadly 
neutralizing antibodies by active vaccination remains extremely difficult, requiring the 
development of improved envelope immunogens. 
This thesis focused on the problem that both membrane-anchored and soluble Env trimers 
are flexible structures that exhibit different conformational states, influencing the 
presentation of structure-dependent bnAb epitopes and presenting non-neutralizing 
epitopes usually hidden in the pre-fusion closed state.
22,122
 This is further aggravated when 
Env trimers bind to CD4 and undergo the CD4-induced conformational change.
49
 Thus, 
Env variants with (i) improved bnAb binding, (ii) decreased recognition of non-
neutralizing antibodies and CD4 as well as (iii) improved trimer structure and stability 
would likely support a cross-neutralizing humoral immune response. Here, an innovative 
screening technology for the identification of such Env variants according to their antibody 
binding properties was investigated. This system combined mammalian cell display of 
membrane-bound envelope variants with flow cytometry-based cell sorting to select 
envelopes with high or low affinity to the applied screening antibody. In addition, results 
obtained from analyzing envelope-bnAb and envelope-sCD4 interactions with an Env 
alanine scanning library were utilized for the rational design of novel Env immunogens 
with improved stability and antigenicity profiles. 
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5.1. Analysis of a mammalian cell display-based panning 
system for the high-throughput discovery of new 
AIDS vaccine candidates 
 
 
5.1.1. Advantages of the applied stable cell line-based mammalian 
cell display system 
In order to analyze the antigenic profiles of HIV-1 envelope variants in the described 
panning process, recombinant Env proteins are displayed on inducible, stably transfected 
HEK cell lines, which are widely used e.g. for producing pseudoviruses for neutralization 
assays.
55,54,134
 This provides several advantages over other currently used methods. In 
contrast to yeast display of HIV-1 envelopes,
135,136
 it not only allows the expression of 
functional Env trimers in their natural membrane context, but also ensures mammalian 
glycosylation and native folding. Second, contrary to screening approaches with soluble 
trimers,
137,138,139
 this approach also enables the assessment of untruncated envelope 
variants, which was recently shown to have an important influence on Env folding and 
antigenicity.
65
 Hence, this display technique should provide all proposed requirements of 
envelope presentation, including glycan-dependent epitopes on Env,
55,45,58
 the preservation 
of promising quaternary structure-dependent epitopes
59,58
 as well as membrane-proximal 
epitopes like the MPER domain,
140,48
 which is e. g. deleted in soluble trimer-stabilized 
SOSIP variants.
49
 
Notably, the genomic integration of library vector pQL13 at a single, distinct FRT site 
allows a highly stringent linkage of genotype and phenotype within the library. In addition, 
the defined integration locus also reduces expression variations that could potentially be 
caused by the genomic context (such as promotors or regulatory regions). Residual 
deviations in expression levels of the different variants can be efficiently normalized by the 
translational coupling of Env and eGFP by a "self-cleaving" TaV 2A peptide
104
 (Figure 
13).  
In addition, the eGFP/Env expression cassette is under inducible regulation of the Tat 
operator/repressor system, preventing Env cytotoxicity effects during cell cultivation and 
thus, variations in library composition caused by growth advantages or disadvantages of 
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specific variants. Moreover, if multiple panning cycles have to be applied to achieve 
satisfying enrichment rates, this stable cell line-based screening approach also allows the 
simple re-expansion of a portion of the sorted cells, while the remaining cells can be 
subjected to further enrichment rate analysis.  
 
 
 
5.1.2. Single-round FACS panning of the Env/V3 model library 
Taken together, the above described stringent genotype-phenotype linkage and expression 
normalization accounted for high enrichment rates for both low and high affinity variants 
in only a single round of panning, as exemplified using a five-member chimeric model 
library and mAbs 447-52D and HGN194. Notably, high affinity chimera Env/V3-MN 
could be selectively enriched to represent 71 - 93 % of all sequences out of an equimolar 
mixture of the five chimeras, resulting in enrichment rates of up to 56- and 55-fold for 447-
52D and HGN194, respectively. Similarly, the abundance of low affinity variant Env/V3-
SF33 for 447-52D and the two non-binders Env/V3-SF33 and -RF for HGN194 was 
significantly increased in the respective low affinity fractions: Env/V3-SF33 showed an up 
to 237-fold enrichment in the low affinity gate for 447-52D (72 - 97 % out of an equimolar 
mixture of all five chimeras), while the two low affinity variants for HGN194, Env/V3-
SF33 and -RF, were enriched approximately 5-fold (ca. 50 % each out of an equimolar 
mixture of all five chimeras) (Table 1 and Figure 16). Importantly, we were able to 
replicate those results using qPCR, capillary sequencing of single clones as well as next 
generation sequencing on both the re-cloned plasmid DNA as well as directly on the 
genomic DNA of sorted cells and input controls (Figure 16), although enrichment rates 
varied slightly between the different methods (Table 1). However, the utilized formula
108
 
not only considers the enrichment of the respective selected variants, but also the depletion 
of all other chimeras and is thus highly sensitive to slight variations between the different 
analyses.  
In conclusion, this procedure represents a strong improvement over the panning approach 
previously published by Bruun et al., which utilized a lentiviral vector system for stable 
transgene integration. There, even a low multiplicity of infection (MOI) of 0.1 could not 
prevent multiple infections and thus multiple integration events in single cells. The 
resulting lack of stringent genotype-phenotype linkage made two panning cycles necessary 
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to obtain 81 % Env/V3-MN sequences out of an equimolar mixture of all five variants, 
representing an enrichment of only 20-fold (estimated by qPCR).
96
  
 
 
 
5.1.3. Future directions 
Notably, next generation sequencing was successfully applied directly to the genomic 
DNA of sorted cells and input controls (Figure 16), enabling the facilitated and efficient 
analysis of large libraries. Hence, this approach would be easily applicable to more 
comprehensive trimeric Env libraries and highly potent broadly neutralizing antibodies like 
VRC01,
141
 PG9/PG16
142
 or members of the PGT family.
55,59
 Including available 
engineered unmutated common bnAb ancestors (UCAs) into the screening, this system 
could also be extended to identify Env variants for sequential immunization 
approaches.
143,144,145,146
 Such a strategy was e.g. recently reported with envelope variants 
identified from a panning approach which used lentiviral transgene integration and 
subsequent FACS sorting,
147
 similar to the approach published by Bruun et al.
96
 The 
problem of multiply infected cells was thereby apparently solved by extended cultivation 
of stable cell lines and MOIs of less than 0.1. Using different BG505 SOSIP gp140 based 
libraries fused to a PDGFR-transmembrane domain, Steichen et al. engineered several 
HIV-1 Env trimers with affinity for germline PGT121-class bnAbs, intermediates with 
increasing levels of epitope modification and mature envelope variants. Sequential 
immunization with these soluble trimers effectively induced bnAbs in two PGT121 knock-
in mouse models,
84
 demonstrating the practical applicability of such a panning technology.  
In contrast to this approach, the here described strategy offers the possibility to include 
membrane-proximal bnAb epitopes by administering the isolated membrane-bound Env 
immunogens via non-viral or viral vectors.  
In addition to the membrane-bound variants, antigenicity profiles of the model library to 
447-52D and HGN194 were also investigated for soluble gp140, with comparable results 
(Figure 17, Table 2). Although the magnitude of KD values varied between flow 
cytometry of gp145 variants and ELISA analysis of gp140 trimers, most probably due to 
different inherent conditions of the two methods, the overall order of binding affinities for 
each investigated epitope was equal. Hence, vaccine candidates selected with this approach 
may, similarly to the BG505 SOSIP-based constructs described above,
147,84
 also be potent 
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immunogens as soluble Env trimers. To this end, however, secreted variants would have to 
be evaluated individually, as phenotypes might not always be easily transferable from 
membrane-bound to soluble trimers, e.g. where epitopes on gp41 are concerned.  
 
 
 
5.1.4. Conclusion 
In conclusion, we have provided an efficient mammalian cell display and panning system 
that allows the selection of complete trimeric HIV envelopes. The stable cell line-based 
display of membrane-bound Env variants provides the advantages of (i) inducible Env 
expression, (ii) mammalian folding and glycosylation, (iii) efficient normalization for Env 
expression via GFP fluorescence and (iv) stringent genotype-phenotype linkage due to 
single integration into the predefined FRT site (Figure 13). Data generated for the five-
member model library demonstrate a clear correlation between (i) the MFIs measured at a 
distinct 447-52D or HGN194 antibody concentration for the individual membrane-bound 
Env/V3 chimeras (Figure 14A and C), (ii) gp145 binding affinities to 447-52D or 
HGN194 (Table 2), (iii)  the copy number (qPCR) or number of sequences (capillary 
sequencing / NGS) of the respective Env/V3 chimeras after one panning cycle (Figure 16) 
and (iv) binding affinities of 447-52D or HGN194 to soluble Env/V3 trimers (Table 2). 
The limits regarding feasible library sizes still have to be explored in greater detail, which 
is currently further investigated by Julia Koop as part of her PhD thesis. However, this 
technology may ultimately be applicable to diverse viral vaccines, including not only HIV, 
but also other bnAb-dependent vaccine endeavors like Influenza,
148,19
 Hepatitis C 
virus
149,150
 or Cytomegalovirus, where the proper assembly of several envelope subunits is 
necessary for the induction of highly quaternary structure-dependent broadly neutralizing 
antibodies.
151
 Although not specifically addressed in this thesis, this panning system may 
additionally be useful for the rapid epitope mapping of yet uncharacterized antibodies. To 
this end, alanine scanning libraries of envelope surface residues or glycan scanning 
libraries with modified N-glycosylation sites or patterns could be employed to investigate 
the footprints of mature bnAbs and their engineered germline variants.   
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5.2. Development of HIV-1 envelope immunogens with 
improved antigenicity and stability using a cell-based 
epitope mapping platform 
 
 
5.2.1. Epitope mapping with the 96ZM651 alanine scanning library 
Recent progress in sorting patient B cell populations with engineered well-folded envelope 
baits
152,52,153
 and high-throughput neutralization scans of immortalized B cell 
repertoires
54,48,44
 has led to the identification of various new broadly neutralizing 
antibodies. This has resulted in an increased demand for methods which facilitate and 
accelerate the fine mapping of antibody-envelope interfaces to gather knowledge for the 
rational design of new Env immunogens. While peptide scans only yield information about 
linear epitopes
44
 and are therefore not suitable for most of the newly identified structure-
dependent bnAbs,
42,58,60
 Env-antibody co-crystallization reveals the interaction at atomic 
level resolution.
42,110
 However, some of the available bnAb structures were not solved by 
Env co-crystallization, but in an unbound state, like for example PGT145 (PDB ID: 
3UIS)
117
 or PGDM1400 (PDB ID: 4RQQ).
51
 In addition, some antibodies proved to be 
difficult to crystallize, e.g. HJ16, which was only recently co-crystallized with Env (PDB 
ID: 4YE4, Chen et al., to be published). In this thesis, a mammalian cell display and flow 
cytometry-based high-throughput alanine scanning technique was employed to map 
envelope interactions with sCD4, CD4 binding site-targeting bnAb VRC01
42
 and the 
quaternary structure preferring bnAb PG9
58
 targeting the trimer apex.  
 
 
 
5.2.1.1. General setup and evaluation of the alanine scanning procedure 
Display of Env alanine variants on HEK cells ensured native folding and mammalian 
glycosylation, providing all proposed requirements of Env presentation (see 5.1.1) to 
facilitate the analysis of glycan
45,55,58
 or structure-dependent
58,59,60
 as well as MPER-
targeting
48,140
 bnAbs.  
Discussion 
107 
 
Since the well-folded SOSIP and NFL variants, which are better suited for the analysis of 
conformation-dependent antibodies, have only recently become available,
49,82
 a cleavage-
incompetent gp145 envelope of clade C isolate 96ZM651 was used to avoid gp120 
shedding.
116
 It is now known that cleavage site mutation disturbs Env quaternary 
structure;
81
 however, sCD4 and VRC01 both recognize soluble gp120
20,42
 and PG9 is 
quaternary-preferring,
127
 but was reported to also bind several gp120 proteins and 
cleavage-incompetent gp140 monomers and trimers.
49,57
 Here, these investigated 
interaction partners were able to tolerate cleavage site mutation in comparison to the 
cleavage-competent wildtype (Figure 19). However, other newly identified bnAbs like 
PGT145,
58
 PGT151-158
59
 or 35O22
60
 are heavily reliant on well-folded envelope trimers 
and did not bind cleavage-defective 96ZM651 (Figure 37), prohibiting mapping 
approaches of highly structure-dependent mAbs with this library. To overcome these 
limitations, fully cleaved alanine scanning libraries based on BG505 SOSIP
49,154
 gp145 
(resulting in enhanced Env surface expression levels
64
), and gp160 (excluding antigenicity 
effects of cytoplasmic tail deletion
64,65
) are currently being established in the course of 
Benjamin Zimmer`s PhD thesis within the group.  
To normalize for varying Env surface presentation levels and transfection efficiencies, co-
staining with mAb 5F3 was implemented, which recognizes a linear epitope in gp41.
46
 
This limits the mapping technology mostly to the analysis of gp120-targeting screening 
reagents, due to sterical constraints caused by simultaneous staining with two antibodies. 
To overcome these limitations, a panel of different reference antibodies (including e.g. 
HGN194, which recognizes a linear epitope in V3,
44
 or 2G12, which targets a conserved 
mannose-patch in gp120
45
) could be utilized to include all alanine variants into the assay 
and enable the characterization of gp41-targeting bnAbs. Moreover, normalizing reagents 
of smaller sizes would also diminish sterical hindrances. To this end, Fab fragments could 
be applied, as well as heavy chain antibodies of shark or camelid origin
155,156
 or Env-
targeting aptamers
157,158
, although such reagents would be more complex to obtain. 
Moreover, Steichen et al.
147
 inserted a c-Myc tag into different BG505 SOSIP gp140 based 
libraries, located between gp140 and a PDGFR transmembrane domain. As this strategy 
was already proven to effectively normalize for Env expression in FACS sorting 
experiments, it could also be employed in future libraries, e.g. by inserting a linker-tag-
linker sequence between amino acid position 664, where gp140 SOSIP constructs are 
terminated,
49
 and the HIV-1 envelope transmembrane domain. 
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5.2.1.2. Analysis of envelope interactions with sCD4, VRC01 and PG9 
All alanine scans conducted in this thesis were able to map the interaction between 
96ZM651 Env and the analyzed ligands (sCD4, VRC01 and PG9) to the respective 
targeted region. However, the screenings did not result in a 100 % overlap with published 
crystal structure data (Figures 23, 25 and 28), possibly due to an interplay of several 
reasons. First, while co-crystallization detects the whole interaction surface of two binding 
partners, not all contact residues actually contribute to the interaction energy. Mutational 
studies therefore confirmed that epitopes defined structurally differ from epitopes 
identified in functional assays.
124
 On the other hand, alanine substitutions do not induce 
extreme electrostatic or steric effects and hence, do not significantly alter a protein`s main 
chain conformation. Therefore, alanine scanning libraries allow the identification of amino 
acid side chain interactions, but main-chain-only contacts are likely to be unaffected.
111,125
 
This, for example, can explain the negative influence on sCD4 binding for mutations 
N425A and W427A, where main chain and side chain contacts account for the interaction. 
In contrast, neighbouring residues like M426, Q428 and G431 were not influenced, as only 
main chain interactions play a role at these positions (Figure 23A).
42
 
In addition to contacts determined by crystallography, all alanine scans identified further 
significant loss of binding mutations, often located on the inside of the envelope trimer and 
highly conserved (Appendix Table 3). Hence, these mutations supposedly have a negative 
influence on Env structure, resulting in decreased binding for all tested interaction partners, 
although PG9 targets a completely different epitope compared to sCD4 and VRC01. This 
is in agreement with previous reports stating that e.g. mutations F92A or M99A inside the 
envelope trimer disrupt Env conformation.
159
 The generation of more extensive datasets, 
including different envelope epitopes and highly structure-dependent mAbs like PGT151
59
 
or PGT145
58
 could help to exclude such positions from future epitope mapping analyses.  
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5.2.2. Development of next generation envelope immunogens 
 
 
5.2.2.1. Identification of significant mutations for the rational design of 
next generation envelope immunogens 
Interestingly, the performed alanine scans not only allowed characterization of the 
respective epitopes, but also yielded mutations which can be directly introduced into next 
generation envelope immunogens. T278A and H were found to enhance VRC01 binding in 
the flow cytometry-based assay, with fold changes of approximately twofold and four- to 
fivefold, respectively (Figure 26, Table 7). In addition, L111A led to about twofold 
increased signal intensities for PG9 (Tables 9 and 10). Notably, these effects of T278A/H 
and L111A were also transferable to soluble gp140 trimers (Tables 8 and 10). 
Both T278 mutants result in the disruption of an N-glycosylation site at position 276 at the 
edge of the CD4 binding site (Figure 25). This glycan was previously shown to be 
essential for bnAb HJ16
160
 (Figure 37). However, its removal also results in increased 
neutralization of other CD4BS-targeting antibodies, for example bnAb NIH45-46 and 
germline reverted versions of NIH45-46 or VRC01,
144
 supposedly by improving 
accessibility of the CD4 binding site. Apart from glycan removal, the additional benefit of 
T278H might be explained by advantageous interactions of histidine`s positive charge with 
VRC01 (Figure 26B). However, T278H not only positively affected VRC01 binding with 
fold changes of about fivefold for membrane-bound Env and an approximately threefold 
improved KD for soluble gp140, but also enhanced binding of quaternary-preferring bnAb 
PG9 to both gp145 and gp140 (Table 13). As PG9 targets the trimer apex and can 
therefore not directly interact with position 278 at the CD4 binding site, this might suggest 
improved folding of mutant T278H, supporting both tertiary structure representation of the 
CD4 binding site epitope as well as quaternary packing of the trimer. 
L111A was previously described to decrease aberrant gp120 dimerization as well as 
recognition of sCD4 and CD4i antibodies, thereby improving the neutralizing antibody 
response.
129,130
 Recently, BG505 L111A gp120 has been implemented in several 
immunization studies in comparison to trimeric BG505 SOSIP.
49,80,84
 This thesis 
demonstrated that L111A not only affects gp120, but also impacts envelope trimerization, 
as demonstrated by the profoundly reduced monomer fraction of gp140 L111A (Figure 
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32). Furthermore, L111A positively influenced trimer antigenicity. While the previously 
described effect of impaired sCD4 and CD4i binding could be replicated for 96ZM651 
membrane-bound gp145 and soluble gp140, both also depicted increased binding to 
structure-dependent bnAb VRC01 and quaternary structure-dependent PG9 (Tables 9 and 
13). However, position L111 is located in the inner domain of Env, at the distal end of the 
α1 helix161 and is therefore not available for direct antibody interactions. Interestingly, 
though, this particular region was shown to play a role in the conformational change 
leading to the CD4 bound state of gp120.
161
 In conjunction with the more homogeneous 
melting curve observed by DSC analysis of L111A gp140 (Figure 31), this hints at a 
favorable impact of L111A on envelope structure. Thereby, Env quaternary folding may be 
improved. However, as PG9 also binds distinct gp120 and gp140 monomers
49,57
 and 
reduced binding of CD4 and CD4i mAbs was also observed for gp120,
129,130
 L111A could 
also result in improved folding of the gp120 subunits, while trimer integrity might not be 
affected. To properly elucidate the proposed structural influence of both T278H and 
L111A on HIV Env, negative-stain electron microscopy
81
 could be applied to the 
respective soluble trimers in comparison to wildtype gp140. 
Notably, the effects of L111A and T278A/H as originally determined for 96ZM651 
envelope (clade C) were also well transferable to other gp145 and gp140 variants of clades 
A, B and C, including trimer-stabilized SOSIP constructs (Figures 32 and 34, Tables 8 
and 10). Thereby, T278H exhibited a slight advantage over T278A in all tested gp145 
variants, while increasing VRC01 affinity to the soluble trimers approximately two- to 
threefold (Table 8). Most likely due to the different effects of L111A (i.e. on PG9 affinity, 
Env trimerization and possibly Env structure), fold changes in signal intensities for 
membrane-bound L111A variants and KD values for secreted trimers were not conform for 
all isolates. However, most tested soluble L111A variants displayed approximately twofold 
increased affinity to both PG9 and VRC01 (Table 10), as well as markedly improved 
trimerization. For the latter, the only exception presented BG505 and BG505 SOSIP. This 
may be explained by the inherent predisposition of BG505 to form stable trimers,
162,81
 
which is further enhanced by the SOSIP mutations
49
 and might not be additionally 
improvable by L111A. Notably, the most pronounced effect regarding envelope 
trimerization was observed for 16055 SOSIP, where introduction of L111A resulted in a 
markedly increased trimer fraction (Figure 32). 
In conclusion, the identified gain of binding mutations improved affinities of bnAbs 
VRC01 and PG9 as well as envelope trimerization. In addition, both T278H and L111A 
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may additionally affect trimer folding, which could further be elucidated with negative-
stain electron microscopy.
81
 Originally identified for membrane-bound 96ZM651, the 
beneficial phenotypes were not only transferable to soluble 96ZM651 trimers, but also to 
membrane-bound and soluble variants of different isolates and SOSIP constructs. This 
reinforces the notion that results obtained from the 96ZM651 based CSAM procedure are 
also of value for other applications and can provide indications for the development of 
soluble vaccine candidates from different subtypes. Antigenicity profiles were, however, 
not invariably applicable to all tested constructs. For instance, L111A did reduce the 
monomer fraction of soluble gp140 in B clade isolate HXB2, but nevertheless impaired 
PG9 affinity (Figure 32, Table 10).  Thus, the potential of mutations which were 
identified in 96ZM651 gp145 on other membrane-bound or soluble envelope isolates 
would always have to be evaluated individually. 
 
 
 
5.2.2.2. Combination of antigenicity improving single mutations 
Membrane-bound gp145 and soluble gp140 Env proteins containing both L111A and 
T278A/H mutations resulted in next generation envelope immunogens with increased 
bnAb binding, decreased recognition of non-neutralizing antibodies and improved 
envelope trimerization (Tables 12 and 13, Figures 33 and 34). Most interestingly, the 
effects of L111A and T278H thereby seemed to be additive, resulting in six- to sevenfold 
improved affinity of double mutant L111A/T278H to PG9 and 47-fold improved affinity to 
VRC01 in the case of 96ZM651. In addition, the KD values of L111A/T278H variants 
based on other Env isolates were reduced approximately twofold for PG9 and fivefold for 
VRC01 (Table 13, Table 15). In agreement with results observed for the L111A single 
mutants, double mutants of BG505 and the associated SOSIP construct again exhibited no 
effect regarding trimerization, while the most prominent impact was observed for 16055 
SOSIP, where the trimer fraction was markedly increased in SEC elution profiles (Figure 
34).  
Furthermore, the alanine scanning procedure revealed significantly impaired binding of 
W427A to sCD4 and the non-neutralizing antibody 17b, which targets the open, CD4-
induced envelope conformation (Appendix Table 4). The highly conserved tryptophan 
residue is located in the bridging sheet of Env
163
 and directly interacts with both VRC01 
Discussion 
112 
 
and CD4 (Figures 23 and 25).
42
 However, while VRC01 contacts only its main chain, CD4 
forms both main chain and side chain interactions.
42
 Hence, we were able to optionally 
include W427A into the next generation Env immunogens, resulting in preserved bnAb 
binding, while recognition of sCD4 and 17b was severely inhibited (Table 12). Abolishing 
CD4 binding would supposedly support antigen bioavailability and hence a neutralizing 
antibody response, as envelope immunogens could not be depleted by binding to CD4
+
 
host immune cells before they had the opportunity to interact with B-cell receptors or be 
taken up by antigen-presenting cells.
79
  More importantly, however, reduced CD4 
recognition may be relevant to prohibit the CD4-induced opening of the Env trimer and the 
resulting presentation of potentially distractive non-neutralizing epitopes in vivo.
164
 
However, to thoroughly analyze these effects on immunogenicity, a human CD4 
transgenic
165,166,167
 or humanized animal model
168
 would have to be used. As W427A in 
both gp145 and gp140 also slightly decreased VRC01 and PG9 binding compared to 
L111/T278 double mutants in both gp145 and gp140 (Tables 12 and 13), it was, for the 
time being, excluded from further analysis. 
 
 
 
5.2.2.3. Chemical cross-linking of L111A/T278H envelope variants 
 
Since combination of L111A and T278H resulted in the most prominent increase in 
VRC01 and PG9 recognition (Tables 13 and 14), we decided to investigate the potential 
for further stabilization of L111A/T278H variants by chemical cross-linking. To this end, 
double mutants of 96ZM651, BG505/BG505 SOSIP and 16055/16055 SOSIP were used. 
Cross-linking of vaccine antigens was first applied to create inactivated polio vaccines and 
has since been used more widely with an excellent safety record.
169,170
 Here, we utilized a 
recently published protocol for HIV-1 envelope cross-linking with glutaraldehyde (GLA), 
which cross-links amine groups by inserting a five-member carbon-chain. In addition, 
EDC/NHS was applied, which cross-links carboxyl- and amine-groups without inserting 
additional atoms.
78,79,50
 For GLA-treated antigens, extensive safety data are available for 
clinical trials of heart
171
 and vascular
172
 transplants, as well as allergy 
immunotherapy.
173,174
 However, GLA cross-linking severely impaired PG9 binding for all 
variants (Figure 35) and was thus excluded from further analysis. This is in line with a 
Discussion 
113 
 
recent report of Schiffner et al., who found that GLA cross-linking drastically decreased 
binding of PGT145, which shares the core epitope of PG9.
58
  
In contrast to GLA, no clinical trials have been conducted with EDC/NHS cross-linked 
proteins to date, however, as it does not insert additional linker atoms into the immunogen, 
safety issues seem unlikely.
175
 Supposedly due to different cross-linking chemistries and 
the absence of linker atoms, EDC/NHS could, in contrast to GLA, successfully stabilize 
envelope trimers. While presentation of non-neutralizing epitopes for all L111A/T278H 
variants was further reduced, bnAb binding to various epitopes could largely be preserved 
(Figure 37). Notably, contrary to Schiffner et al.,
79
 who hypothesized that cross-linked 
trimers can only display one of the two quaternary structure-dependent epitopes for 
PGT145 and PGT151 efficiently, the epitopes of both antibodies could be maintained.  
Due to the inhomogeneous folding of cleavage-incompetent gp140 trimers and the 
resulting low signal intensities for melting curves of 96ZM651, BG505 and 16055, 
thermostability of cross-linked trimers could only reliably be determined for the two 
SOSIP constructs.  In agreement with recent reports,
79,50
 both cross-linked SOSIP 
constructs depicted increased melting temperatures (Table 16), which was proven to 
correlate with improved immunogenicity.
50
 
In summary, the reduced presentation of non-neutralizing epitopes and increased stability 
of cross-linked variants may contribute to improved neutralizing antibody responses in 
vivo, which will further be analyzed in a preclinical immunization study (Figure 39).  
 
 
 
5.2.3. Conclusion 
In conclusion, the described alanine scanning procedure is a fast and effective method to 
characterize antibody-Env interactions. It provides the advantages of native folding and 
mammalian glycosylation and can, in combination with other techniques like co-
crystallization, supply additional information about bnAb footprints. Furthermore, this 
approach is able to directly yield mutations for the rational design of envelope 
immunogens, as demonstrated with L111A and T278A/H, which both increased VRC01 
and PG9 affinity. While L111A was proven to additionally enhance envelope 
trimerization, both L111A and T278H might also improve trimer folding. Originally 
identified for membrane-bound 96ZM651, these mutations also enhanced antigenicity and 
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supposedly the structure of soluble 96ZM651 trimers as well as membrane-bound and 
secreted variants from different clades. Hence, this screening approach is able to guide the 
development of novel membrane-bound and soluble vaccine candidates from different 
subtypes.  
Combination of the identified mutations resulted in envelope immunogens with reduced 
recognition of non-neutralizing antibodies, improved trimerization as well as increased 
bnAb affinity. Specifically, mutations L111A and T278H appeared to have an additive 
effect, leading to six- to sevenfold improved affinity of PG9 and 47-fold improved affinity 
of VRC01 for 96ZM651. Of note, L111A/T278H double mutants from other clades 
exhibited approximately twofold reduced KD values for PG9 and about fivefold decreased 
KDs for VRC01. These favourable antigenicity profiles could additionally be enhanced by 
chemical cross-linking, which further reduced recognition of non-neutralizing antibodies 
and increased thermostability, which should both support a neutralizing antibody response 
in vivo.
50
  
Notably, the different isolates inherently displayed different magnitudes of affinities 
towards the applied bnAb panel. Thereby, 96ZM651 exhibited markedly higher KD values 
to both PG9 and VRC01 compared to BG505/BG505 SOSIP and 16055/16055 SOSIP 
(Tables 8, 10 and 15), while also showing the weakest signals for quaternary-specific 
PGT145 and PGT151 (Figure 38). Interestingly, the trimer-stabilized BG505 SOSIP 
repeatedly exhibited lower affinity to both VRC01 and PG9 than the unmodified clade A 
isolate (Tables 8, 10 and 15), which was similarly reported for CD4BS bnAbs VRC01 and 
b12.
81
 In summary, 16055 and 16055 SOSIP L111A/T278H variants exhibited one of the 
more promising antigenic profiles, including binding of quaternary-specific bnAbs (Figure 
38). In addition, the 16055 SOSIP double mutant depicted the highest increase in 
thermostability after cross-linking as well as the most profound improvement of 
trimerization. While thermostability was recently shown to correlate with serum 
neutralization capacity after vaccination,
50
 a shift towards a higher trimer proportion on the 
surface of Env producing cells will likely also support induction of a more potent, 
quaternary-specific antibody response after DNA priming. Hence, these variants were 
chosen to be further evaluated in a preclinical immunization study in rabbits, to analyze 
whether the demonstrated improved antigenicity and stability will ultimately translate into 
enhanced immunogenicity. 
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6. Perspective 
The herein described flow cytometry-based mammalian cell display and panning approach 
was evaluated with a five-member chimeric model library. As a next step, the procedure 
has to be expanded to larger and more sophisticated libraries. For this, a sequential 
permutation library of 16055 gp145 is available. Analyses of the panning technique with 
five, 15 and 45 permutated positions, i.e. a maximum of 100, 300 or 900 different variants, 
was part of Julia Koop`s PhD thesis. These sublibraries were exclusively composed of 
variants with mutations at the CD4BS of Env. Of note, each library contained the 
permutated position 278, where T278A and H were shown to increase VRC01 binding in 
this thesis. Preliminary results suggest that both mutants could be isolated in the high 
affinity gate of the five positions screen after one panning cycle, while the superior T278H 
was also enriched from the sublibrary containing 15 positions. Other variants from the high 
and low affinity gate are currently tested by flow cytometry to verify their increased or 
decreased binding to VRC01. Eventually, the screening should be applicable to the 
complete 16055 sequential permutation library of approximately 13,000 variants. 
Furthermore, this panning approach is intended to be the basis of projects within the 
EHVA (European HIV Vaccine Association) consortium. In particular, an envelope library 
based on the well-folded BG505 SOSIP construct is to be established, to identify germline-
targeting envelope variants for the highly effective bnAb PGT145 for sequential 
immunization approaches. Other projects in cooperation with Dr. Rogier Sanders at the 
Amsterdam Medisch Centrum (AMC), who first published BG505 SOSIP,
49
 include the 
increase of expression yields or improved trimer folding for not yet published SOSIP 
versions. To be able to screen these extensive envelope libraries, the library generation 
procedure as well as the sorting strategy will have to be adapted to be applicable to a large 
number of different variants. 
The 16055 and 16055 SOSIP variants identified with the alanine scanning technique will 
be applied in a preclinical immunization study to survey whether improved antigenicity 
and stability in vitro will translate into improved immunogenicity in vivo. Formulation of 
all antigens will occur in GLA-LSQ (Glucopyranosyl Lipid Adjuvant-Liposome QS21), 
which was already effective for vaccine candidates of leishmania, influenza or 
malaria.
176,177,178
 Recently, a formulation study in cooperation with the Infectious Diseases 
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Research Institute (IDRI), Seattle, USA, demonstrated physicochemical stability of all 
envelope antigens for the intended rabbit study with this adjuvant. 
Each immunization arm will consist of five rabbits. The first four groups will receive 
protein primes and boosts of one protein each (either 16055 WT, 16055 L111A/T278H, 
16055 SOSIP WT or 16055 SOSIP L111A/T278H), to evaluate the influence of the 
L111A/T278H and SOSIP mutations on immunogenicity. Three further groups will receive 
DNA primes and protein boosts of 16055 and 16055 SOSIP variants in different 
combinations. DNA priming and the resulting expression of envelope variants on the 
surface of affected host cells will be valuable to elucidate the impact of the profoundly 
improved trimerization of the 16055/16055 SOSIP double mutants. In all these groups, 
protein stability will increase with the time point of administration to analyze whether 
stabilized immunogens are needed as priming or boosting reagents to support a 
neutralizing antibody response. For all seven groups, the fourth and last boost will consist 
of the respective cross-linked envelope trimer to determine whether this further 
stabilization can additionally improve neutralizing activity or maintenance of the humoral 
immune response. An overview of the immunization study, which is anticipated to start in 
June 2017, is shown in Figure 39. 
 
 
 
Figure 39: Schematic overview of the preclinical immunization study. Upper panel: New Zealand White 
rabbits will receive four immunizations at weeks 0, 4, 8 and 20. Red arrows indicate samplings of sera for the 
analysis of antibody titers (ELISA) and neutralization capacity against tier 1 and tier 2 viruses (TZM-bl or 
A3R5 assays). Lower panel: Groups 1-4 will receive protein (P) primes and boosts of one gp140 trimer each 
(16055 WT, 16055 L111A/T278H (LT), 16055 SOSIP WT or 16055 SOSIP L111A/T278H). Groups 5-7 will 
receive DNA (D) primes and protein boosts of different combinations of 16055 and 16055 SOSIP variants, 
with trimer stability increasing with the time point of administration. The last boost of each group will 
contain the respective cross-linked (CL) envelope trimer.  
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7. Abstract 
HIV`s vast genetic diversity has prevented the success of common vaccine approaches. 
Currently, HIV-1 vaccine development focuses on the induction of broadly neutralizing 
antibodies (bnAbs), which target various epitopes on the trimeric envelope (Env) protein. 
The most potent bnAbs known today are able to neutralize more than 90 % of circulating 
virus strains; however, their development requires a complex co-evolution of virus and 
humoral immune system. Therefore, induction of bnAbs by active immunization remains 
extremely difficult, demanding both improved Env immunogens as well as innovative 
screening techniques for their identification.  
The first project of this thesis investigated a mammalian cell display and cell sorting-based 
panning technique for the identification of vaccine candidates with improved antigenicity. 
This panning procedure combines the advantages of (i) single integration of Env into a 
distinct FRT site to link genotype and phenotype within a stable cell line library, (ii) 
inducible Env expression to avoid cytotoxicity effects, (iii) translational coupling of Env 
and GFP to normalize for induced Env expression and (iv) display on HEK cells to ensure 
native folding and mammalian glycosylation. Using a model library of five envelope 
chimeras with distinct binding profiles to mAbs 447-52D and HGN194, cell sorting 
selectively enriched the high affinity variant up to 55- and 56-fold, respectively, and low 
affinity variants up to 237-fold after only a single round of panning. Notably, affinity 
rankings of cell surface displayed and purified secreted trimers were equal, suggesting that 
binding properties of Env variants selected with this approach can also guide the 
identification of soluble envelope antigens. Applying more elaborate Env libraries to 
screen the currently available set of broadly neutralizing monoclonal antibodies and their 
engineered unmutated common ancestors, this stable cell line-based panning technology 
therefore provides a valuable tool for the selection of new HIV-1 Env vaccine candidates. 
Ultimately, this technique may also be applicable to other bnAb-dependent vaccine 
endeavors targeting e.g. Influenza-, Hepatitis C- or Cytomegalovirus. 
A second project focused on the mapping of envelope-bnAb interactions for the rational 
design of novel Env immunogens. To this end, mammalian cell display of an envelope 
alanine library based on C clade isolate 96ZM651 was applied in a high-throughput flow 
cytometry assay to map envelope interactions with different mAbs as well as soluble CD4 
(sCD4). Interestingly, this approach was able to directly identify amino acid substitutions 
Abstract 
118 
 
which improved Env antigenicity and folding. Combination of these mutations ultimately 
resulted in both membrane-bound and soluble envelope immunogens with increased 
affinity to bnAbs PG9 (targeting the trimer apex) and VRC01 (targeting the CD4 binding 
site), while the binding of non-neutralizing mAb 17b could be profoundly reduced. 
Notably, these trimers also exhibited enhanced trimerization and potentially improved 
folding. Optionally, a mutation which drastically reduced recognition of CD4 could be 
included, which could be beneficial for a neutralizing antibody response in vivo by 
prohibiting the profound CD4-induced conformational change of Env. Although the 
improved structural and antigenic phenotypes of those mutants were originally identified 
for 96ZM651 envelope, these favourable properties were also applicable to variants of 
other clade A, B and C isolates, including engineered, trimer-stabilized SOSIP constructs. 
Of note, membrane-bound gp145 and soluble gp140 variants thereby exhibited the same 
effects, indicating that this flow cytometry-based mapping procedure is able to guide the 
design of membrane-bound and soluble vaccine candidates from different subtypes. 
Additionally, affinity-enhanced soluble envelope trimers were stabilized by chemical 
cross-linking. This further reduced the binding of non-neutralizing antibodies and 
markedly increased thermostability, which correlates with the elicitation of neutralizing 
antibodies. The most potent envelope immunogens developed in this thesis will be 
analyzed in a preclinical immunization study starting in June 2017 to determine whether 
their improved antigenicity and stability in vitro will ultimately translate into enhanced 
immunogenicity in vivo. 
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8. Zusammenfassung 
Aufgrund der enorm hohen genetischen Variabilität von HIV-1 sind konventionelle 
Impfstoffstrategien bislang gescheitert. Heute fokussiert sich die HIV-1 
Vakzineentwicklung vor allem auf die Induktion breitneutralisierender Antikörper 
(bnAbs), die sich gegen verschiedene Epitope auf dem trimeren Oberflächenprotein 
Envelope (Env) richten. Die Besten heute bekannten bnAbs können über 90 % der 
zirkulierenden Virusstämme neutralisieren. Ihre Entstehung erfordert allerdings eine 
komplexe Koevolution zwischen Virus und humoralem Immunsystem, sodass ihre 
Induktion durch aktive Immunisierung immer noch enorm schwierig ist. Aus diesem 
Grund sind sowohl verbesserte Env Immunogene, als auch Methoden zu deren 
Identifizierung nötig. 
Das erste Projekt dieser Promotion beschäftigte sich mit einer Panning-Technologie, mit 
der durch Zellsortierung Envelopes mit verbesserten Antigenitätsprofilen aus einer 
Bibliothek basierend auf stabilen Zelllinien selektiert werden können. Dabei werden 
folgende Vorteile miteinander kombiniert: (i) Integration nur einer Env Variante in eine 
definierte FRT-Stelle pro Zelle, um Genotyp und Phänotyp innerhalb der Bibliothek 
effektiv zu verlinken, (ii) induzierbare Env Expression, um Zytotoxizitätseffekten 
vorzubeugen, (iii) translationale Verknüpfung von GFP und Env, um auf die induzierte 
Env Expression normalisieren zu können und (iv) Expression der Env Varianten auf HEK-
Zellen, um native Faltung und Säugetierglykosylierung zu gewährleisten. Unter 
Verwendung einer Modelbibliothek aus fünf Env-Chimären mit definierten 
Bindungsprofile zu den monoklonalen Antikörpern 447-52D und HGN194 konnte die 
Variante mit der höchsten Affinität zu beiden Antikörpern in nur einem Panningzyklus 
jeweils bis zu 55- bzw. 56-fach angereichert werden. Gleichzeitig zeigten die jeweiligen 
niedrig affinen Varianten Anreicherungsfaktoren von bis zu 237-fach. Interessanterweise 
zeigten membranständige und gereinigte lösliche Env Trimere die gleiche Rangfolge 
bezüglich ihrer Affinitäten. Somit kann diese Technologie auch für die Identifizierung 
löslicher Antigene wegweisend sein. Mit Hilfe komplexerer Envelope-Bibliotheken und 
dem derzeit vorhandenen Set an bnAbs und deren berechneter Keimbahnvarianten stellt 
diese Methode somit ein wertvolles Instrument zur Identifizierung neuer HIV 
Vakzinekandidaten dar. Dabei ist dieses Verfahren nicht nur auf HIV beschränkt, sondern 
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kann auch auf andere bnAb-abhängige Impfstoffvorhaben ausgeweitet werden, wie z.B. 
Influenza, Hepatitis C oder Cytomegalievirus. 
Das zweite Projekt dieser Promotion beruhte auf der Kartierung von Envelope-bnAb-
Interaktionen für das rationale Design neuer Env Immunogene. Dazu wurde eine 
membranständige Envelope Alanin-Bibliothek des Subtyp C Isolats 96ZM651 in einem 
Durchflusszytometrie-basierten Hochdurchsatzverfahren verwendet. Die Expression der 
Varianten fand dabei ebenfalls auf HEK-Zellen statt, um native Faltung und 
Säugetierglykosylierung zu gewährleisten. Mit Hilfe dieser Technologie wurden die 
Interaktionsflächen von Env sowohl zu den breitneutralisierenden Antikörpern PG9, 
welcher den Apex des Trimers angreift, und VRC01, der die CD4 Bindestelle erkennt, als 
auch zu löslichem CD4 (sCD4) untersucht. Interessanterweise wurden dabei Mutationen 
identifiziert, welche sowohl die Antigenität, als auch die Trimerisierung und Faltung von 
Env positiv beeinflussen. Die Kombination dieser Mutationen resultierte schließlich in 
erhöhter Affinität zu PG9 und VRC01, verringerter Bindung des nicht neutralisierenden 
Antikörpers 17b und verbesserter Trimerbildung. Optional konnte durch Einfügen einer 
weiteren Mutation außerdem die Bindung an sCD4 verhindert werden. Da diese eine 
tiefgreifende Konformationsänderung in Env auslöst, welche eine Vielzahl nicht 
neutralisierender Antikörperepitope freilegt, würde dies in vivo wahrscheinlich eine 
neutralisierende Antikörperantwort unterstützen. Die ursprünglich für 96ZM651 Envelope 
identifizierten Mutationen und deren Kombinationen konnten erfolgreich auf andere 
Isolate der Subtypen A, B und C, sowie auf trimerstabilisierte SOSIP-Varianten übertragen 
werden. Außerdem zeigten membranständige und lösliche Envelope Trimere die gleichen 
Effekte, was den Wert dieses Verfahrens für die Entwicklung löslicher Vakzinekandidaten 
unterschiedlicher Subtypen verdeutlicht.  
Außerdem konnten die generierten Mutanten durch chemisches Cross-Linking weiter 
stabilisiert werden. Dies reduzierte zusätzlich die Bindung nicht-neutralisierender 
Antikörper, während die Thermostabilität der Trimere, und somit deren Fähigkeit 
neutralisierende Antikörperantworten zu induzieren, deutlich erhöht wurde. Eine 
präklinische Immunisierungsstudie wird ab Juni 2017 prüfen, ob die in vitro demonstrierte 
verbesserte Antigenität und Stabilität der generierten Immunogene letztendlich auch deren 
Immunogenität positiv beeinflusst. 
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9. Appendix 
Appendix Table 1: Oligonucleotide sequences used in this thesis. 
Primer Name Primer Sequence Primer Name Primer Sequence 
Mutagenesis primer for the insertion of point mutations into different HIV-1 isolates 
96ZM651 L110A 
for 
GGACATCATCAGCGCCTGGGACCAG
AGCC 
zm96 T290Q rev 
GGTTTTCACGTTGTTCTGCAGGTTCTCG
CTTC 
96ZM651 L110A 
rev 
GGCTCTGGTCCCAGGCGCTGATGAT
GTCC 
zm 96 T290E for 
GAAGCGAGAACCTGGAGAACAACGTGA
AAACC 
96ZM651 S162A 
for 
CGACATGAAGAACTGCGCCTTCAACA
TCACCAC 
zm 96 T290E rev 
GGTTTTCACGTTGTTCTCCAGGTTCTCG
CTTC 
96ZM651 S162A 
rev 
GTGGTGATGTTGAAGGCGCAGTTCTT
CATGTCG 
zm96 T290K for 
GAAGCGAGAACCTGAAGAACAACGTGA
AAAC 
96ZM651 S162D 
for 
CGACATGAAGAACTGCGACTTCAACA
TCACCACC 
zm96 T290K rev 
GTTTTCACGTTGTTCTTCAGGTTCTCGC
TTC 
96ZM651 S162D 
rev 
GGTGGTGATGTTGAAGTCGCAGTTCT
TCATGTCG 
96ZM651 L110A 
W111A for 
GGACATCATCAGCGCCGCCGACCAGAG
CC 
96ZM651 S162T 
for 
CATGAAGAACTGCACCTTCAACATCA
CCAC 
96ZM651 L110A 
W111A rev 
GGCTCTGGTCGGCGGCGCTGATGATGT
CC 
96ZM651 S162T 
rev 
GTGGTGATGTTGAAGGTGCAGTTCTT
CATG 
MG_REKS>2xG4
S_Fwd 
ATATGGTCTCACTGGCGGAGGGGGAAG
TGCCGTGGGCATCGGCGCCGTG 
96ZM651 F163D 
for 
CATGAAGAACTGCAGCGACAACATCA
CCACCGAG 
MG_REKS>2xG4
S_Rev 
ATATGGTCTCACCAGATCCGCCTCCGC
CCTCCACCACCCGCCGCTTGGCC 
96ZM651 F163D 
rev 
CTCGGTGGTGATGTTGTCGCTGCAGT
TCTTCATG 
BG505 L110A 
for 
CCGACATCATCAGCGCCTGGGACCAGA
GCC 
96ZM651 N164M 
for 
GAACTGCAGCTTCATGATCACCACCG
AGCTG 
BG505 L110A 
rev 
GGCTCTGGTCCCAGGCGCTGATGATGT
CGG 
96ZM651 N164M 
rev 
CAGCTCGGTGGTGATCATGAAGCTGC
AGTTC 
BG5O5 L110W 
for 
CCGACATCATCAGCTGGTGGGACCAGA
GCC 
96ZM651 N164S 
for 
GAACTGCAGCTTCAGCATCACCACCG
AG 
BG5O5 L110W 
rev 
GGCTCTGGTCCCACCAGCTGATGATGT
CGG 
96ZM651 N164S 
rev 
CTCGGTGGTGATGCTGAAGCTGCAGT
TC 
BG505 V126A 
for 
GACCCCCCTGTGCGCCACCCTGCAGTG
CAC 
96ZM651 N164V 
for 
GAAGAACTGCAGCTTCGTGATCACCA
CCGAGCTG 
BG505 V126A 
rev 
GTGCACTGCAGGGTGGCGCACAGGGG
GGTC 
96ZM651 N164V 
rev 
CAGCTCGGTGGTGATCACGAAGCTG
CAGTTCTTC 
BG505 L128A 
for 
CCTGTGCGTGACCGCCCAGTGCACCAA
CG 
96ZM651 E168I for 
CAGCTTCAACATCACCACCATCCTGA
AGGACAAGAAAAAG 
BG505 L128A 
rev 
CGTTGGTGCACTGGGCGGTCACGCACA
GG 
96ZM651 E168I rev 
CTTTTTCTTGTCCTTCAGGATGGTGGT
GATGTTGAAGCTG 
BG505 N160A 
for 
GGGCGAGCTGAAGGCCTGCAGCTTCAA
C 
96ZM651 E168Q 
for 
CAACATCACCACCCAGCTGAAGGACA
AG 
BG505 N160A 
rev 
GTTGAAGCTGCAGGCCTTCAGCTCGCC
C 
96ZM651 E168Q 
rev 
CTTGTCCTTCAGCTGGGTGGTGATGT
TG 
BG505 S162A 
for 
GAGCTGAAGAACTGCGCCTTCAACATG
ACCAC 
96ZM651 E168T 
for 
CAGCTTCAACATCACCACCACCCTGA
AGGACAAGAAAAAG 
BG505 S162A 
rev 
GTGGTCATGTTGAAGGCGCAGTTCTTC
AGCTC 
96ZM651 E168T 
rev 
CTTTTTCTTGTCCTTCAGGGTGGTGG
TGATGTTGAAGCTG 
BG5O5 S162T 
for 
CGAGCTGAAGAACTGCACCTTCAACAT
GACCACCG 
96ZM651 K172C 
for 
CACCGAGCTGAAGGACTGCAAAAAGA
ACGTGTACGC 
BG5O5 S162T 
rev 
CGGTGGTCATGTTGAAGGTGCAGTTCT
TCAGCTCG 
96ZM651 K172C 
rev 
GCGTACACGTTCTTTTTGCAGTCCTTC
AGCTCGGTG 
BG505 F163A 
for 
CTGAAGAACTGCAGCGCCAACATGACC
ACCG 
96ZM651 K172L 
for 
CACCGAGCTGAAGGACCTGAAAAAGA
ACGTGTAC 
BG505 F163A 
rev 
CGGTGGTCATGTTGGCGCTGCAGTTCT
TCAG 
96ZM651 K172L 
rev 
GTACACGTTCTTTTTCAGGTCCTTCAG
CTCGGTG 
BG505 N164A 
for 
GAACTGCAGCTTCGCCATGACCACCGA
GC 
96ZM651 K172P 
for 
CACCGAGCTGAAGGACCCCAAAAAGA
ACGTGTACG 
BG505 N164A 
rev 
GCTCGGTGGTCATGGCGAAGCTGCAGT
TC 
96ZM651 K172P 
rev 
CGTACACGTTCTTTTTGGGGTCCTTC
AGCTCGGTG 
BG505 T166A 
for 
CAGCTTCAACATGGCCACCGAGCTGC 
96ZM651 K173I for 
GAGCTGAAGGACAAGATCAAGAACGT
GTACGCC 
BG505 T166A 
rev 
GCAGCTCGGTGGCCATGTTGAAGCTG 
96ZM651 K173I rev 
GGCGTACACGTTCTTGATCTTGTCCT
TCAGCTC 
BG505 E168A 
for 
CTTCAACATGACCACCGCCCTGCGGGA
CAAGAAAC 
96ZM651 K173L 
for 
CGAGCTGAAGGACAAGCTGAAGAAC
GTGTACGCC 
BG505 E168A 
rev 
GTTTCTTGTCCCGCAGGGCGGTGGTCA
TGTTGAAG 
96ZM651 K173L 
rev 
GGCGTACACGTTCTTCAGCTTGTCCT
TCAGCTCG 
BG505 K172A 
for 
CCGAGCTGCGGGACGCCAAACAGAAG
GTGTAC 
96ZM651 T290A 
for 
CAGAAGCGAGAACCTGGCCAACAAC
GTGAAAAC 
BG505 K172A 
rev 
GTACACCTTCTGTTTGGCGTCCCGCAG
CTCGG 
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Primer Name Primer Sequence Primer Name Primer Sequence 
96ZM651 T290A 
rev 
GTTTTCACGTTGTTGGCCAGGTTCTC
GCTTCTG 
BG505 K173A 
for 
GAGCTGCGGGACAAGGCCCAGAAGGT
GTACAG 
zm96 T290R for 
GAAGCGAGAACCTGAGGAACAACGT
GAAAAC 
BG505 K173A 
rev 
CTGTACACCTTCTGGGCCTTGTCCCGC
AGCTC 
zm96 T290R rev 
GTTTTCACGTTGTTCCTCAGGTTCTCG
CTTC 
BG505 I185A for 
CTACCGGCTGGACGCCGTGCAGATCAA
CG 
zm96 T290Q for 
GAAGCGAGAACCTGCAGAACAACGT
GAAAACC 
BG505 I185A rev 
CGTTGATCTGCACGGCGTCCAGCCGGT
AG 
BG505 T290A for 
CAGAAGCGAGAACATCGCCAACAACG
CCAAGAAC 
16O55 T290A 
rev 
GTTTTCACGTTGTTGGCCAGGTTCTCGC
TTCTG 
BG505 T290A rev 
GTTCTTGGCGTTGTTGGCGATGTTCT
CGCTTCTG 
16O55 T290H for 
GAAGCGAGAACCTGCACAACAACGTGA
AAAC 
BG5O5 T290H for 
CAGAAGCGAGAACATCCACAACAACG
CCAAGAAC 
16O55 T290H 
rev 
GTTTTCACGTTGTTGTGCAGGTTCTCGC
TTC 
BG5O5 T290H rev 
GTTCTTGGCGTTGTTGTGGATGTTCT
CGCTTCTG 
16O55 N426A for 
GATCAAGCAGATCATCGCCATGTGGCA
AGAAGTG 
BG5O5 N426A for 
GATCAAGCAGATCATCGCCATGTGGC
AGCGGATCGG 
16O55 N426A 
rev 
CACTTCTTGCCACATGGCGATGATCTG
CTTGATC 
BG5O5 N426A rev 
CCGATCCGCTGCCACATGGCGATGAT
CTGCTTGATC 
16O55 W428A 
for 
CAGATCATCAATATGGCCCAAGAAGTG
GGCAGAG 
BG5O5 W428A for 
GCAGATCATCAATATGGCCCAGCGGA
TCGGCCAGGC 
16O55 W428A 
rev 
CTCTGCCCACTTCTTGGGCCATATTGAT
GATCTG 
BG5O5 W428A rev 
GCCTGGCCGATCCGCTGGGCCATATT
GATGATCTGC 
16055 SOSIP 
W428A for 
GATCATTAACATGGCCCAGGAAGTGGG
CAG 
BG505 REKR to 
REKS fw 
GTGGGACGGGAGAAGAGGGCCGTGG
GCATCGG 
16055 SOSIP 
W428A rev 
CTGCCCACTTCCTGGGCCATGTTAATG
ATC 
BG505 REKR to 
REKS rev 
CCGATGCCCACGGCCCTCTTCTCCCG
TCCCAC 
16055 SOSIP 
T290H for 
CATCAGAAGCGAGAATCTGCACAACAA
TGTGAAAACCATC 
16055 L110A for 
GGACGTGATCAGCGCCTGGGACCAG
AGCC 
16055 SOSIP 
T290H rev 
GATGGTTTTCACATTGTTGTGCAGATTC
TCGCTTCTGATG 
16055 L110A rev 
GGCTCTGGTCCCAGGCGCTGATCAC
GTCC 
HXB2 L110A for 
GGACATCATCAGCGCCTGGGACCAGAG
CC 
16O55 L110W for 
GACGTGATCAGCTGGTGGGACCAGA
G 
HXB2 L110A rev 
GGCTCTGGTCCCAGGCGCTGATGATGT
CC 
16O55 L110W rev CTCTGGTCCCACCAGCTGATCACGTC HXB2 L110W for GACATCATCAGCTGGTGGGACCAGAG 
16055 V126A for 
GACCCCCCTGTGCGCCACCCTGGAA
TGCAG 
HXB2 L110W rev CTCTGGTCCCACCAGCTGATGATGTC 
16055 V126A rev 
CTGCATTCCAGGGTGGCGCACAGGG
GGGTC 
HXB2 S162T for GATCAAGAACTGCACCTTCAACATCAGC 
16055 L128A for 
CCCTGTGCGTGACCGCCGAATGCAG
ACAGG 
HXB2 S162T rev GCTGATGTTGAAGGTGCAGTTCTTGATC 
16055 L128A rev 
CCTGTCTGCATTCGGCGGTCACGCAC
AGGG 
HXB2 T290A for GCGTGAACTTCGCCGACAACGCC 
16055 N160A for 
GCGAGGAAATCAAGGCCTGCAGCTTC
AATGC 
HXB2 T290A rev GGCGTTGTCGGCGAAGTTCACGC 
16055 N160A rev 
GCATTGAAGCTGCAGGCCTTGATTTC
CTCGC 
HXB2 T290H for 
GAAGCGTGAACTTCCACGACAACGCCA
AG 
16055 S162A for 
GAAATCAAGAACTGCGCCTTCAATGC
CACCACC 
HXB2 T290H rev 
CTTGGCGTTGTCGTGGAAGTTCACGCT
TC 
16055 S162A rev 
GGTGGTGGCATTGAAGGCGCAGTTCT
TGATTTC 
HXB2 N426A for 
GATCAAGCAGATCATCGCCATGTGGCA
GAAAGTG 
16O55 S162T for TCAAGAACTGCACCTTCAATGCCACC HXB2 N426A rev 
CACTTTCTGCCACATGGCGATGATCTG
CTTGATC 
16O55 S162T rev GGTGGCATTGAAGGTGCAGTTCTTGA HXB2 W428A for 
CAGATCATCAATATGGCCCAGAAAGTG
GGCAAG 
16055 F163A for 
CAAGAACTGCAGCGCCAATGCCACCA
CCG 
HXB2 W428A 
rev 
CTTGCCCACTTTCTGGGCCATATTGATG
ATCTG 
16055 F163A rev 
CGGTGGTGGCATTGGCGCTGCAGTT
CTTG 
JRFL L110A for 
GAAGATATCATCAGCGCCTGGGACCAG
AGCCTG 
16055 N164A for 
CAAGAACTGCAGCTTCGCCGCCACCA
CCGAGATC 
JRFL L110A rev 
CAGGCTCTGGTCCCAGGCGCTGATGAT
ATCTTC 
16055 N164A rev 
GATCTCGGTGGTGGCGGCGAAGCTG
CAGTTCTTG 
JRFL L110W for GATATCATCAGCTGGTGGGACCAGAGC 
16055 T166A for CAGCTTCAATGCCGCCACCGAGATCC JRFL L110W rev GCTCTGGTCCCACCAGCTGATGATATC 
16055 T166A rev 
GGATCTCGGTGGCGGCATTGAAGCT
G 
JRFL S162T for GATCAAGAACTGCACCTTCAACATCACC 
16055 E168A for 
CTTCAATGCCACCACCGCCATCCGGG
ACAAGAAAC 
JRFL S162T rev 
GGTGATGTTGAAGGTGCAGTTCTTGAT
C 
16055 E168A rev 
GTTTCTTGTCCCGGATGGCGGTGGTG
GCATTGAAG 
JRFL T290A for GCGACAACTTCGCCAACAACGCC 
16055 K172A for 
CACCGAGATCCGGGACGCCAAACAG
AAGGTGTAC 
JRFL T290A rev GGCGTTGTTGGCGAAGTTGTCGC 
16055 K172A rev 
GTACACCTTCTGTTTGGCGTCCCGGA
TCTCGGTG 
JRFL T290H for 
GAAGCGACAACTTCCACAACAACGCCA
AG 
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Primer Name Primer Sequence Primer Name Primer Sequence 
16055 K173A for 
GAGATCCGGGACAAGGCCCAGAAGG
TGTACGC 
JRFL T290H rev 
CTTGGCGTTGTTGTGGAAGTTGTCGCTT
C 
16055 K173A rev 
GCGTACACCTTCTGGGCCTTGTCCCG
GATCTC 
JRFL N426A for 
CAAGCAGATCATTGCCATGTGGCAGGA
AG 
16055 I185A for 
GTTCTACCGGCTGGACGCCGTGCCC
CTGGAAGAG 
JRFL N426A rev 
CTTCCTGCCACATGGCAATGATCTGCTT
G 
16055 I185A rev 
CTCTTCCAGGGGCACGGCGTCCAGC
CGGTAGAAC 
JRFL W428A for 
CAGATCATTAACATGGCCCAGGAAGTG
GGCAAG 
16O55 T290A for 
CAGAAGCGAGAACCTGGCCAACAAC
GTGAAAAC 
JRFL W428A rev 
CTTGCCCACTTCCTGGGCCATGTTAATG
ATCTG 
Primer Name PrimerSequence Primer Name PrimerSequence 
Cloning primer for the insertion of envelope variants into pWLXLd and different QL vectors 
pWPXLd 96ZM651 
for BamHI 
ACGGGATCCCGTCTCGCTAGCCGG 
pWPXLD 16055 
rev EcoRI 
CGGGAATTCGTCTCCTCGAGCCTGCAG
GTCATCAGCTGTATCCCTGCCGCACTC
TGTTCACCAC 
pWPXLd 96ZM651 
rev EcoRI 
CGGGAATTCGTCTCCTCGAGCCTGCA
G 
pWPXLD 16O55 
for 
GAGGTTTAAACTACGGGATCCCGTCTC
G 
pWPXLd zm96 for 
ACGGGATCCCGTCTCGCTAGCCGGA
CCGGCCACCATGGGAGTGCGGGAGA
TCCTGCG 
pWPXLD 16O55 
rev 
CGGGAATTCGTCTCCTCGAGCC 
pWPXLd zm96 rev 
CGGGAATTCGTCTCCTCGAGCCTGCA
GGTCATCAGGCGTAGTCGGGCACAT
CG 
16055-QL-For 
ATAATAGCTAGCCGTCTCCCTAGCATGA
GAGTGCGGGGCATCCTGCG 
96ZM651 QL for 
ATAATACGTCTCGCTAGCATGGGAGT
GCGGGAGATCCTGCGGAACTGGCAG
CGGTGGTGG 
16055-gp145 QL 
Rev 
ATATATACTCGAGCGTCTCGTCGAGTCA
TCAGCTGTATCCCTGCCGC 
96ZM651 gp145 
QL rev 
ATATTCGTCTCCTCGAGCTAGTAGCC
CTGCCGCACTCTGTTCACGATGGACA
GCACGGCG 
16055-gp145 
HA-Tag QL Rev 
ATATATCGTCTCCTCGAGTTATCATCAG
GCGTAGTCGGGCACGTCGTAGGGGTA
GTATCCCTGCCGCACTCTGTTCACC 
96ZM651 QL for2 
ATAATACGTCTCGCTAGCATGGGAGT
GCGGGAGATCC 
16055 gp140 
Flag/His-Tag QL 
ATATTCGTCTCCTCGAGCTATCAGTGGT
GATGGTGGTGGTGCTTGTCGTCGTCGT
CCTTGTAGTCGCTGCCGCCTCCGCCGC
TCTTGATGTACCACAGCCACTTGG 
96ZM651 gp145 
HA-Tag QL rev 
ATATTCGTCTCCTCGAGCTATCATCAG
GCGTAGTCGGGCACATCGTAGGGGT
AGTAG 
16055 SOSIP 
gp140 QL Rev 
ATATATACTCGAGCGTCTCGTCGAGTCA
GTCCAGGGCCAGCAGGTCC 
96ZM651 gp140 
QL rev 
ATATTCGTCTCCTCGAGCTATCATCAC
TTGATGTACCACAGCCACTTGG 
HXB2 QL for 
ATAATACGTCTCGCTAGCATGCGGGTG
AAAGAGAAGTACCAGCAC 
96ZM651 gp140 
Flag/His-Tag QL 
rev 
ATATTCGTCTCCTCGAGCTATCAGTG
GTGATGGTGGTGGTGCTTGTCGTCGT
CGTCCTTGTAGTCGCTGCCGCCTCCG
CCGCTCTTGATGTACCACAGCCACTT
GG 
HXB2 gp140 tag 
QL 
ATATATCGTCTCCTCGAGTCAGTGGTGA
TGGTGGTGGTGCTTGTCGTCGTCGTCC
TTGTAGTCGCTGCCGCCTCCGCCGCTC
TTGATGTACCACAGCCAGTTGGTGATG 
pWPXLd BG505 
for BamHI 
ACGGGATCCCGTCTCGCTAGCCGGA
CCGGCCACCATGAGAGTGATGGGCA
TCCAGCGGAACTGCCAGC 
HXB2 gp145 QL 
rev 
ATATTCGTCTCCTCGAGCTATCATCAGC
TGTAGCCCTGCCG 
pWPXLd BG505 
rev EcoRI 
CGGGAATTCGTCTCCTCGAGCCTGCA
GGTCATCAGGCGTAGTCGGGCACAT
CGTAGGGGTAGTAGCCCTGCCGCAC
TCTGTGGATCACGCTCAGCAC 
JRFL pWPXLd 
for 
ACGGGATCCCGTCTCGCTAGCCGG 
BG505 QL for 
ATAATACGTCTCGCTAGCATGAGAGT
GATGGGCATCCAGCG 
JRFL pWPXLd 
gp145 rev 
CGTCTCCTCGAGCCTGCAGG 
BG505 gp145 QL 
rev 
ATATTCGTCTCCTCGAGCTATCAGTA
GCCCTGCCGCACTCTG 
JRFL QL for 
ATAATACGTCTCGCTAGCATGAGAGTGA
AGGGCATCCGGAAG 
BG505 gp140 
Flag/His-Tag QL 
rev 
ATATTCGTCTCCTCGAGCTATCAGTG
GTGATGGTGGTGGTGCTTGTCGTCGT
CGTCCTTGTAGTCGCTGCCGCCTCCG
CCGCTGTCCAGGGCCAGCAGGTCC 
JRFL gp140 
Flag/His-tag QL 
rev 
ATATATCGTCTCCTCGAGTCAGTGGTGA
TGGTGGTGGTGCTTGTCGTCGTCGTCC
TTGTAGTCGCTGCCGCCTCCGCCGCTC
TTGATGTACCACAGCCACTTGG 
pWPXLD 16055 
Pme1 for 
GAGGTTTAAACTACGGGATCCCGTCT
CGCTAGCCGGACCGGCCACCATGAG
AGTGCGGGGCATCCTGCGGAACTAC
CAGCAG 
JRFL gp145 QL 
rev 
ATATTCGTCTCCTCGAGTCATCAGTAGC
CCTGCCGCAC 
Sequencing Primer 
pC-CMV-For GTAGGCGTGTACGGTGGGAGG 16055 seq2 for AGAGAGTGGGCAAGAAGCTGGC 
pC-BGH-Rev GCAACTAGAAGGCACAGTCGAGG 16055 seq3 for CCTGCTGAAGGCCATCGAGG 
pWPXLD seq for ATCTCGACGGTATCGGTTAAC HXB2 seq1 for GATCATGGAAAAGGG 
pWPXLd rev seq GGGAATTCGTCTCCTCGAGCCTGC HXB2 seq2 for GCAGGCCCACTGCAAC 
pQL13_seq_for CATGGTCCTGCTGGAGTTCGTG JRFL seq1 for CGGGACGAGGTGCAGAAAG 
96Zm651 seq1 for ATCCCCATCCACTACTGCG JRFL seq2 for CCAGATCAGATGCAGCAGC 
96ZM651 seq2 fwd AGCACCAACGACAGCACC BG505 seq1 GGACAAGAAGTTCAACGG 
16055 seq1 for GGTCAACACCACCAACGCC BG505 seq2 AGAGAAGAGTCGTGGGACG 
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Appendix Table 2: Plasmid vectors used in this thesis 
Description 
Selection 
marker 
Specification  
pOG44 Amp
R
 
Mammalian vector for transient expression of the Flp recombinase
179
 
(Thermo Fisher Scientific, # V600520); used for generation of all stable cell 
lines of the FACS panning section 
pWPXLd Amp
R
 
Lentiviral vector (Addgene, #12258). Used for all gp145 envelope variants 
used in this thesis, including the 96ZM651 alanine library. 
pcDNA3.1(+) 
QL 
Amp
R
 
Derivative of pcDNA3.1(+) (Invitrogen/Thermo Fisher Scientific, # V790-
20), including a CcdB cloning cassette inserted at the MCS; used for all 
gp140 envelope sequences, except the Env/V3 model library. 
pQL13 Amp
R
 
Lentiviral vector including a CcdB cloning cassette and eGFP; used for 
generation of the gp145 Env/V3 stable cell lines of the FACS panning 
procedure and gp140 envelopes of the Env/V3 model library 
 
 
Appendix Table 3: Alanine mutations potentially influencing envelope structure. A comparison of 
alanine mutants exhibiting loss or gain of signal effects in the alanine scans of sCD4, VRC01 and PG9 is 
given, including regions where those mutations are located, the exact amino acid position (HXB2 numbering) 
and 5F3 normalized fold changes compared to WT binding levels. Conservation in % was calculated based 
on an alignment of HIV-1 envelope sequences from 2013 available at the Los Alamos HIV Database 
(http://www.hiv.lanl.gov). Bold: statistically significant residues (FDR<0.05); underlined: contact residues to 
the respective screening reagent as determined by crystallography
20,42,117
. 
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Appendix Table 4: Alanine scanning data of PG9, VRC01, sCD4 and 17b. 5F3 normalized fold changes are given for each variant relative to the 96ZM651 WT and 
statistically significant results (FDR<0.05) are bolded. Locations of the variants are indicated with i: inner domain, o: outer domain, b: bridging sheet, α: α helix, β: β sheet 
  
AA Position Relative FC 
  
AA Position Relative FC 
Domain Region 96ZM651 HXB2 PG9 VRC01 sCD4 17b Domain Region 96ZM651 HXB2 PG9 VRC01 sCD4 17b 
 
 
G31A E32 1.05 1.01 0.58 0.74 
 
 
D77A D78 1.14 0.92 0.46 0.90 
 
N32A K33 1.05 1.09 0.51 1.70 
 
P78A P79 1.00 0.90 0.53 0.64 
 
L33A L34 1.08 1.04 0.63 1.13 
 
N79A N80 1.09 0.93 0.70 0.74 
 
W34A W35 0.98 1.02 0.44 1.49 
 
P80A P81 1.21 0.90 0.43 0.75 
 
V35A V36 1.23 1.33 0.56 1.12 
 
Q81A Q82 1.13 0.91 0.46 0.68 
 
T36A T37 0.94 1.01 0.75 1.42 
 
E82A E83 0.75 0.69 0.31 0.16 
 
V37A V38 1.05 1.15 0.53 1.26 
 
I83A V84 1.01 0.84 0.75 0.64 
 
Y38A Y39 0.97 1.21 0.53 1.32 
 
V84A V85 0.75 0.88 0.66 0.53 
 
Y39A Y40 1.07 1.42 0.46 1.41 
 
L85A L86 0.72 0.75 0.31 0.49 
 
G40A G41 0.98 0.91 0.60 0.77 
 
G86A V87 0.95 1.10 0.46 0.88 
 
V41A V42 1.08 0.98 0.42 0.69 
 
N87A N88 0.79 0.77 0.48 0.50 
 
P42A P43 1.38 1.18 0.77 0.21 
 
V88A V89 1.02 0.83 0.43 0.95 
 
V43A V44 1.55 1.02 0.57 0.78 i T89A T90 0.72 0.78 0.50 0.47 
 
W44A W45 0.77 0.71 0.39 0.64 i E90A E91 0.89 0.86 0.52 0.87 
 
K45A K46 1.03 0.87 0.60 0.76 i 
β1 
N91A N92 1.40 1.03 0.61 0.33 
 
E46A E47 0.93 0.90 0.46 0.71 i F92A F93 0.56 0.57 0.03 0.14 
 
K48A T49 0.78 0.83 0.37 0.48 i N93A N94 0.58 0.55 0.20 0.33 
 
T49A T50 0.94 0.87 0.56 1.07 i 
 
M94A M95 0.86 0.79 0.60 0.68 
 
T50A T51 0.89 0.90 0.46 0.98 i W95A W96 0.59 0.57 0.15 0.23 
 
L51A L52 0.86 0.79 0.38 0.23 i K96A K97 1.02 0.82 0.49 0.64 
 
F52A F53 0.87 0.85 0.45 0.12 i N97A N98 0.54 0.58 0.14 0.15 
 
S55A S56 1.03 0.89 0.67 0.90 i D98A D99 0.80 1.01 0.67 0.60 
 
D56A D57 0.85 0.88 0.59 0.66 i 
α1 
M99A M100 0.56 0.59 0.12 0.54 
 
K58A K59 0.76 0.87 0.53 0.84 i V100A V101 0.86 0.83 0.39 0.43 
 
S59A A60 0.71 0.90 0.71 0.65 i D101A E102 0.67 0.76 0.46 0.65 
 
Y60A Y61 0.87 0.82 0.47 0.78 i Q102A Q103 0.66 0.76 0.52 0.35 
 
E61A D62 0.94 0.88 0.66 0.80 i M103A M104 0.66 0.65 0.42 0.28 
 
K62A T63 0.78 0.84 0.80 0.89 i H104A H105 0.70 0.57 0.36 0.16 
 
E63A E64 0.73 0.82 0.58 0.13 i E105A E106 0.84 1.03 0.52 0.90 
 
V64A V65 0.72 0.89 0.53 0.95 i D106A D107 0.63 0.76 0.26 0.46 
 
H65A H66 0.81 0.80 0.54 0.46 i I107A I108 0.67 0.66 0.46 0.29 
 
N66A N67 0.68 0.72 0.38 0.33 i I108A I109 0.71 0.82 0.59 0.74 
 
V67A V68 0.75 0.80 0.57 0.42 i S109A S110 1.26 1.04 0.42 0.72 
 
W68A W69 0.73 0.73 0.40 0.31 i L110A L111 2.27 1.54 0.51 0.19 
 
T70A T71 0.84 0.85 2.78 0.60 i W111A W112 0.74 0.69 0.16 0.14 
 
H71A H72 1.03 0.96 0.53 0.63 i D112A D113 1.15 0.94 0.49 1.07 
 
V74A V75 1.02 0.98 0.48 0.13 i Q113A Q114 0.97 1.02 0.67 0.87 
 
P75A P76 1.22 0.93 0.53 0.90 i S114A S115 1.22 1.15 0.64 0.62 
 
T76A T77 1.13 0.94 0.56 0.71 i L115A L116 0.78 0.72 0.53 0.20 
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AA Position Relative FC 
Domain Region 96ZM651 HXB2 PG9 VRC01 sCD4 17b Domain Region 96ZM651 HXB2 PG9 VRC01 sCD4 17b 
i α1 K116A K117 1.08 0.86 0.66 0.77 o 
V1 
M158A I154 0.59 0.84 0.57 0.67 
i 
 
P117A P118 1.59 0.93 0.33 0.60 o K159A K155 0.63 0.87 2.44 0.81 
b 
β2 
V119A V120 1.49 0.94 0.66 0.38 o N160A N156 0.59 0.83 0.39 0.61 
b K120A K121 1.25 0.82 0.65 0.24 o 
V2 
S162A S158 0.42 0.79 0.58 0.45 
b L121A L122 1.01 0.84 0.54 0.51 o F163A F159 0.49 0.74 0.54 0.59 
b T122A T123 0.88 0.92 0.80 0.80 o N164A N160 0.44 1.11 0.61 1.20 
b P123A P124 1.33 1.05 0.71 0.72 o I165A I161 1.01 0.80 0.46 0.75 
  
L124A L125 0.66 0.89 0.72 1.39 o T166A S162 0.44 1.02 0.54 1.21 
o 
V1 
V126A V127 0.55 0.91 0.57 1.34 o T167A T163 0.75 0.91 0.47 0.93 
o T127A S128 1.05 1.01 0.76 1.25 o E168A S164 0.58 1.01 0.47 0.80 
o L128A L129 0.38 0.82 0.38 1.09 o L169A I165 0.66 1.00 0.66 0.96 
o N129A K130 1.60 1.06 0.76 0.91 o K170A R166 0.82 0.98 0.64 0.74 
o T131A T132 1.43 0.97 0.55 0.63 o D171A G167 0.85 0.92 0.55 0.61 
o E132A D133 0.83 0.82 0.46 0.66 o K172A K168 0.59 0.86 0.78 0.84 
o V133A L134 0.79 0.98 0.62 0.65 o K173A V169 0.51 1.11 0.76 0.92 
o N134A K135 1.12 1.02 0.74 0.87 o K174A Q170 0.88 0.98 0.77 0.90 
o V135A N136 0.68 0.96 0.59 0.96 o N175A K171 1.38 1.08 0.61 0.69 
o T136A D137 1.36 1.04 0.76 0.88 o V176A E172 0.96 1.11 0.72 1.06 
o R137A T138 1.06 0.87 0.67 0.87 o Y177A Y173 0.78 0.97 NA 0.80 
o N138A N139 1.22 1.00 0.82 0.89 o L179A F175 0.66 0.85 0.34 0.56 
o V139A T140 1.27 1.14 0.70 0.82 o F180A F176 0.63 0.88 0.36 0.67 
o 
 
N140A N141 1.29 1.09 0.47 0.79 o 
 
Y181A Y177 0.82 0.99 0.65 1.09 
o N141A S142 1.06 1.03 0.62 0.98 o K182A K178 0.89 0.96 0.54 0.86 
o S142A S143 1.16 1.04 0.65 1.01 o L183A L179 1.27 1.11 0.66 1.54 
o V143A S144 1.14 1.05 0.56 0.99 o D184A D180 0.88 0.83 0.49 0.58 
o V144A G145 1.00 1.05 0.57 1.13 o I185A I181 0.57 1.04 0.69 0.71 
o N145A R146 0.98 1.06 0.78 0.82 o V186A I182 0.96 1.05 0.62 0.72 
o N146A M147 1.09 0.99 0.82 1.02 o S187A P183 1.13 1.10 0.82 1.12 
o T147A I148 0.95 0.97 0.69 1.17 o L188A I184 1.03 1.05 0.77 0.77 
o T148A M149 1.08 1.06 0.62 1.01 o N189A D185 1.17 1.12 0.76 0.83 
o N149A E150 1.12 1.08 0.71 1.00 o E190A N186 1.00 1.10 0.61 0.87 
o V150A K151 0.74 0.94 0.57 0.90 o T191A - 1.15 1.13 0.87 0.82 
o N151A - 1.53 1.26 0.56 1.27 o D192A - 0.99 1.10 0.67 0.88 
o N152A - 1.32 1.24 0.60 0.97 o D193A - 0.98 0.98 0.58 0.25 
o S153A - 1.74 1.33 0.52 1.04 o S194A - 0.89 1.04 0.57 0.78 
o M154A - 0.72 1.03 0.49 0.89 o E195A - 0.99 0.94 0.54 0.80 
o N155A - 1.16 1.35 0.59 1.43 o T196A - 0.95 0.99 0.67 1.12 
o G156A G152 1.09 1.34 0.50 0.88 o G197A - 0.78 0.95 0.89 0.95 
o D157A E153 0.79 0.93 2.42 0.88 o N198A - 0.91 1.05 0.60 0.97 
Appendix 
VII 
 
 
  
AA Position Relative FC 
  
AA Position Relative FC 
Domain Region 96ZM651 HXB2 PG9 VRC01 sCD4 17b Domain Region 96ZM651 HXB2 PG9 VRC01 sCD4 17b 
o 
V2 
S199A D187 0.88 1.09 0.67 1.07 i 
loopA 
G247A G235 0.80 0.53 0.05 0.11 
o S200A T188 0.94 1.08 0.64 0.96 i T248A T236 0.97 1.16 0.72 0.64 
o K201A T189 0.89 0.95 0.63 1.01 i 
β6 
G249A G237 0.71 0.56 0.23 0.19 
o Y202A S190 0.96 1.03 0.79 0.93 i P250A P238 0.84 0.82 0.57 0.69 
o Y203A Y191 0.70 0.88 0.65 0.51 i 
 
H252A T240 0.92 0.80 0.84 0.54 
o R204A K192 0.74 0.80 0.55 0.54 i 
β7 
N253A N241 0.74 0.59 0.41 0.41 
o L205A L193 0.64 0.93 0.71 0.73 i V254A V242 0.68 0.60 0.26 0.31 
o I206A T194 0.86 1.06 0.66 1.01 i S255A S243 0.64 0.58 0.45 0.65 
o N207A S195 0.94 0.86 0.54 0.83 i T256A T244 1.10 1.19 1.08 0.17 
o 
 
N209A N197 0.65 0.96 0.47 0.63 i 
 
V257A V245 0.75 0.65 0.47 0.29 
b 
β3 
T210A T198 1.34 0.91 0.71 0.74 i 
β8 
Q258A Q246 0.89 0.81 0.61 0.75 
b S211A S199 1.11 1.21 0.56 0.57 i T260A T248 0.64 0.57 0.13 0.15 
b L213A I201 1.05 0.86 0.84 0.69 i H261A H249 0.77 0.67 0.60 0.34 
b T214A T202 1.04 0.87 0.94 0.65 i 
β8 
G262A G250 0.76 0.79 0.92 0.38 
b Q215A Q203 1.13 0.97 0.59 0.68 i I263A I251 0.62 0.53 0.35 0.17 
i 
 
P218A P206 1.20 1.06 1.04 0.55 o 
loopB 
K264A R252 0.68 0.60 0.52 0.22 
i K219A K207 1.11 0.97 0.76 0.28 o P265A P253 0.69 0.59 0.66 0.36 
i V220A V208 1.09 0.90 0.78 0.51 o V266A V254 0.65 0.63 0.70 0.26 
i S221A S209 0.94 0.90 0.46 0.75 o V267A V255 0.80 0.87 0.95 0.44 
i F222A F210 1.07 0.75 0.43 0.16 o S268A S256 0.77 0.66 0.62 0.48 
i D223A E211 1.09 0.90 0.55 0.24 o T269A T257 0.70 0.53 0.40 0.21 
i P224A P212 1.05 0.81 0.57 0.21 o Q270A Q258 0.62 0.33 0.29 0.29 
i I225A I213 1.01 0.89 0.37 0.18 o L271A L259 0.75 0.34 0.12 0.21 
i 
β4 
P226A P214 0.63 0.80 0.50 0.14 o L272A L260 0.63 0.39 0.13 0.15 
i I227A I215 0.59 0.72 0.14 0.28 o 
β9 
L273A L261 0.65 0.39 0.08 0.15 
i H228A H216 0.85 0.91 0.40 0.18 o N274A N262 0.68 0.37 0.16 0.10 
i Y229A Y217 0.64 0.72 0.21 0.12 o G275A G263 0.64 0.54 0.10 0.13 
i 
 
P232A P220 0.81 0.96 0.53 0.21 o 
loopC 
S276A S264 0.56 0.41 0.18 0.11 
i 
β5 
G234A G222 0.83 0.86 0.20 0.55 o L277A L265 0.66 0.49 0.58 0.36 
i Y235A F223 0.80 0.79 0.32 0.26 o E279A E267 0.63 0.74 0.60 0.57 
i I237A I225 0.66 0.66 0.05 0.64 o E280A E268 0.74 0.84 0.83 0.95 
i L238A L226 0.71 0.73 0.24 0.79 o G281A E269 0.78 0.80 0.99 1.20 
i K239A K227 0.60 0.65 0.29 0.80 o I282A V270 0.99 0.49 0.30 0.27 
i N241A N229 0.65 0.71 0.18 0.73 o 
β10 
I283A V271 0.98 0.76 0.77 0.46 
i 
loopA 
N242A N230 0.76 1.07 0.66 0.82 o I284A I272 0.90 0.58 0.49 0.30 
i K243A K231 1.07 0.80 0.78 0.61 o R285A R273 0.95 0.80 0.72 0.49 
i T244A T2432 1.08 0.98 0.58 0.79 o 
 
S286A S274 1.03 0.84 0.85 0.69 
i F245A F233 0.83 0.52 0.08 0.18 o E287A V275 0.98 0.85 0.62 0.57 
i N246A N234 1.02 1.31 0.66 0.77 o loopD N288A N276 0.86 0.87 0.60 0.80 
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    AA Position  Relative FC     AA Position Relative FC 
Domain Region 96ZM651 HXB2  PG9    VRC01   sCD4   17b  Domain Region 96ZM651 HXB2  PG9    VRC01   sCD4   17b  
o 
loopD 
L289A F277    0.90       0.55       0.46       0.30    o 
V3 
T330A T319    0.78       0.86       0.99       0.61    
o T290A T278    0.98       1.81       0.62       0.83    o G331A I320    0.88       1.03       1.11       1.07    
o N291A D279    0.90       0.26       0.74       0.48    o D332A G321    1.19       0.87       0.88       0.51    
o N292A N280    1.01       0.40       0.92       0.82    o I333A K322    0.88       0.88       0.90       1.02    
o V293A A281    1.07       1.21       1.08       0.96    o I334A I323    0.90       0.82       0.88       1.08    
o K294A K282    0.99       0.71       0.68       0.56    o G335A G324    0.74       0.72       0.92       0.65    
o T295A T283    0.72       0.59       0.42       0.30    o D336A N325  NA   NA   NA     1.58    
o 
β11 
I296A I284    0.81       0.57       0.37       0.41    o I337A M326    0.76       0.85       0.94       0.75    
o I297A I285    0.65       0.57       0.28       0.16    o R338A R327    0.75       0.82       1.36       0.69    
o V298A V286    0.88       0.69       0.68       0.44    o Q339A Q328    0.87       0.85       0.77       0.68    
o H299A Q287    1.06     NA     0.64       0.81    o 
β14 
H341A H330    0.71       0.56       0.68       0.60    
o L300A L288    0.73       0.35       0.04       0.13    o N343A N332    0.76       0.59       0.85       0.54    
o   
  
  
N301A N289    0.86       0.88       0.59       0.62    o I344A I333    0.76       0.42       0.57       0.37    
o R302A T290    0.95       0.91       1.02       0.56    o S345A S334    0.71       0.45       0.65       0.65    
o S303A S291    0.89       0.93       0.71       0.67    o 
α2 
R346A R335    0.95       0.57       0.58       0.49    
o 
β12 
I304A V292    0.78       0.60       0.64       0.42    o T347A A336    1.08       0.90       1.03       1.52    
o E305A E293    1.52       0.86       0.99       0.57    o N348A K337    1.01       0.86       0.93       1.43    
o I306A I294    0.83       0.54       0.92       0.40    o W349A W338    0.87       0.42       0.24       0.66    
o V307A N295    0.86       0.95       0.84       0.66    o T350A N339    0.94       0.74       0.78       1.84    
o V309A T297    0.89       0.95       1.27       0.40    o K351A N340    0.95       0.80       0.93       0.61    
o   R310A R298    0.65       0.78       1.31       0.38    o T352A T341    1.00       0.71       0.96       0.86    
o 
V3 
P311A P299    0.68       0.76       1.20       0.53    o L353A L342    0.85       0.40       0.47       0.49    
o N312A N300    0.67       0.90       0.93       0.91    o R354A K343    1.01       0.88       1.04       0.71    
o N313A N301    0.69       0.74       1.02       0.84    o E355A Q344    0.94       0.78       1.06       1.50    
o N314A N302    0.71       0.98       1.00       0.89    o 
  
  
  
  
  
  
  
  
  
  
  
  
V356A I345    1.06       0.45       0.83       0.54    
o T315A T303    0.69       0.73       0.75       1.13    o R357A A346    0.92       0.97       1.16       0.71    
o R316A R304    0.59       0.80       0.91       0.84    o N358A S347    1.04       0.82       1.17       1.14    
o Q317A K305    0.68       0.86       1.03       0.86    o K359A K348    0.93       0.87       0.91       1.17    
o S318A R306    0.80       0.95       1.11       1.05    o L360A L349    0.62       0.37       0.69       1.33    
o I319A I307    1.02       0.87       0.88       1.29    o R361A R350    0.88       0.87       1.14       1.38    
o R320A R308    1.19       0.94       0.99       0.86    o E362A E351    1.45       0.85       2.88       1.54    
o I321A I309    0.96       0.91       0.87       0.85    o H363A Q352    0.90       0.69       1.25       0.91    
o G322A Q310    1.63       1.08       0.95       0.76    o F364A F353    0.78       0.30       0.22       0.65    
o P323A R311    1.02       0.85       1.05       0.71    o P365A G354    0.89       0.61       0.88       0.74    
o G324A G312    0.94       0.85       1.11       0.49    o N366A N355    0.93       0.68       1.08       0.95    
o Q325A P313    0.98       0.85       0.88       0.86    o K367A K357    0.81       0.69       1.11       0.58    
o T326A R315    0.90       0.81       0.86       1.07    o 
β14 
N368A T358    0.90       0.83       1.20       0.78    
o F327A A316    0.85       0.97       0.83       0.64    o I369A I359    0.80       0.42       0.80       0.28    
o Y328A F317    0.85       0.96       1.07       0.63    o T370A T360    0.88       1.07       0.97       1.14    
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    AA Position Relative FC     AA Position  Relative FC 
Domain Region 96ZM651 HXB2  PG9    VRC01   sCD4   17b  Domain Region 96ZM651 HXB2  PG9    VRC01   sCD4   17b  
o β14 F371A F361    0.93       0.27       0.10       0.25    o 
V4 
G412A G410    0.76       1.03       1.08       0.86    
o   
  
  
  
K372A K362    0.84       1.02       1.09       1.09    o T413A D412    0.76       0.99       1.24       0.41    
o P373A Q363    0.84       0.63       0.75       0.64    o 
β19 
P414A T413    0.75       0.99       1.00       1.08    
o S374A S364    0.74       0.64       1.12       0.95    o I415A I414    0.69       0.59       0.20       0.20    
o S375A S365    0.81       0.91       0.95       0.96    o T416A T415    0.72       0.67       0.99       0.50    
o 
β15 
G376A G366    0.90       0.36       0.64       0.81    o L417A L416    0.73       0.55       0.58       0.33    
o G377A G367    0.85       0.29       0.27       1.23    o P418A P417    0.64       0.63       0.76       0.45    
o D378A D368    0.72       0.49       0.26       0.88    o R420A R419    0.58       0.69       1.54       0.26    
o 
α3 
L379A P369    0.81       0.23       0.91       0.96    o I421A I420    1.00       0.63       0.69     NA  
o E380A E370    0.86       0.53       0.63       0.78    o   R422A K421    0.82       0.70       0.90       0.36    
o I381A I371    0.87       0.30       0.48       0.75    b 
β20 
Q423A Q422    0.98       0.78       1.07       1.20    
o T382A V372    1.17       0.81       1.05       0.75    b I424A I423    0.91       0.80       1.86       0.25    
o   
  
T383A T373    1.19       0.72       0.82       0.63    b I425A I424    0.86       0.92       0.95       0.19    
o H384A H374    1.19       0.71       0.91     NA  b N426A N425    0.96       0.75       0.45       0.53    
o 
β16 
S385A S375    1.20       0.82       1.02       1.07    b M427A M426    0.93       0.83       0.91       0.95    
o F386A F376    0.96       0.38       0.27       0.94    b   
  
  
W428A W427    0.85       0.81       0.07       0.13    
o N387A N377    1.08       0.64       0.97       1.03    b Q429A Q428    1.24       0.84       0.88       0.28    
o   
  
R389A G379    1.19       0.88       0.82       0.40    b E430A K429    1.33       1.04       1.14     NA  
o G390A G380    0.89       0.54       0.63       0.60    b 
β21 
V431A V430  NA   NA   NA   NA  
o 
β17 
E391A E381    1.23       0.94       1.20       0.60    b G432A G431    0.98       0.76       0.88     NA  
o F392A F382    0.97       0.55       0.73       0.26    b R433A K432    0.66       0.60       1.36       0.61    
o F393A F383    0.90       0.41       0.27       0.45    b M435A M434    0.72       0.62       1.06       0.84    
o Y394A Y384    1.02       0.49       1.15       0.60    b Y436A Y435    0.64       0.58       0.90       0.89    
o N396A N386    0.95       0.53       0.62       0.85    o   
  
  
  
  
  
P438A P437    0.70       0.64       0.52       0.87    
o 
α4 
T397A S387    0.74       0.50       0.34       0.57    o P439A P438    0.75       0.74       1.27       0.85    
o S398A T388    0.92       0.75       0.84       0.97    o I440A I439    0.76       0.74       1.21       1.01    
o G399A Q389    0.91       1.01       1.08       0.24    o E441A S440    0.87       0.83       1.32       0.88    
o L400A L390    0.90       0.76       0.85       1.07    o G442A G441    0.69       0.68       0.94       0.84    
o F401A F391    0.80       0.48       0.12       0.14    o N443A Q442    0.89       1.13       1.15       0.42    
o   S402A N392    0.87       0.82       1.15       0.96    o 
β22 
I444A I443    0.73       0.65       0.85     NA  
o 
β18 
I403A S393    0.85       0.82       1.22       0.89    o K447A S446    0.80       0.64       1.20       0.35    
o N404A T394    0.88       0.93       1.14       0.77    o S448A S447    0.62       0.46       0.75       0.34    
o Y405A W395    0.87       0.81       1.27       1.40    o D449A N448    1.09       1.08       0.80       0.64    
o 
V4 
T406A F396    0.82       0.96       1.15       0.75    o I450A I449    0.85       0.46       0.27       0.43    
o E407A E403    1.17       1.04       1.24       0.76    o   T451A T450    0.87       0.44       0.35       0.57    
o N408A N406    0.85       0.93       1.24       0.86    o 
β23 
G452A G451    1.31       0.68       0.75       0.87    
o N409A N407    0.78       1.03       1.09       0.84    o L453A L452    0.94       0.47       0.27       0.54    
o T410A T408    0.76       0.94       1.14       0.50    o L454A L453    0.92       0.68       0.77       0.41    
o D411A E409    0.77       0.92       1.01       1.16    o L455A L454    0.98       0.45       0.22       0.27    
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    AA Position   Relative FC     AA Position   Relative FC 
Domain Region 96ZM651 HXB2  PG9    VRC01   sCD4   17b  Domain Region 96ZM651 HXB2  PG9    VRC01   sCD4   17b  
o 
β23 
V456A T455    1.06       1.19       1.20       0.23    i 
α5 
S486A S481    1.07       0.95       0.12       0.55    
o R457A R456    0.70       0.33       0.16       0.22    i E487A E482    0.98       0.68       0.57       0.17    
o D458A D457    0.92       0.45       0.09       0.28    i L488A L483    0.96       0.73       0.75       0.15    
o 
V5 
G459A G458    0.93       0.66       0.69       0.31    i Y489A Y484    1.06       0.66       0.91       0.30    
o G460A G459    0.87       0.51       1.03       0.51    i 
β25 
K490A K485    0.97       0.79       1.02       0.40    
o S461A N460    1.13       0.83       0.96       0.70    i Y491A Y486    0.91       0.56       1.05       0.12    
o T462A S461    0.96       0.94       0.80       0.58    i K492A K487    0.88       0.81       0.66       0.25    
o N463A NA    0.88       1.21       1.16       1.00    i V493A V488    1.03       0.77       0.61       0.17    
o D464A NA    0.89       0.64       1.03       1.05    i V494A V489    0.93       0.75       0.51       0.23    
o S465A NA    0.92       1.29       1.20       1.06    i E495A K490    1.05       0.91       1.01       0.25    
o T466A NA    0.94       0.94       2.21       1.07    i I496A I491    1.00       0.90       0.78       0.23    
o N467A N462    0.86       0.68       1.62       1.09    i 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
K497A E492    1.10       1.08       1.06       0.34    
o N468A N463    0.97       0.79       1.51       1.08    i P498A P493    0.97       1.13       1.36       0.51    
o N469A E464    0.96       0.90       1.22       1.05    i L499A L494    0.91       0.98       0.91       0.38    
o 
β24 
T470A S465    0.82       0.89       1.63       0.73    i G500A G495    0.96       0.99       1.18       0.40    
o E471A E466    0.82       0.54       0.87       0.66    i I501A V496    0.92       0.86       0.90       0.31    
o I472A I467    0.83       0.51       0.32     NA  i P503A P498    0.97       0.94       0.92       0.30    
o F473A F468  NA   NA     0.01       1.11    i T504A T499    0.94       0.95       0.79     NA  
o R474A R469    0.82       0.31       0.28       0.97    i E505A K500    0.78       1.01       0.83       0.37    
o P475A P470    0.69       0.34       0.41       0.83    i K507A K502    0.82       1.00       0.89     NA  
o G477A G472    0.72       0.42       0.12       0.91    i R508A R503    0.90       0.96       1.20       0.45    
o   
  
G478A G473    0.84       0.60       0.30       0.47    i R509A R504    0.86       1.01       1.13       0.68    
o D479A D474    0.78       0.52       0.57       0.19    i V510A V505    0.85       0.99       0.94       0.55    
i 
α5 
M480A M475    0.82       0.78       0.81       0.12    i V511A V506    0.64       0.95       0.84       0.68    
i R481A R476    0.75       0.55       0.50       0.12    i E512A Q507    0.93       1.02       1.29       0.60    
i D482A D477    0.93       0.55       0.88       0.26    i R513A R508    0.77       1.03       1.14     NA  
i N483A N478    0.86       0.57       0.80       0.40    i E514A E509    0.67       0.84       1.23       0.27    
i W484A W479    0.56       0.44       0.24       0.20    i K515A K510    0.78       1.04       1.46     NA  
i R485A R480    0.66       0.76       0.88       0.29    i S516A R511    0.81       1.01       1.27       0.63    
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Clade Isolate PG9 FC S158T 
A BG505 0.95 ± 0.08 
B HXB2 0.58 ± 0.03 
B JRFL 0.87 ± 0.08 
C 16055 0.95 ± 0.08 
C 96ZM651 1.83 ± 0.19 
Variant TM 
  96ZM651 WT 58.4 ± 1.8 
96ZM651 L111A 58.9 ± 0.7 
96ZM651 T278A 56.6 ± 0.1 
96ZM651 W427A 59.1 ± 0.5 
96ZM651 L111A/T278A 57.5 ± 0.1 
96ZM651 L111A/T278H 61.1 ± 0.7 
96ZM651 L111A/T278A/W427A 59.45 ± 0.8 
Appendix Table 5: Transfer of mutation S158T to 
different isolates. S158T was analyzed in gp145 variants 
of the indicated isolates via flow cytometry (n=3). 5F3 
normalized fold changes of PG9 binding levels relative to 
the respective WT are shown. The gain of signal effect 
observed for 96ZM651 was not transferable. 
 
Appendix Table 6: NanoDSF analysis of 
96ZM651 single, double and triple mutants. 
(n=2). Insertion of L111A, T278A/H, W427A 
or combinations of these mutations did not 
significantly alter trimer thermostability. TM: 
melting temperature. 
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Appendix Table 7: KD values of gp140 WT, L111A/T278H (LT – EDC/NHS) and L111A/T278H cross-linked with EDC/NHS (LT + EDC/NHS) from different 
isolates to a panel of Envelope antibodies targeting different epitopes. KD values affiliate with Figure 38 of the main results section. n=2. 
 
 
 
 
 
Appendix Figure 1: 
PG9 FACS titration 
of 96ZM651 gp145 
WT and L111A. 
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Appendix Figure 2: 
ELISA titration of soluble 
gp140 trimers from 
different isolates. Secreted 
gp140 trimers were purified 
from the supernatant of 
HEK293-F suspension cells 
using lectin affinity 
chromatography and 
subsequent size exclusion. 
Trimers were compared for 
VRC01 and PG9 binding in 
relation to the respective 
WT. Curves were analyzed 
with GraphPad Prism 5.0, 
non-linear regression 
(hyperbolar one-site 
binding. Data were 
generated by Christina 
Schmalzl and Matthias 
Glögl during my 
experimental supervision 
and by me. 
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Appendix Figure 3: ELISA titration of 96ZM651 gp140 variants with a panel of different antibodies 
and sCD4. 96ZM651 gp140 trimers were titrated to analyze the influence of mutations L111A, T278A/H, 
W427A and their combinations on Env antigenicity. One concentration located in the linear increase of the 
sigmoidal binding curve was chosen (highlighted in red) to compare binding fold changes in the heat map 
formats of the main results section (Tables 7, 9 and 12). 
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Appendix Figure 4: DSC analysis of 96ZM651 gp140 wildtype and mutant L111A. Although comparable 
protein concentrations were administered, 96ZM651 WT (A) depicted only a weak signal intensity and very 
inhomogeneous raw data. For mutant L111A (B), higher signal intensity and a more homogeneous melting 
curve could be obained. No significant difference was observed for WT and L111A thermostability. Black: 
raw data; red: fitted data used for the calculation of melting temperatures (Tm). 
 
 
 
 
Appendix Figure 5: NanoDSF analysis of cross-linked envelope trimers. Thermostability of EDC/NHS 
cross-linked L111A/T278H variants (LT+EDC) was analyzed by nanoDSF in comparison to unmodified 
WTs and L111A/T278H (LT) variants (n=2). Note that only signal intensities of 16055 SOSIP and BG505 
SOSIP allowed reliable analysis of melting temperatures. Signals for 96ZM651, 16055 and BG505 were low 
supposedly due to inhomogeneous folding caused by furin cleavage site mutation. 
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Appendix Figure 6A: Antigenicity profile 
of EDC/NHS cross-linked soluble envelope 
trimers. Antibody binding to WT, 
L111A/T278H and EDC/NHS cross-linked 
L111A/T278H gp140 trimers was analyzed 
by lectin capture (preserves trimer integrity) 
and direct ELISA (mildly denaturating 
conditions supporting trimer 
opening/unfolding). A panel of different 
antibodies was used including the non-
neutralizing mAbs 17b (CD4i) and F105 
(CD4BS), as well as bnAb HJ16 (CD4BS). 
One of two biological replicates is shown. 
The second dataset, which depicted the same 
results, is shown in Figure 37A. 
L111A/T278H resulted in decreased 17b 
recognition, which could further be enhanced 
by EDC/NHS cross-linking. Also, cross-
linking diminished F105 binding. HJ16 
recognition was impeded due to T278H, but 
was not further influenced by cross-linking. 
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Appendix Figure 6B: Antigenicity profile 
of EDC/NHS cross-linked soluble 
envelope trimers. Antibody binding to 
WT, L111A/T278H and EDC/NHS cross-
linked L111A/T278H gp140 trimers was 
analyzed by lectin capture (preserves trimer 
integrity) and direct ELISA (mildly 
denaturating conditions supporting trimer 
opening/unfolding). A panel of different 
antibodies was used including bnAbs 
VRC01 (CD4BS), HGN194 (V3) and 
PGT121 (V3-Glycan). One of two 
biological replicates is shown. The second 
dataset, which depicted the same results, is 
shown in Figure 37B. L111A/T278H 
resulted in increased VRC01 recognition, 
which was not severely influenced by cross-
linking. The two mutations as well as cross-
linking had no effect on V3 antibodies 
HGN194 and PGT121.  
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Appendix Figure 6C: Antigenicity profile 
of EDC/NHS cross-linked soluble envelope 
trimers. Antibody binding to WT, 
L111A/T278H and EDC/NHS cross-linked 
L111A/T278H gp140 trimers was analyzed 
by lectin capture (preserves trimer integrity) 
and direct ELISA (mildly denaturating 
conditions supporting trimer opening/ 
unfolding). A panel of different antibodies 
was used including quaternary structure 
dependent bnAbs PG9 (V1/V2), PGT145 
(V1/V2) and PGT151 (gp120/gp41 interface). 
One of two biological replicates is shown. 
The second dataset, which depicted the same 
results, is shown in Figure 37C. 
L111A/T278H led to increased PG9 
recognition of varying magnitude, which was 
not further influenced by cross-linking. 
PGT145 and PGT151 recognition was not 
influenced by either L111A/T278H or cross-
linking; however, these antibodies only 
showed noteworthy binding to the two SOSIP 
constructs.  
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Abbreviations 
 
6HB Six-Helix-Bundle  HR1/2 Heptad Repeats / Helical Regions 1 and 2 
of HIV-1 Envelope 
AA Amino Acids  HRP Horse-Raddish Peroxidase 
Ad5 Adenovirus 5  IC Intracellular Space 
ADCC Antibody-Dependent Cellular Cytotoxicity  IgG Immunoglobulin G 
ADCP Antibody-Dependent Cellular Phagocytosis  LB Lysogeny Broth 
AUC Area under the Curve  mAb Monoclonal Antibody 
bnAb Broadly Neutralizing Antibody  MES 2-(N-morpholino)ethanesulfonic acid 
BSA Bovine Serum Albumine  MFI Mean Fluorescence Intensity 
C1-C5 Constant Regions of HIV-1 Envelope  MOI Multiplicity of Infection 
CcdB Control of Cell Death Toxin B  MPER Membrane-Proximal External Region of 
HIV-1 Envelope 
CCR5 C-C Chemokine Receptor Type 5  mRNA messenger Ribonucleic Acid 
CD4 Cluster of Differentiation 4 (receptor)  nAb Neutralizing Antibody 
CD4i CD4-induced conformation of HIV-1 Env  NFL Native Flexibly Linked 
CDR H3 Complementarity Determining Region 3 of 
the Antibody Heavy Chain 
 NGS Next Generation Sequencing 
CRF Circulating Recombinant Form  NHS N-Hydroxysuccinimide 
CSAM Cell Surface Antibody Mapping   NIH National Institute of Health 
CT Cytoplasmic Tail of HIV-1 Envelope  OD Optical Density 
CV Column Volume  PAGE Polyacrylamide Gel Electrophoresis 
CXCR4 C-X-C Chemokine Receptor Type 4  PBS Phosphate Buffered Saline 
DMEM Dulbecco`s Modified Eagle Medium  PCR Polymerase Chain Reaction 
Dox Doxycycline  PE Phycoerythrin 
DSC Differential Scanning Calorimetry  PEI Polyethylenimine 
dsDNA double-stranded Deoxyribonucleic Acid  Pen/Strep Penicillin/Streptomycin 
DSF Differential Scanning Fluorimetry  pI Isoelectric Point 
E. coli Escherichia Coli  PIC Pre-Integration Complex 
EC Extracellular Space  PM Plasma Membrane 
EDC 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide 
hydrochloride 
 pol HIV-1 Enzymes ( genetic material 
encoding integrase, protease and reverse 
transcriptase) 
EDTA Ethylenediaminetetraacetic acid  pro Protease open reading frame 
EGTA Ethylene glycol-bis(β-aminoethyl ether)-
N,N,N',N'-tetraacetic acid 
 QL Quick Ligation 
Env HIV-1 Envelope protein  Rev Regulator of Expression of Virion Proteins 
eOD Engineered Outer Domain  sCD4 soluble CD4 (terminated before before the 
transmembrane domain) 
ER Endoplasmatic Reticulum  SDS Sodium Dodecyl Sulfate 
FACS Fluorescence-Activated Cell Sorting  SEC Size Exclusion Chromatography 
FC Fold Change  SHIV Simian-Human Immunodeficiency Virus 
(chimeric) 
FCS Fetal Calf Serum  SHM Somatic Hypermutation 
FDR False Discovery Rate (corrects p-values for 
multiple testing) 
 SOSIP SOS: Disulfide Bridge between gp120 and 
gp41, IP: I559P Mutation in gp41 
FP Fusion Peptide  SPR Surface Plasmon Resonance 
FPPR Fusion Peptide Proximal Region  Tat Transactivator of Transcription 
Gag HIV-1 Group-Specific Antigens (genetic 
material encoding HIV structural proteins) 
 TB Terrific Broth 
gDNA genomic Deoxyribonucleic Acid  TD Trimer Derived (HIV-1 Envelope trimer 
stabilizing mutations 
GFP Green Fluorescent Protein  TM Transmembrane Domain of HIV-1 
Envelope 
Gl Germline  TM Melting Temperature 
GLA Glutaraldehyde  UNAIDS The Joint United Nations Program on 
HIV/AIDS 
gp Glycoprotein  v/v volume per volume 
GT X Envelope Variant with X Germline-
Targeting Mutations 
 V1-V5 Variable Loops of HIV-1 Envelope 
HA Influenza Hemagglutinin  w/v weight per volume 
HEK Human Embryonic Kidney  WHO World Health Organization 
HIV-1 Human Immunodeficiency Virus type 1  WT Wildtype 
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